University of Wollongong

Research Online
University of Wollongong Thesis Collection
1954-2016

University of Wollongong Thesis Collections

2015

Synthetic and biological investigations into hypoxia-activated anti-tumour
codrugs
Nicholas Kirk
University of Wollongong
Follow this and additional works at: https://ro.uow.edu.au/theses
University of Wollongong
Copyright Warning
You may print or download ONE copy of this document for the purpose of your own research or study. The University
does not authorise you to copy, communicate or otherwise make available electronically to any other person any
copyright material contained on this site.
You are reminded of the following: This work is copyright. Apart from any use permitted under the Copyright Act
1968, no part of this work may be reproduced by any process, nor may any other exclusive right be exercised,
without the permission of the author. Copyright owners are entitled to take legal action against persons who infringe
their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court
may impose penalties and award damages in relation to offences and infringements relating to copyright material.
Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the
conversion of material into digital or electronic form.
Unless otherwise indicated, the views expressed in this thesis are those of the author and do not necessarily
represent the views of the University of Wollongong.

Recommended Citation
Kirk, Nicholas, Synthetic and biological investigations into hypoxia-activated anti-tumour codrugs, Doctor
of Philosophy thesis, School of Chemistry, University of Wollongong, 2015. https://ro.uow.edu.au/theses/
4537

Research Online is the open access institutional repository for the University of Wollongong. For further information
contact the UOW Library: research-pubs@uow.edu.au

Synthetic and Biological Investigations into
Hypoxia-Activated Anti-Tumour Codrugs

A thesis submitted in fulfilment of the requirements for the award of the
degree

Doctor of Philosophy
from
University of Wollongong

by

Nicholas Kirk
Bachelor of Medicinal Chemistry (Advanced, Honours 1)

School of Chemistry

2015

Declaration

I, Nicholas Kirk, declare that this thesis, submitted in fulfilment of the requirements for
the award of Doctor of Philosophy in the School of Chemistry, University of
Wollongong, is wholly my own work unless otherwise referenced or acknowledged.
The work has not been submitted for qualification at any other academic institution.

Nicholas Kirk
09/11/2015

ii

Acknowledgements
Firstly, I would like to thank my supervisor Assoc. Prof. Michael Kelso. Without your
guidance, I would not have been able to make even the first step of what was a very
rewarding experience. Thank you for all of the time and energy spent explaining,
guiding and inspiring me to do the best I could. I have learned a lot from working under
you. To Pichit: your work ethic, insight and methodical approach to chemistry was an
inspiration. Your consistent cheer was even more impressive than that. Almost
everything I achieved was by standing on the shoulders of your work. To Rhys, Claudia,
Anna Bezos and Tony Willis and everyone else who directly helped with this project,
thanks for your contributions. I wouldn’t have completed anything close to what I have
without your hard work. To Marie and Nat: thank you for all your help in the scary
world of tissue culture. Thank you for being so welcoming and generous with your time
and energy.
To Ardeshir (dorood!), Alex (B.O. Basher), Ben (ooh bay-bee), Con(athon), Louise,
Ramesh, Naveen and all of the other Kelso Lab and School of Chemistry members
(especially Alireza): thanks for all the laughs, the singing and yelling, all the ideas, the
occasional strangely deep discussions and inappropriate translations. I’m sure I’ll see
you all again soon.
To mum, dad, my brothers and friends: thank you for (trying to) encourage me to have a
life. Thank you for being there even when we were in very different places, both
figuratively and literally.
Finally to Erica: thank you for all of your love and support. Thank you for
understanding the frustration and appreciating the wins and being beside me on the
whole rollercoaster of experiences that this ended up being.
iii

Publications Arising from this Thesis
1. Sudta, P., Kirk, N., Bezos, A., Gurlica, A., Mitchell, R., Weber, T., Willis, A.C.,
Prabpai, S.,

Kongsaeree, P.,

Parish, C.R.,

Suksamrarn, S.,

Kelso,

M.J.,

Synthesis, Structural Characterisation, and Preliminary Evaluation of NonIndolin-2-one-based

Angiogenesis

Inhibitors

Related

to

Sunitinib

(Sutent®). Aust. J. Chem. 2013, 66, 864.

Manuscripts in Preparation
2. Kirk, N., Sudta, P., Suksamram, S., Kelso, M.J. Design and synthesis of a
reductively activated anti-tumour codrug. Target Journal: ChemMedChem

3. Kirk, N., Sudta, P., Bezos, A., Ries, C., Willis, A.C., Parish, C.R., Ranson, M.,
Kelso, M.J. Synthesis and biological assessment of 2-aryl-3H-pyrrolizin-3-ones
angiogenesis inhibitors. Target Journal: Bioorg. Med. Chem. Lett.

4. Kirk, N., Sudta, P., Willis, A.C., Kelso, M.J. Synthesis and unusual reactivity of
3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(2-nitrophenyl)acrylic acid. Target Journal:
Tet. Lett.

iv

Abstract
Tumour-selective, non-cytotoxic chemotherapeutics are much sought after in oncology.
Two cancer-selective drug types are angiogenesis inhibitors, drugs which halt the
growth of new blood vessels in tumours, and hypoxia-activated prodrugs, which are
non-toxic agents that are activated into cytotoxins selectively within tumours. It is
possible to conceive a dual-action prodrug (a.k.a. codrug) which releases both an
angiogenesis inhibitor and a cytotoxin selectively within a tumour after bio-reductive
activation. Specifically, prodrugs designed to release nitrogen mustard cytotoxins along
with SU5416 from a 2-nitrophenylacetamide precursor were of particular interest.
A synthesis of the prototype hypoxia-activated anti-tumour codrug (Z)-1 was
successfully achieved with an overall yield of 12% over 7 steps. A synthetically more
convenient route through carboxylic acid intermediate (Z)-5 was unsuccessful, as
ester/amide coupling conditions produced the cyclisation product 5,7-dimethyl-2-(2nitrophenyl)-3H-pyrrolizin-3-one 14 in high yield. Instead, it was necessary to optimise
a

step-wise

synthesis

through

N-(4-(bis(O-tert-butyldimethylsilyl-2-

hydoxyethyl)amino)phenyl)-2-(2-nitrophenyl)acetamide 8, then perform a Knoevenagel
condensation with N-protected pyrrole aldehyde 9 to form (Z)-7. After deprotection and
chlorination of (Z)-7, prototype codrug (Z)-1 was obtained as an air-stable solid.
In order to demonstrate that reduction of (Z)-1 spontaneously produced SU5416 as
necessary for in vivo activity, chemical NO2 reductions were performed. (Z)-1 was
demonstrated to spontaneously produce SU5416 and the N-hydroxy SU5416 analogue
2-OH in good yields after reduction. Similar results were observed for the ethyl ester
(Z)-10 and anilide (Z)-29. These results represented a crucial proof-of-concept for the
scaffold as a codrug and supported further investigation into (Z)-1 in biological systems.
v

Several side reactions from the synthesis of (Z)-1 were also explored in depth. IndolineN-oxides 15 and 16 were the result of attempted amide couplings of 5 and HBTU or
HATU with N,N-dimethyl-p-phenylenediamine (15) or p-phenylenediamine (16).
Significant efforts were made to delineate the reaction mechanism. Through NMR
studies, it was shown that (Z)-5 spontaneously decarboxylated in chloroform to form
(E)-alkene 18. It was also shown that p-phenylenediamine reacted with HBTU or
HATU in solution to form 2-(4-aminophenyl)-1,1,3,3-tetramethylguanidine 19. A
reaction mechanism combining these two transformations to form 15 was proposed,
supported by mass spectral data. 16 was also shown to spontaneously form indolinoneN-oxide 17, a novel analogue of a known antimalarial series, which showed IC50 = 381
nM against the K1 strain of P. falciparum.
Alkene intermediates synthesised during optimisation of the Knoevenagel condensation
necessary for (Z)-1 were tested for activity in a rat aortic ring angiogenesis assay. This
assay showed that small ester derivatives such as (E)-10 and (Z)-10 represented a novel
class of angiogenesis inhibitors, however all amide analogues tested (such as anilide
(Z)-29) were inactive. The structurally similar 3H-pyrrolizin-3-one 14 was also shown
to be a potent angiogenesis inhibitor. A facile one-step synthesis of substituted 2-aryl
derivatives of 14 was developed, using pyrrole carboxaldehyde 4 and commercially
available phenylacetic acid derivatives. 18 derivatives were synthesised through this
reaction and tested for angiogenesis inhibition in a semi-quantitative HUVEC tube
formation assay. Compound 14 was shown to be the most potent compound, with
unsubstituted phenyl derivative 51 and o-fluoro derivative 69 also producing significant
inhibition of HUVEC tube formation. Compounds 14 and 51 were then tested in a rat
aortic ring angiogenesis assay which confirmed their inhibitive capacity, with
compound 14 producing similar inhibitory potency to SU5416.
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Chapter 1: Introduction

1

1.1 Cancer Statistics
Cancer is a highly complex group of diseases characterised by uncontrolled
proliferation of cells. In 2011, cancer accounted for about 3 in every 10 deaths in
Australia, with lung and gastrointestinal tumours the leading contributors.1,2 Cancer is
also responsible for the greatest health-care economic burden in Australia, costing
upwards of $3.8 billion per year (7.2% of all direct health expenditure).1 Domestic
research efforts in cancer attract $358 million in funding annually, representing 22% of
the health and medical research budget.1 Improvements in early detection, diagnosis and
treatment have drastically improved prognoses for cancer patients over the years.3 In
Australia, 5-year survival rates have improved over 25 years from 45.1% to 66.1%.1,2
The mortality-to-incidence ratio for all cancer types in Australia has declined at a
similar rate over the same period, representing a significant improvement in successful
treatment (Figure 1.1).1

Figure 1.1. Mortality-to-incidence ratios for all cancer types in Australia from 1982 to
2015.1

2

1.2 Molecular Mechanisms of Cancer
Cell division is an intricately controlled process where an array of positive and negative
feedback mechanisms finely balance DNA replication, mitosis and apoptosis
(programmed cell death) to maintain healthy tissues. This balance is managed by layers
of signalling pathways that modulate a plethora of cellular processes involved in tissue
homeostasis.4,5 Cancer occurs when a population of cells is no longer subject to the
entirety of these control processes and cell proliferation proceeds to the detriment of the
host organism. The simplistic historical notion that cancer is a disease of proliferation
has been replaced in recent times by an evolutionary model.5 According to this model,
cancer occurs when a population of cells accumulates a variety of mutations that gives
them a survival advantage over neighbouring healthy cells.5 While cancer actually
represents a myriad of different diseases, a number of commonalities are observed
amongst most malignant tumours.5 These include:


an ability to signal their own growth and bypass anti-growth signals.



insensitivity to apoptotic messages.



an ability to overcome internal cell division limits.



consistent promotion of angiogenesis (growth of new blood vessels).



superior invasive and metastatic capabilities

With some or all of these characteristics, a population of mutated cells (the cancer) is
able to grow unchecked, extravasate into the bloodstream and metastasise to distant
tissues to create secondary tumours that can lead to death.

3

1.3 Traditional Cancer Treatment Protocols
Surgical resection and radiation therapy remain the primary methods of treatment for
solid tumours as they allow direct, targeted action on cancerous tissues. Modern cancer
treatments combine these with chemotherapy in order to improve outcomes and increase
the likelihood of remission.6
There are many methods of applying chemotherapy in modern cancer treatments. For
instance, drugs are often used as ‘adjuvant’ therapy to kill circulating cancerous or precancerous cells remaining after surgery and/or radiation.7–9 Conversely, ‘neoadjuvant’
therapy uses chemotherapy before other treatments in order to reduce the tumour mass
and consequently the extent, complexity and risks of surgery, or the effects of
radiotherapy on surrounding tissues.10,11 Anti-cancer drugs can also be used as palliative
agents (i.e. to reduce pain and improve quality of life) in terminal patients.12–15
Non-solid cancers are treated primarily with chemotherapy. Treatment of leukaemia
(cancer of leukocytes or white blood cells), for instance, is typically layered into
multiple chemotherapy protocols. The first aims to kill cancerous cells such that they
are undetectable in a patient’s blood. This is known as ‘remission induction’ and
involves aggressive treatment with combinations of cytotoxins.15–18 A second regimen,
termed ‘consolidation’, is then cycled for months or even years to reduce the risk of
relapse.16,19,20 These protocols can also be combined with radiation and bone marrow
transplants depending on the nature and severity of a patient’s disease. Chemotherapy is
also a primary treatment for many lymphomas (cancers derived from lymphocytes).21
The availability of biochemical and genetic methods for analysis of cancers has allowed
the molecular mechanisms behind many cancer sub-types to be determined. This has
spurred the development of more selective chemotherapeutic agents that specifically
4

target the mechanism(s) identified, reducing the need for cytotoxic agents. These
modern drugs tend to be less harmful to patients.22 Indeed, most FDA-approved
chemotherapeutics these days tend to be targeted agents, which are often fast-tracked
for approval.23 Aggressive combination chemotherapy treatments continue to be used,
but the physiological burden on patients has been reduced significantly by inclusion of
targeted agents.24

1.4 Types of chemotherapeutics
Traditional cytotoxic chemotherapeutics target DNA replication and cell division under
the premise that cancer cells are selectively killed over healthy cells due to their higher
proliferation rates. Classes of cytotoxic agents include the DNA alkylators, DNA
intercalators, anti-metabolites and tubulin-binders. Chemotherapy treatments have
generally used combinations of these agents to reduce the risk of persistent cancer cells
and adaptive resistance.7,25,26
DNA-alkylators, such as melphalan, chlorambucil and carmustine (Figure 1.2(a)),
function by alkylating DNA (usually via the nucleophilic guanine N7) and cross-linking
strands (Figure 1.2(b)).27,28 These lesions can disrupt DNA replication directly by
causing strand-breakages and preventing the binding of proteins, or indirectly by
promoting apoptosis through formation of unnatural DNA complexes.28 Cisplatin and
the related carboplatin are traditional DNA alkylators that continue to be used due to
their effectiveness in treating testicular cancer. Use of these agents has seen 5-year
survival rates in Australia increase to nearly 98%.1 In contrast, chlorambucil and
melphalan tend to be limited to palliative therapy due to their high immunotoxicity.29,30

5

(a)

(b)

Figure 1.2. (a) Structures of FDA-approved DNA-alkylators. (b) Mechanism of DNA
alkylation by nitrogen mustards.

Anti-metabolites like 5-fluorouracil (5-FU), cytarabine, gemcitabine and methotrexate
(Figure 1.3) compete with endogenous metabolites during genetic replication cycles.
These agents are close structural analogues of nucleosides or vitamins, where small
changes have been introduced to ablate their function whilst maintaining their binding
to endogenous targets. 5-Fluorouracil is an unnatural analogue of uracil, a nucleobase
found in RNA and used in the synthesis of thymine for incorporation into DNA.
Metabolites of 5-FU are misincorporated into RNA resulting in a general loss of cellular
protein function.31 5-Fluorouracil is also a ‘suicide inhibitor’ of thymidylate
synthase.31,32 The drug is a mainstay of many treatment protocols for head and neck
cancers, lymphomas, skin cancers and gastrointestinal tumours.33 Cytarabine is a
6

nucleoside mimic that contains a modified arabinose sugar (a stereoisomer of
deoxyribose) conjugated to cytosine. It is misincorporated into DNA and causes cell
cycle seizure and DNA polymerase inhibition.34,35
Methotrexate functions by blocking the activity of dihydrofolate reductase, thus
inhibiting production of folic acid (vitamin B9), which is required for DNA and RNA
synthesis.36 Methotrexate is used in a wide variety of indications, including lung and
breast cancers and advanced non-Hodgkin’s lymphoma.17 A more recent antimetabolite, gemcitabine, has become an important addition to chemotherapy. This drug
is an analogue of deoxycytidine, where the 2’-position of the deoxyribose has been
difluorinated. The compound is misincorporated into DNA and causes apoptosis,
although like many anti-metabolites, other targets are affected, e.g. ribonucleotide
reductase.

37–40

Unlike other anti-metabolites, however, gemcitabine is effective against

solid tumours and is used as a first-line treatment for pancreatic adenocarcinoma. It is
also used in combination with other agents for advanced or metastatic non-small cell
lung carcinomas and bladder cancer.41–43

Figure 1.3. Structures of FDA-approved anti-metabolites.

DNA intercalators are planar, aromatic compounds that insert into double-stranded
DNA, distorting the tertiary structure and promoting apoptosis (Figure 1.4).44 These
distorted complexes are stabilised by polar interactions with the phosphate backbone.44
While many DNA-intercalators are limited to use as reagents and probes in biology due
7

to their toxicity and mutagenicity, doxorubicin continues to be used as a frontline
treatment for many cancer types.45
(a)

(b)

Figure 1.4. Insertion of DNA-intercalators like doxorubicin into double-stranded DNA
(i.e. intercalation) distorts DNA tertiary structure.44,46 (a) Normal double-helical and (b)
distorted DNA structure with intercalated doxorubicin.

Paclitaxel and vinblastine are examples of anti-mitotic agents, which target cell division
rather than DNA replication.47 Specifically, anti-mitotic agents impair the function of
tubulin, a key protein constituent of the microtubules required for physical budding and
division of cells.47,48 Paclitaxel binding to microtubules leads to their structural
stabilisation, preventing disassembly and separation. Vinca alkaloids like vinblastine,
on the other hand, inhibit tubulin polymerisation (Figure 1.5).49,50 Paclitaxel was the
first ‘blockbuster’ oncology drug and continues to be used in ovarian, breast and nonsmall cell lung cancers, along with several other indications.51 Vinca alkaloids continue
to be widely used for childhood and adult acute lymphocytic leukemias, Hodgkin and
non-Hodgkin lymphomas, Wilms tumor, Ewing sarcoma, neuroblastoma and
rhabdomyosarcoma.52
8

(a)

(b)

Figure 1.5. (a) Anti-mitotic agents vinblastine and paclitaxel inhibit cell division by
targeting tubulin. (b) Structures of vinblastine and paclitaxel.

Drugs targeting DNA-replication and cell-division can affect healthy cells leading to
unpleasant side effects. Rapidly dividing cells tend to be the worst affected, including
hair follicles (leading to alopecia), blood and immune cells (anaemia, fatigue and
immunosuppression) and gastrointestinal cells (nausea, vomiting and diarrhoea).28,44,53,54
Other side effects commonly experienced with cytotoxins are neutropenia and skin
rashes. While the side effects can be somewhat mitigated with other drugs, toxicity to
organs (particularly the kidneys and liver) is dose-limiting and often severe. It is well
established that many cancers are also resistant to these types of drugs when used alone.
9

In the past two decades there has been a push to develop more selective agents that
target the underlying molecular mechanisms of uncontrolled proliferation in cancer
rather than directly targeting replication and cell division.

1.5 Targets for Non-Cytotoxic Chemotherapy
1.5.1 Apoptosis
Millions of mutations occur daily in healthy human DNA due to the sheer volume of
replication and mutation rates are increased by various risk factors. Nucleotides can be
added, removed or mis-matched during DNA polymerisation, while mutagenic
chemicals, UV or ionising radiation and oxidative stress can contribute to base
modification, bonding between bases, cross-linkage or other DNA lesions.55,56
Several protective mechanisms exist in cells to detect mutations, repair the damage,
control cells that contain the mutations and signal apoptosis, where necessary. Genes
that code proteins involved in these processes are called tumour-suppressor genes. One
key example is p53. The p53 protein is a nuclear transcription factor that responds to
DNA damage by influencing cell cycle regulation, DNA repair, apoptosis and cell
homeostasis.57 Mutations or deletions in p53 are found in over 50% of all human
tumours.58 Unfortunately, the complexity of p53’s actions and its function as a nuclear
transcription factor make it a difficult drug target.59,60 Efforts to replace dysfunctional
p53 in tumour cells using gene therapy techniques have shown considerable promise
and there is now an approved adenovirus vector in China (Gendicine).61 Advexin is a
similar vector in Phase III clinical trials in the USA.62
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1.5.2 Internal Cell Division Limits
All chromosomes are terminated by telomeres; endcaps of repeating DNA sequences
that serve to protect the DNA. Telomeres contain a guanine-rich overhang that promotes
formation of a protein complex called shelterin. This complex prevents inappropriate
cellular processing and chromosomal fusion.63,64 During DNA replication, a portion of
genetic material is lost from the telomere and, as this process repeats, the telomeres
continue to shorten, eventually affecting genetic coding sequences.65 Without telomeres,
chromosomal fusion can also occur leading to apoptosis.65 Telomere shortening limits
the number of times a diploid cell can divide (the ‘Hayflick limit’), which suppresses
cell line immortalisation and excessive proliferation.66 The ribonucleoprotein reverse
transcriptase enzyme telomerase (transcribed from the hTERT gene) functions to
maintain the protective endcaps in immortal stem cells.65 Telomerase activation is
central to the survival and proliferation of cancer cells. Over 90% of cancers express
telomerase and its function is suspected to be replicated by alternate pathways in the
remainder. 67,68
Telomerase is currently being explored as a new drug target for cancer.69 Drugs in
clinical development include inhibitors of its reverse transcriptase activity,70,71 small
molecule or siRNAs that target the RNA template component hTR72,73 and Gquadruplex-stabilising ligands.74

1.5.3 Invasiveness
An increase in invasiveness and motility is typically observed during later stages of
tumour maturation.5 To grow and eventually metastasise, a tumour needs to be able to
degrade its surrounding extracellular matrix, enter a nearby blood vessel and extravasate
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into a distant tissue.75 Tumours can use a number of different chemical and enzymatic
processes to achieve this. One hallmark of advanced tumours is that they switch from
oxidative phosphorylation for energy production to glycolysis, even when the supply of
oxygen is not limited (known as the Warburg effect – Figure 1.6).76 This process
consumes high levels of glucose and produces increased lactic acid, which is expelled
into the extracellular matrix.77,78 The associated decrease in pH can promote
extracellular protease activity and matrix degradation.79

Lactate production and

transport are considered possible drug targets for reducing invasiveness.78,80

Figure 1.6. The ‘Warburg effect’ in tumour cells. Oxidative glycolysis is promoted in
tumour cells even with a normal oxygen supply, increasing production (and efflux) of
lactate. The resulting low extracellular pH promotes invasiveness, motility and
metastasis.77,78

Tumours can also directly promote pro-metastatic enzymatic activity. For example, the
broad spectrum serine protease plasmin, which is important in tissue breakdown and
clotting, has been shown to be upregulated in metastatic tumours.81 Other commonly
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upregulated proteolytic enzymes include matrix metalloproteinases, cathepsins and the
urokinase plasminogen activator (uPa), which are all involved in various stages of
detachment and motility pathways.81–84 Inhibitors of MMPs have generally been
disappointing in clinical trials, a feature attributed to the complexity and redundancy of
extracellular proteolytic signalling.85 The uPA system has shown promise as an antimetastasis target, with an orally bioavailable uPA inhibitor WX-671 currently in 8
different clinical trials.86,87

1.5.4 Growth Signalling
Cell proliferation and differentiation in healthy tissues is promoted by cytokines, growth
factors and hormones. These signalling molecules affect cells by modulating
intracellular reaction cascades. Growth factors promote growth and differentiation and
their activity is controlled by endogenous inhibitors and transcription factors. Cancer
cells can co-opt growth factor signalling through direct or upstream mutations, leading
to constitutive expression and uncontrolled growth.88 In recent times, targeted cancer
drugs have focused sharply on intercepting growth factors and hormones that activate
receptor tyrosine kinases (RTKs). These enzymes catalyse the transfer of phosphate
groups from ATP to downstream proteins, affecting cell growth, proliferation and cell
survival in response to extracellular signals.89
The epidermal growth factor (EGF) family of receptors plays a role in the normal
growth and development of various tissues90 and it has been estimated that 50-70% of
lung, colon and breast carcinomas (the most common solid tumours) overexpress EGF
receptors (e.g. EGFR or ErbB-3).90 Several RTK inhibitors that block EGFR function
have been developed as anti-cancer drugs.22 These include the small molecules gefitinib
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and erlotinib and the monoclonal antibodies (mAbs) cetuximab and panitumumab
(Figure 1.7).91

Figure 1.7. Inhibition of EGFR signalling pathways with small molecule RTK
inhibitors and mAbs. EGF = epidermal growth factor, EGFR = epidermal growth factor
receptor, RTKi = receptor tyrosine kinase inhibitor, mAb = monoclonal antibody.

Another tumour-promoting growth factor is transforming growth factor-β (TGF-β).
TGF-β regulates proliferation and differentiation of cells, embryonic development,
wound healing and angiogenesis by acting on epithelial, endothelial and haematopoietic
cells.92 Cell motility and invasiveness is enhanced by TGF-β.92 Mutations causing
resistance to TGF-β are observed in over 85% of epithelium-derived human cancers.93
In these cases, TGF-β primes the surrounding matrix and promotes invasiveness of
TGF-β insensitive cancer cells.93 TGF-β also affects expression of hTERT promoting
cell immortality.94
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While growth factors control the progression of most cancers, some tissues are
susceptible to highly aggressive tumours because of tissue-specific hormones. Blocking
these hormones can greatly improve efficacy of treatments for sub-types of gonadial,
prostate and breast cancers. Trastuzumab (Herceptin) is a monoclonal antibody used in
breast cancer that targets HER2, an EGF RTK that promotes cell proliferation.91,95
Lapatinib is a small-molecule dual HER2/EGFR inhibitor that is used to treat “triple
positive” breast cancers.96 Tamoxifen is a particularly effective small molecule
oestrogen receptor antagonist that is used as an adjuvant to surgery when treating
oestrogen-dependent breast cancers.11,97 Early and late-stage prostate cancers are often
treated with bicalutamide (Casodex), which antagonises the nuclear androgen receptor
(AR).98 Figure 1.8 shows the structures for these hormone receptor-targeting agents.

Figure 1.8. Examples of hormone receptor-targeting anti-cancer drugs.

1.5.5 Angiogenesis
Angiogenesis is the growth of new blood vessels from pre-existing vasculature. It is a
complex process and is carefully regulated in healthy tissues by families of growth
factors and their corresponding nuclear, cytosolic and membrane-bound receptors.99–101
As localised tumours grow, sections of the tumour become hypoxic (i.e. low oxygen
concentration) because of the increased distance of cells from blood vessels due to the
aberrant vasculature and their increased metabolic needs (Figure 1.9).102 Hypoxia is
correlated with poor drug uptake and resistance to radiotherapy (due to lower
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production of reactive oxygen species) and is considered a marker of poor prognosis.103–
105

Tumours respond to hypoxia by entering latent phases, modifying their metabolism

and by promoting angiogenesis; a hallmark of advanced solid tumours.5,106,107

Figure 1.9. Hypoxic and necrotic cells arise in solid tumours due to their increased
distance from the nearest blood vessels.108

A major pro-angiogenic response to hypoxia is initiated by hypoxia-inducible factor-1
(HIF-1). HIF-1 is a nuclear signalling protein that binds to hypoxia responsive elements
on DNA in response to hypoxia, increasing transcription of proteins that restore normal
oxygen supply.107,109 HIF-1 is a heterodimeric protein consisting of two subunits;
oxygen-sensitive HIF-1α and constitutively expressed HIF-1β.110 When oxygen is
present, cytosolic HIF-1α is hydroxylated and ubiquitinated by the von Hippel-Lindau
tumour suppressor protein and targeted to the proteasome for removal.111 When a cell
becomes hypoxic, the hydroxylation process is slowed and dimerisation of HIF-1αβ
occurs, resulting in signal activation.112
HIF-1 is often overexpressed in human cancers and its expression is correlated with
poor prognosis.103,104,113,114 Drugs that target several aspects of HIF-1 activity have been
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developed.115 For example, some drugs bind to targets in the phosphatidylinositol 3kinase (PI3K), mammalian target of rapamycin (mTOR) and extracellular-signal-related
mitogen-activated protein kinase (MAPK) pathways, reducing the transcription of HIF1α mRNA.116–119 Several drugs that inhibit mTOR have been approved, including the
rapamycin derivative Temsirolimus (Figure 1.10), which is used for renal cell
carcinomas and other advanced tumours.120,121

Figure 1.10. Temsirolimus targets mTOR to reduce transcription of HIF-1α.

Important downstream pro-angiogenic signalling proteins include platelet-derived
growth factors (PDGFs), vascular endothelial growth factors (VEGFs) and epidermal
growth factors (EGFs).122,123 These RTKs activate a wide variety of downstream targets
that promote angiogenesis, cell motility, differentiation, matrix degradation and
survival.91,124 Transcription of these proteins is often upregulated in cancers and their
function is poorly controlled, leading to formation of a disorganised, highly permeable
vasculature (tumour-associated vasculature, TAV).99,100,107,124-126
Two main strategies have been developed to target these processes: (1) sequestration of
the signalling proteins using mAbs and (2) inhibition of RTKs using small molecules
(Figure 1.11).123,126,127 Bevacizumab (Avastin®) is a monoclonal antibody that binds to
VEGF-A triggering its removal by immune cells. The drug was approved for colorectal
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cancer in 2004 and was the first FDA-approved angiogenesis inhibitor.128 It has since
been approved for a variety of advanced lung, renal, ovarian and brain tumours.128
Imatinib (Gleevec®, Figure 1.12) is a small molecule RTK inhibitor that shows high
specificity for the bcr-abl RTK (also known as the “Philadelphia chromosome” or Ph+),
a constitutively “on” mutant RTK found in 95% of chronic myelogenous leukaemia
(CML) patients.129 It has since been approved for gastrointestinal stromal tumours and
several mutant kinase-related leukaemias.130 A related analogue dasatinib (Sprycel®) is
approved as a first line treatment for CML and Ph+ acute lymphoblastic leukaemia.131
Sunitinib (Sutent®) is an FDA-approved angiogenesis inhibitor that was originally
indicated for use in imatinib-resistant gastrointestinal stromal tumours.132 The
compound is a multi-target RTK inhibitor that binds to several related PDGF family
receptors.133 Sunitinib was developed in favour of its predecessor semaxinib (SU5416),
a VEGFR-2 selective RTK inhibitor that reached Phase II clinical trials.134 Sunitinib
shows a broader inhibition profile across RTKs than SU5416, which is attributed to the
F-substituent at the 5-position of the oxindole moiety. A hydrophilic N,Ndiethylethylenediamine carboxamide moiety at the 3-position of the pyrrole improved
the compound’s ADMET properties. Sunitinib later received approval as a first-line
therapy in advanced renal cell carcinoma and against metastatic or unresectable
pancreatic neuroendocrine tumours.135 Both sunitinib and semaxinib are compounds of
direct relevance in this PhD project (see later).

18

Figure 1.11. Inhibition of angiogenesis and tumour growth by VEGF-A-targeting mAbs
and small molecule RTK inhibitors.

Other angiogenesis inhibitors approved for use in cancer include sorafenib (Nexavar®)
and erlotinib (Tarceva®), which show similar RTK selectivity profiles to sunitinib.
Another drug pazopanib (Votrient®) targets EGFR selectively (Figure 1.12).127 These
targeted RTK inhibitors are often used in combination with traditional cytotoxic drugs
as they show mostly cytostatic action.136 Compared to traditional cytotoxins, however
angiogenesis inhibitors tend to be well-tolerated, although it is clear that they are not the
‘magic bullets’ as originally hoped.137
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Figure 1.12. Small molecule RTK angiogenesis inhibitors approved for use in cancer
treatment. Semaxinib and Sutent (sunitinib) are compounds relevant to the PhD project
(red).

1.6 Anti-Cancer Prodrugs
1.6.1 Prodrugs - General
Prodrugs are biologically inert or only weakly active compounds that are modified to
active forms by metabolic reactions in vivo. Prodrug forms have been investigated for
many cytotoxic agents as a means of improving their efficacy and safety profiles.138,139
Masking the cytotoxic moieties can improve bioavailability, reduce systemic toxicity
and modulate first-pass metabolism and plasma half-life. Prodrugs of anti-cancer agents
often aim to reduce the gastrointestinal toxicity of their active components and improve
selectivity for tumours over healthy tissues.139,140
Examples of approved anti-cancer prodrugs are capecitabine and tegafur; both prodrugs
of 5-fluorouracil (5-FU).138 Capecitabine is a hydrophobic carbamate derivative of 5fluoro-2’-deoxyuridine and is used for treating metastatic colorectal and breast
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cancers.141 Tegafur is a tetrahydrofuran-linked aminal derivative of 5-fluorouracil used
primarily in the treatment of gastric and colorectal cancers.142 Capecitabine and tegafur
are enzymatically converted in vivo to 5-fluorouridine, the activate metabolite of 5-FU
(Figure 1.13). The prodrugs reduce gastrointestinal toxicity and show improved oral
bioavailability over the parent 5-FU.138,141,142 Cyclophosphamide is an inert prodrug
activated by a mixed function microsomal oxidase system in the liver to produce
multiple active forms, many of which are DNA-alkylators.143 It is used to treat several
leukaemias, lymphomas and brain cancers.144
(a)

(b)

Figure 1.13. (a) Capecitabine and tegafur are FDA-approved prodrug forms of 5-FU
that generate the active metabolite 5-fluorouridine in vivo. (b) Mechanism of activation
of cyclophosphamide in vivo.
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1.6.2 Tumour-Targeted Prodrugs
Tumour-targeted prodrugs are designed to make use of a variety of activation processes
unique to or introduced into cancers. These prodrugs reduce the side effects of highly
toxic agents by localised activation in the immediate tumour environment.145,146 Two
major classes of tumour-targeted prodrugs are antibody-drug conjugates and hypoxiaactivated prodrugs.

1.6.2.1 Antibody-Drug Conjugates
Antibody-drug conjugates are biologics that use selective recognition of tumourassociated antigens and receptors to deliver an extremely potent cytotoxin selectively to
tumours.147,148 This approach uses the exquisite selectivity of monoclonal antibodies
(mAbs) to provide highly specific cancer cell killing. The mAbs are typically linked via
a plasma-stable, enzyme-cleavable tether and chemical spacer to the cytotoxin. The
conjugates are localised to tumours through antigen recognition and, following
internalisation, are cleaved by intracellular enzymes, e.g. cathepsins (Figure 1.14).149
Fewer than 10 cytotoxin molecules are usually linked to the mAbs to maintain avidity,
thus necessitating the use of extremely potent toxins.148–150
Two FDA-approved examples are brentuximab-vedotin (Adcetris®) and trastuzumabemtansine (Kadcyla®).151 Brentuximab targets CD30, a membrane protein associated
with tumour necrosis factor (TNF) signal transduction that is expressed on active T- and
B-cells in malignant lymphomas.152,153 The vedotin portion of the conjugate is
comprised of the potent cytotoxin monomethyl auristatin E (MMAE), a p-aminobenzoic
acid spacer and a cathepsin-cleavable citrulline-valine linker.151 MMAE is a tubulin
polymerisation inhibitor that is 200 times more potent than vinblastine.154 Brentuximab22

vedotin was approved in 2011 for use in relapsed or refractory Hodgkin’s lymphoma
and systemic anaplastic large cell lymphomas.155
Trastuzumab-emtansine combines trastuzumab’s avidity for HER2 with mertansine, a
maytansine

alkaloid

that

inhibits

microtubule

assembly

at

subnanomolar

concentrations.150,156 These two agents are linked with a succinimidyl-trans-4(maleimidylmethyl)cyclohexane-1-carboxylate moiety. Trastuzumab-emtansine was
approved in 2013 for use in HER2+ breast cancers that have progressed following
standard treatments.157 Many other antibody-drug conjugates are likely to enter the
clinic as new mAbs, linking strategies and cytotoxins are being discovered.148,149

Figure 1.14. Cell killing mechanism of tumour-targeted antibody-drug conjugates.

1.6.2.2 Hypoxia-Activated Prodrugs
Another approach for targeting prodrugs to tumours is to invoke hypoxia-activation. As
described earlier, when hypoxia develops in normal healthy tissues HIF-1 signalling
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triggers angiogenesis and other cellular mechanisms to restore oxygen levels.107,158–161
In comparison, virtually all solid tumours over 1 mm3 contain regions that are at least
transiently hypoxic.102,103,162–164 Many tumours remain viable in spite of hypoxia due to
a variety of survival and growth factors, glycolytic enzymes and enzymes involved in
invasiveness.103,106,112,158
The low concentration of oxygen and low pH in hypoxic tumour microenvironments
can promote tumour-selective reduction reactions.115 Several oxidative enzymes exist
ubiquitously across tissues and are responsible for many aspects of catabolism,
recycling of important species (e.g. nucleobases) and energy generation. Examples
include xanthine oxidases, NADPH-cytochrome reductases, lipoxygenases, DTdiaphorase and cytochrome P450. Each of these enzymes catalyse redox reactions that
use water and O2 to oxidise organic substrates.165–167 This process results in reduced
oxygen products, including peroxide and other reactive oxygen species like superoxide,
which can be further scavenged by enzymes such as superoxide dismutase and catalase
to prevent damage to the cell.168
In hypoxic and anoxic tumour cells, oxygen is not present in sufficient quantities to
counter the reduction reactions, meaning that when reduced species are formed they are
susceptible to further reduction reactions. This tumour-specific feature can be exploited
with prodrugs that are activated to produce cytotoxins only after multiple-electron
reduction reactions.108,169 Under normoxic conditions in healthy tissues, the initial
reduction products are reversibly reoxidised by systems coupled to molecular oxygen.
In hypoxic and anoxic cells in solid tumours, where molecular oxygen supply is limited,
the initial reduction products are not back-oxidised and can undergo further reduction
reactions to generate reactive species (Figure 1.15). As the process is restricted to
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hypoxic tissues, unmasking of the active cytotoxin is localised to the immediate tumour
vicinity, minimising its detrimental effects on normal tissues.
A number of requirements need to be met for a hypoxia-activated prodrug to be
functional. Firstly, it should be inert in plasma and not be activated by hepatic
cytochrome P450s as this can lead to unacceptable liver toxicity. It should accumulate
in hypoxic tumours and undergo selective activation, with the active species then
diffusing sufficiently to kill nearby normoxic tumour cells (i.e. ‘bystander effect’).169

Figure 1.15. Mechanism of selective bioreductive activation of prodrugs in hypoxic
tumours.169

The most studied class of hypoxia-activated prodrugs are the nitroaromatics.169 These
compounds use reduction of an aryl nitro group to an aryl hydroxylamine or amine
moiety to trigger activation of a cytotoxin.108 For example, cytotoxins such as nitrogen
or phosphoramide mustards can be conjugated to nitro aromatic moieties to reduce their
intrinsic reactivity towards DNA.170,171 The strongly electron withdrawing nitro group
reduces electron density and consequently nucleophilicity of the reactive functional
group in the prodrug. When hydroxylamine or amine groups are revealed following
bioreduction, these nucleophilic and/or electron donating groups trigger spontaneous
reactions that lead to formation of a cytotoxin.
The first hypoxia-selective prodrug developed for use in cancer was misonidazole
(Figure 1.16), a derivative of the anaerobic antibacterial agent metronidazole.172
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Misonidazole was observed to accumulate in cancer cells after hypoxia-selective
reduction, producing species that bind cellular nucleophiles at the 4- or 5-positions of
the imidazole ring (Figure 1.16).173 The compound was originally conceived as a
radiosensitiser that could confer radiation sensitivity to hypoxic tumours.174,175
Unfortunately, clinical evaluation of misonidazole in cancer did not show sufficient
efficacy. Nevertheless,
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F-labelled misonidazole has proven to be an effective PET

agent for imaging hypoxia in tumours.165
TH-302 (evofosfamide) is a related prodrug that uses the nitro-imidazole scaffold as a
hypoxia-selective trigger for release of a bromoisophosphoramide alkylating mustard
(Figure 1.16).167,171 It is currently being investigated in Phase III trials in combination
with doxorubicin for use in soft-tissue sarcomas. A separate Phase III trial is
investigating the compound against advanced pancreatic adenocarcinomas in
combination with gemcitabine.145
(a)

(b)

Figure 1.16. Hypoxia-selective activation mechanism of the nitroaromatic prodrugs (a)
Misonidazole, and (b) TH-302 (evofosfamide).

In 1994, Denny et al. described nitroaromatic prodrug chemistry for hypoxia-selective
activation of cytotoxins that utilise 2-nitrophenylacetic acid as the trigger.176 An
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electron-withdrawing amide bond para to a phenylenediamine mustard nitrogen served
to reduce its nucleophilic character, preventing aziridinium ion formation and
subsequent DNA alkylation. Upon reduction to the hydroxylamine or aniline, a
spontaneous 5-membered intramolecular cyclisation occurred to release the active
phenylenediamine nitrogen mustard (Figure 1.17). A molecule of oxindole (or Nhydroxyoxindole) was released from the prodrug as a waste fragment.

Figure

1.17.

Hypoxia-activated

2-nitrophenylacetate-based

prodrug

chemistry

described by Denny et al.176

Similar chemistry was later deployed with the angiogenesis inhibitor SU5416 (Figure
1.18), where the 2-nitrophenylacetate group was appended to the oxindole nitrogen of
SU5416 to create a hypoxia-activated angiogenesis inhibitor prodrug.177

Figure 1.18. Hypoxia-triggered activation of a 2-nitrophenylacetate prodrug derivative
of angiogenesis inhibitor SU5416.177
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1.7 Mutual Prodrugs (Codrugs)
1.7.1 General
Mutual prodrugs (or codrugs) are compounds that combine two active agents into a
single prodrug molecule. A number of codrugs are currently in development, as
reviewed by Das et al.178 Examples are being assessed for use in alcohol and tobacco
withdrawal, ocular disorders, neurodegenerative disorders, HIV therapy, cardiovascular
disease and as anti-cancer and antibacterial agents.178
Benorylate (Figure 1.19) is an FDA-approved codrug that combines paracetamol and
aspirin via an ester linkage to produce a single, orally active dual-action analgesic.179
Sulfasalazine is a codrug of the anti-inflammatory agent 5-aminosalicylic acid and the
sulfa antibacterial sulfapyridine, which is used to treat rheumatoid arthritis and the
inflammatory bowel disorder Crohn’s disease.180,181 The codrug links the two agents via
an azo bond. Sultamicillin is an antibiotic codrug that links the two antibacterials
ampicillin and sulbactam via an acetal-type linkage. The codrug form shows excellent
absorption and decreased gastrointestinal side effects relative to the individual
compounds.182

Figure 1.19. Structure of codrugs benorylate, sulfasalazine and sultamicillin.
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1.7.2 Rational Design of a Hypoxia-Activated Anti-Tumour Codrug
Inspired by the 2-nitrophenylacetate prodrug chemistry described earlier, we conceived
a codrug structure 1, containing the components of angiogenesis inhibitor SU5416 and a
phenylenediamine-based nitrogen mustard (Figure 1.20). In this codrug, the benzylic
position of the 2-nitrophenylacetate triggering moiety is substituted by the alkenyl
pyrrole portion of SU5416. Attachment of the phenylenediamine mustard via an amide
bond should lower the nucleophilic character of the mustard nitrogen, thus preventing
aziridinium ion formation and non-selective DNA alkylation. The phenylenediamine
mustard proportion should also provide steric bulk that prevents angiogenesis inhibition
by the SU5416-like portion (i.e. prevents binding to RTK targets). Hypoxia-selective
bioreduction of the aryl nitro moiety to the aniline derivative should trigger a
spontaneous 5-membered cyclisation that simultaneously releases the angiogenesis
inhibitor SU5416 2 (as opposed to an oxindole “waste” fragment, see Figure 1.20) and
the phenylenediamine mustard. No longer deactivated by the amide bond, the p-amino
group of the mustard would feed electron density onto the mustard nitrogen to increase
its nucleophilicity and promote aziridinium ion formation and DNA alkylation.

Figure

1.20.

Putative

hypoxia-selective

activation

mechanism

of

SU5416-

phenylenediamine mustard codrug 1.
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The advantages of such an agent as an anticancer therapeutic are potentially striking.
Due to tumour-selective activation of the codrug, the gastrointestinal and other
toxicities of both the cytotoxin and angiogenesis inhibitor components could be
mitigated, allowing for higher and more efficacious dosages, imitating combination
therapy but without the associated side effects.

1.8 Thesis Aims
The central aim of the PhD thesis was to develop and optimise a synthetic route towards
codrug 1 and demonstrate chemical proof-of-concept showing that chemical reduction
of the NO2 group leads to formation of SU5416 and release of the cytotoxin. As detailed
in the following chapters, these aims were achieved and in the process several novel
discoveries were made.
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Chapter 2
Preliminary Synthetic and
Biological Studies
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2.1 Retrosynthetic Analysis
The concept of a self-immolative codrug like 1 raised a number of questions about its
chemical properties and synthesis. The compound is intended to be stable under
physiological conditions and to become reactive in vivo after triggering. Several issues
were envisioned around when and how to introduce the reactive phenylenediamine
mustard during the synthesis. As outlined in Chapter 1.4, mustards function via
intramolecular nucleophilic activation to form aziridinium ions, which alkylate DNA.
Preventing aziridinium formation was considered essential for the stability and
functioning of the prodrug and for personal safety during the synthesis. The presence of
an amide group para to the mustard nitrogen was expected to suppress activation by
reducing its nucleophilicity through electron withdrawal.170
Two synthetic routes were conceived towards 1 (Figure 2.1). The first (Route 1)
involved an early stage Knoevenagel condensation between ethyl-2-(2-nitrophenyl)
acetate 3 and pyrrole-2-carboxaldehyde 4 (or a protected derivative). Related
condensation chemistry is used in the synthesis of SU5416 and sunitinib from
oxindoles.183,184 Ester hydrolysis would yield the key acid intermediate (Z)-5, which
could be coupled to a suitably protected phenylenediamine mustard precursor 6 to
produce amide 7. Advancing 7 to 1 would proceed via alcohol deprotection and
chlorination (Route 1, Figure 2.1(a)). Alternatively, the amide linkage could be
installed earlier by coupling 2-nitrophenylacetic acid to the protected phenylenediamine
mustard precursor 6 to afford advanced amide intermediate 8. The alkene 7 would
subsequently be generated using a Knoevenagel condensation with 8 and pyrrole 4 (or a
protected derivative). Final alcohol deprotection and chlorination would deliver 1
(Route 2, Figure 2.1(b)).
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Route 1 was the preferred strategy as it was potentially more general, allowing a
multitude of anticancer cytotoxins to be easily appended to the late-stage acid
intermediate (Z)-5 via simple amide (or ester) couplings.
(a) Route 1

(b) Route 2

Figure 2.1. Retrosynthetic analysis for codrug 1.

2.2 Discovery of a Novel Knoevenagel Condensation
Prior to commencing my PhD studies, preliminary synthetic explorations in the Kelso
Lab had determined that a Knoevenagel condensation did not proceed directly between
ethyl-2-(2-nitrophenyl)

acetate

3

and

unprotected

3,5-dimethyl-1H-pyrrole-2-

carbaldehyde 4 under a variety of conditions. Failure of this reaction was attributed to
low reactivity of the aldehyde in 4. In order to increase electrophilicity of the aldehyde,
the pyrrole nitrogen of 4 was protected with various electron withdrawing carbamates.
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The tBu, Et and Me carbamates of 4 were synthesised (by other students) from the
requisite chloroformates and the potassium salt of 4 (generated via reaction of 4 with
KH in THF at 0 oC) in good yields. The N-Me carbamate 9 (Scheme 2.1) proved to be
effective in promoting the desired Knoevenagel condensation with ester 3. Use of
K2CO3 and 18-crown-6 as base in the presence of aldehyde 9 afforded the desired cis
(Z)-10 and trans (E)-10 isomers in 46% and 30% yields, respectively (Scheme 2.1).
Neither the Et nor tBu-protected pyrroles afforded the alkenes under these conditions.
The pyrrole N-carbamoyl group was fortuitously lost during the course of the reaction,
meaning that the product did not require a separate N-deprotection step.
This preliminary finding suggested Route 1 (Figure 2.1(a)) would be feasible, as ester
hydrolysis of (Z)-10 could provide the key carboxylic acid intermediate (Z)-5. The
result suggested that an analogous Knoevenagel condensation using an amide instead of
ester 3 might also be feasible, supporting exploration of Route 2 (if needed).

Scheme 2.1. Knoevenagel condensation developed earlier in the Kelso Lab.

Work by PhD student Pichit Sudta in the Kelso Lab showed that the carboxylic acid (Z)5 could be prepared using a 3-step sequence proceeding via allyl ester 12. Previous
efforts to produce (Z)-5 via ester hydrolysis of (Z)-10 (or the methyl ester) under acidic
and basic conditions had failed, with only isomerisation between (Z)-10 and (E)-10
observed. Allyl ester 12 was formed in good yields by nucleophilic allylation of 234

nitrophenylacetic acid 11 with allyl bromide and K2CO3 in acetone (74%), or via
H2SO4-catalysed esterification of 11 with allyl alcohol (88%).
The newly discovered Knoevenagel condensation was found to work well between allyl
ester 12, providing (Z)-13 and (E)-13 in 41% and 33% yields, respectively.
Deprotection of (Z)-13 with 10 mol% Pd(PPh3)4 in the presence of morpholine (allyl
cation scavenger) in THF provided (Z)-5 in 84% yield, with no alkene isomerisation. An
identical yield of (E)-5 was obtained via deallylation of (E)-12 under the same
conditions.

Scheme 2.2. Synthesis of key carboxylic acid intermediate (Z)-5. Reagents and
conditions: a. K2CO3, allyl bromide, acetone, rt, 74%. b. allyl alcohol, cat. H2SO4, rt,
88%. c. 9 (1.0 mol eq.), K2CO3, 18-crown-6, THF, 65 oC, 14 h; (Z)-13 41%, (E)-13
33%. d. 10 mol% Pd(PPh3)4, morpholine, THF; (Z)-5 84% from (Z)-13, (E)-5 84% from
(E)-13.

2.3 Conformation and Reactivity of Acid Intermediate 5
My attempts (during Honours) and attempts by other students in the Kelso Lab to
perform alcohol and amine couplings with carboxylic acid intermediates (Z)-5 and (E)-5
all failed to give the desired cis- and trans-ester/amide products. The reactions instead
produced the novel compound 5,7-dimethyl-2-(2-nitrophenyl)-3H-pyrrolizin-3-one) 14,
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arising through intramolecular cyclisation of the pyrrole nitrogen onto the activated
carbonyl group (Figure 2.2(a)). It was suspected that cyclisation was being promoted by
an intramolecular hydrogen bond between the pyrrole N-H of (Z)-5 and the carbonyl
oxygen. This H-bond could increase acidity of the pyrrole N-H and weaken the carbonyl
C=O bond and stabilise the tetrahedral transition state leading to intramolecular ring
closure under ester and amide coupling conditions.
As part of my PhD work, I repeated Pichit Sudta’s synthesis of (Z)-5 and was able to
grow a crystal of the compound suitable for X-ray analysis. I also converted a sample of
(Z)-5 to 5,7-dimethyl-2-(2-nitrophenyl)-3H-pyrrolizin-3-one 14 and obtained a crystal
of from Et2O. The X-ray structure of 14 was solved by Tony Willis (ANU) and is
shown in Figure 2.2(b). The structure showed that the 2-nitrophenyl ring was tilted
35.5o relative to the plane of the 3H-pyrrolizin-3-one ring and that the NO2 group was
positioned close to the carbonyl oxygen. The distance between the carbonyl oxygen and
the NO2 nitrogen was 2.8 Å. This close proximity suggests a favourable interaction
between the electronegative oxygen and electropositive NO2 nitrogen.
(a)
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(b)

(Z)-5

14

Figure 2.2. (a) Attempted syntheses of amide and ester derivatives of (Z)-5 using
standard coupling procedures resulted in formation of 3H-pyrrolizin-3-one 14 in good
yields (70-88%). (b) X-ray crystal structures of (Z)-5 and 14. Anisotropic displacement
ellipsoids show 30% probability levels. Hydrogen atoms are drawn as circles with small
radii. Crystallographic data are provided in Chapter 6.1.1. Appendices 1(a) and 1(b).

The X-ray structure of (Z)-5 confirmed the presence of the proposed H-bond stabilising
a pseudo 7-membered ring. Evidence for the H-bond was also observed in the
compound’s 1H NMR spectrum, where the pyrrole N-H signal for (Z)-5 appeared far
downfield at 11.87 ppm, whereas for (E)-5 it was observed at 6.78 ppm (in CDCl3).
These characteristic chemical shifts were also observed in the 1H NMR spectra of
derivatives of 5, as exemplified by allyl esters (Z)-13 and (E)-13, where the pyrrole N-H
appeared at 11.81 ppm and 6.75 ppm, respectively (Figure 2.3(a)). Single crystal X-ray
structures of (Z)-13 (previously obtained in the Kelso Lab) and (E)-13 (obtained during
my Honours) were solved by Tony Willis (ANU). These structures clearly showed the
intramolecular H-bond was present in (Z)-13 and absent in (E)-13 (Figure 2.3(b)).
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(a)

(b)

(Z)-13

(E)-13

Figure 2.3. (a) 1H NMR spectra highlighting the downfield chemical shifts of the
pyrrole N-H signal in (Z)-13 relative to (E)-13. (b) X-ray crystal structures of (Z)-13 and
(E)-13 (solved by Tony Willis, ANU). Anisotropic displacement ellipsoids show 30%
probability levels. Hydrogen atoms are drawn as circles with small radii.
Crystallographic data for (Z)-13 and (E)-13 are provided in Chapter 6.1.1. Appendices
1(c) and 1(d).
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Ester and amide couplings were also explored (by me, during Honours) with the transacid (E)-5. It was rationalised that (E)-5 might not be susceptible to intramolecular
cyclisation due to the unfavourable positioning of the pyrrole N-H trans to the
carboxylic acid moiety and because it lacked the activating H-bond. If the desired
couplings were found to proceed, it was envisaged that the trans products could be
converted to the requisite cis isomers through alkene isomerisation. Under most of the
couplings examined, however, the 3H-pyrrolizin-3-one 14 was again observed as the
major product, suggesting that isomerisation of (E)-5 to (Z)-5 was facile under the
reaction conditions investigated.

2.4 Indole-N-oxides 15 and 16
2.4.1 Discovery of 15 and 16
A notable change in the reactivity of trans acid (E)-5 was observed during attempted
couplings with HBTU and N,N-dimethyl-p-phenylenediamine (DMPD) in the absence
of bases (Figure 2.4(a)). Bases were deliberately excluded from reactions to reduce
base-promoted isomerisation of (E)-5 to (Z)-5 and subsequent 3H-pyrrolizin-3-one
formation. The reactions did not produce the expected trans-amide product or 3Hpyrrolizin-3-one 14, however, but instead formed a deep purple solid as the major
product. A crystal of the compound was obtained from Et2O/pet. spirit and submitted to
Tony Willis (ANU) for X-ray analysis. The structure was solved as (E)-2-(3,5-dimethyl1H-pyrrol-2-yl)-3-((4-(dimethylamino)phenyl)imino)-3H-indole 1-oxide 15 (Figure
2.4(b)). 1H and 13C NMR spectra (Chapter 6.2 Appendix 2) for 15 were consistent with
the structure determined by X-ray analysis.
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The reaction proceeded further to completion when p-phenylenediamine (PPD) was
used in place of DMPD, providing a higher isolated yield (56%) of the dark purple solid
16, (c.f. 40% 15 with DMPD).
(a)

(b)

Figure 2.4. (a) Synthesis of 15 and 16 from (E)-5, (b) X-ray crystal structure of 15
(solved by Tony Willis, ANU). Anisotropic displacement ellipsoids show 30%
probability levels. Hydrogen atoms are drawn as circles with small radii.
Crystallographic data for 15 are provided in Chapter 6.1.1. Appendix 1(e).
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2.4.2 Further Explorations with 15 and 16
Compound 16 was found to be unstable, producing two decomposition products soon
after purification by silica gel column chromatography. The two products were (1) an
intensely coloured violet solid and (2) PPD, suggesting that hydrolysis of 16 to the
novel violet ketone derivative 2-(3,5-dimethyl-1H-pyrrol-2-yl)-3-oxo-3H-indole 1oxide 17 (Figure 2.6(a)) had occurred. Acids (E)-5 and (Z)-5 were similarly observed to
decompose over time, forming the same violet solid 17 and a second red amorphous
solid which was characterised as the trans-alkene 18. The reaction was apparently
proceeding through a spontaneous decarboxylation followed by an electrocyclic
reaction of an intermediate allene ( Figure 2.5(a)).
NMR studies to monitor the spontaneous decompositions were performed by leaving
(Z)-5 in an NMR tube in CDCl3 over a period of two weeks (Figure 2.5(b)). The 1H
NMR spectra shown in Figure 2.5(b) showed that 18 forms spontaneously from (Z)-5.
Trace quantities of 17 were also observed, which could not be explained
mechanistically.
(a)
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(b)

Figure 2.5. (a) Proposed mechanism for decomposition of (Z)-5 to form 18 via allene
18a. (b) Aromatic region of 1H NMR spectra showing signals from the spontaneous
decarboxylation of (Z)-5 in CDCl3 (Top). 1H NMR spectra showing the equivalent
chemical shift regions for pure samples of (Z)-5, 17 and 18.

Attempts to deliberately hydrolyse 15 and 16 under acidic conditions (H2SO4 (cat.),
THF) led to quantitative formation of ketone 17 (Figure 2.6(a)). A single crystal X-ray
structure of 17 was solved by Tony Willis at ANU, confirming its structure (Figure
2.6(b)). 1H and 13C NMR, IR and HRMS were consistent with this structure. The imine
15 and ketone 17 shared similar UV-Vis spectra, with both showing absorption maxima
around 350 nm and a broad maximum at 583 and 563 nm, respectively (Figure 2.6(c)).
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The strong red-absorptions and intense violet colours were consistent with the extensive
conjugation and delocalisation in the structures.
(a)

(b)

(c)

17

15

Figure 2.6. (a) Synthesis of the ketone 17. Reagents and conditions: 1:1 1M HCl:THF,
quant. (b) X-ray crystal structure of 17 (solved by Tony Willis, ANU). Anisotropic
displacement ellipsoids show 30% probability levels. Hydrogen atoms are drawn as
circles with small radii. Crystallographic data for 15 are provided in Chapter 6.1.1.
Appendix 1(f). (c) UV-Vis spectra of imine 15 and ketone 17 in ethanol.
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2.4.3 Proposed Mechanism for Formation of 15 and 16.
Further synthetic studies were undertaken to probe the reaction mechanisms leading to
formation of 15 and 16. Firstly, it was found that cis- and trans-carboxylic acids (Z)-5
and (E)-5 both worked equally well in the reaction. Facile cis to trans isomerisation
promoted by electron donation from the pyrrole nitrogen into the carboxylic acid
carbonyl and NO2 groups would give the alkenic double bond significant single bond
character, allowing facile rotation and isomerisation.
Introduction of TEMPO into the reaction at 10% or 100% by weight (relative to 5) had
no effect on the yield of 15 or 16, suggesting that radicals were not involved in the
mechanisms. Compounds 15 and 16 were not observed when replacing (Z)-5 with
pyrrolizin-3-one 14 or amides such as (Z)-29 (see Table 2.1), eliminating these as
intermediates. Addition of catalytic diisopropylethylamine (DIPEA) to reactions with
HBTU, (Z)-5 and p-phenylenediamines DMPD or PPD resulted in formation of 3Hpyrrolizin-3-one 14 as the major product. Use of the carbodiimide coupling reagent
dicyclohexycarbodiimide (DCC) in base-free conditions yielded 14 as the only product.
The reaction proceeded more rapidly with additional mol eq. of HBTU or PPD. The
reaction also proceeded well with the closely related coupling reagent 1[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium

3-oxide

hexafluorophosphate) (HATU) and was indeed faster, completing in 30 min (c.f. 4 h
with HBTU). No reaction was observed between the acids (Z)-5 or (E)-5 and HBTU or
HATU in the absence of PPD or when PPD and the acids were combined in the absence
of HBTU or HATU. In CH2Cl2, a very slow reaction was observed when HATU and
PPD were added together, however. This reaction resulted in two new peaks at m/z 136
and 207 in the ESI+ mass spectrum. Monitoring this reaction by 1H NMR in d6-DMSO
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indicated formation of 2-(4-aminophenyl)-1,1,3,3-tetramethylguanidine 19 (Figure
2.7(a), MW = 206.29 g/mol). Its structure was subsequently confirmed by 2D NMR
analysis and HRMS. 3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (HOAt, MW = 136.11
g/mol) was also formed in a 1:1 stoichiometric ratio in the reaction. Reactions of this
type are supported by a literature precedent.185 Peaks at m/z 207 and 136 were also
observed in the ESI+ mass spectrum of the crude reaction mixtures that formed 15 or 16
using HBTU or HATU, suggesting that the guanidinium species 19 was being formed in
the reaction.
From a structural perspective, to form 16 from (E)-5, HATU and PPD, the alkenic βcarbon of (E)-5 must attach to the NO2 group’s nitrogen atom and PPD must attach one
of its nitrogen atoms to the α-carbon of (E)-5. This suggested that a pre-transformation
to a resonance-stabilised nitrenium ion of PPD might be occurring. One possible
mechanism for the formation of a nitrenium ion is shown in Figure 2.7(a). The oxygen
atom of a second molecule of HATU could act as a nucleophile that attacks the
guanidine carbon of protonated 19. Elimination of tetramethylurea (TMU) would give
the nitrenium derivative of PPD and reduced HATU. Peaks at 116 m/z (TMU) and 313
m/z (PPD-19 adduct) were suggestive of this transformation.
A mechanism for the formation of 16 from (E)-5, PPD and HATU is proposed in Figure
2.7 (b). Formation of 19 from reaction of HATU with PPD occurs in step 1, which is
followed by deprotonation of (E)-5 to form the carboxylate anion and the protonated
guanidininium form of 19 (step 2). Formation of the PPD+ nitrenium ion from 19 then
occurs. An allene species 18a is formed by decarboxylation of (E)-5 (See Chapter 2.4.2,
step 3). The nascent benzylic anion then attacks PPD+ (step 4). The resulting enamine
triggers an intramolecular cyclisation (step 5) to form 16-H2O. Hydrogen atom transfer
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followed by dehydration yield the final 16 (steps 6 and 7). While the mechanism is
consistent with the available data, further experiments are needed to confirm it.
(a)

(b)

Figure 2.7. Proposed mechanism of formation of (a) nitrenium ion PPD+ from reaction
of HATU with PPD and (b) 16 from reaction of (E)-5, PPD and HATU.
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2.5 Antiplasmodial Activity of 17
A literature search revealed that ketone 17 was a novel analogue of indolone-N-oxides
that have previously been shown to possess in vitro antibacterial, antifungal and
antiplasmodial activity.186–188 The broad antimicrobial properties of the class are
attributed to generation of reactive oxygen species, although antiplasmodial activity was
also attributed to a redox process in infected red blood cells (RBCs) that causes
destabilisation of cells and parasite death.186,187
Reported analogues contained various aryl and alkyl groups at the position occupied by
the 3,5-dimethylpyrrole in 17, along with substituents on 6-membered ring of the
indolone-N-oxide (Figure 2.8), synthesised using Sonogashira couplings between aryl
alkynes and 2-nitrophenyl halides to form 2-nitrophenylalkyne derivatives that cyclised
in situ.186,187 The most potent antiplasmodial was 2-(4-(dimethylamino)phenyl)-5methoxy-3-oxo-3H-indole 1-oxide 20.186,187 Compound 20 showed an IC50 of 1.7 nM
against the 3D7 strain of P. falciparum (African, chloroquine-sensitive strain) and IC50
< 3 nM against the FcB1 (chloroquine-resistant) strain. It also had good selectivity,
showing > 14,600-fold higher activity against the parasite than MCF-7 breast cancer
cells.

Figure 2.8. Reported indolone-N-oxides with antiplasmodial activity.186–188

Compound 17 was tested using the microdilution radioisotope technique against the K1
(multidrug resistant) strain of P. falciparum by collaborators at the National Center for
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Genetic Engineering and Biotechnology (BIOTEC) Thailand, where it returned an IC50
= 381 nM.189,190 Cytotoxicity of 17 against Vero cells was also determined using an
Alamar blue viability assay,191 where it showed CC50 = 58.4 μM, giving it a selectivity
index of 153. As it was less potent and selective than compound 20, and with literature
already published on the indolone-N-oxide series, further biological investigations with
17 were not undertaken.

2.6 Substrate Scope of the Knoevenagel Condensation
With the divergent approach (Route 1) towards codrug 1 (i.e. via the carboxylic acid
(Z)-5) no longer appearing feasible, attention was turned to Route 2, where the amide
bond is formed first followed by the Knoevenagel condensation. Pursuing Route 2
required confirmation that the Knoevenagel condensation could also be carried out with
amides as well as esters. Model amides 23 and 24 were prepared by coupling 2nitrophenylacetic acid to aniline and benzylamine in 95% and 94% yields, respectively,
using HBTU as the coupling reagent. Both amides underwent the desired condensation
with pyrrole aldehyde 9 to form the cis-alkenes (Z)-29 and (Z)-30 in 22% and 16%
yields, respectively, using the standard conditions that had been developed. The
analogous ethyl amide 22 and Knoevenagel product (Z)-28 were prepared in 2012 by a
Kelso Lab Honours student (Rhys Mitchell) in 21% yield.
It was noted that while the ester derivatives tended to form similar proportions of cis
and trans-alkene products, the amides formed mostly the cis isomer. For example, use
of ethyl ester 3 produced (Z)-10 and (E)-10 in 42% and 35% yields, respectively (Table
2.1, Entry 1). The methyl ester 21 produced (Z)-27 and (E)-27 in 36% and 40% yields
(Table 2.1, Entry 2), while allyl ester 12 produced (Z)-13 and (E)-13 in 41% and 31%
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yields, respectively (Table 2.1, Entry 3). In comparison, the ethylamide derivative 22
produced 21% of the cis product (Z)-28 and none of the trans isomer (E)-28 (Table 2.1,
Entry 4). Similarly, the aniline and benzylamine derivatives 23 and 24 produced (Z)-29
and (Z)-30 in 22% and 16% yields, respectively, and less than 5% of (E)-29 and (E)-30
were produced and neither could be isolated in pure form (Table 2.1, Entries 5 and 6).
Rhys was also successful in synthesising ethyl ester derivatives where the 2-nitrophenyl
moiety was replaced with phenyl or 2-chlorophenyl groups. The Knoevenagel
condensation in these cases required use of the much stronger base LDA. Interestingly,
the phenyl derivative 25 produced a 32% yield of the trans-phenyl analogue (E)-31 and
no cis-product (Z)-31 (Table 2.1, Entry 7). A 41% yield of the trans 2-chlorophenyl
product (E)-32 was obtained from 26 with only 5% of (Z)-32 being isolated (Table 2.1,
Entry 8). A summary of all compounds prepared via the Knoevenagel condensation is
provided in Table 2.1. Compounds re-synthesised by me during my PhD studies are
indicated with an *. Compounds I synthesised for the first time during my PhD studies
are indicated with a #. Full characterisation and experimental procedures are provided
for the latter only, along with their associated intermediates.
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Table 2.1. Summary of Knoevenagel condensations. Reagents and conditions: a.
K2CO3, 18-crown-6, THF, reflux, 16 h; b. LDA, THF, -78 oC, 30 min.

Phenylacetic

Reaction

Product,

Product,
yield %

Entry

esterB/amideC

R1

R2

Conditions

yield %

1

3

NO2

OEt

a

(Z)-10, 42*

(E)-10, 35*

2

21

NO2

OMe

a

(Z)-27, 36*

(E)-27, 40*

3

12

NO2

OAll

a

(Z)-13, 41*

(E)-13, 33*

4

22

NO2

NHEt

a

(Z)-28, 21

(E)-28, 0A

5

23

NO2

NHPh

a

(Z)-29, 22#

(E)-29, <5A,#

6

24

NO2

NHBn

a

(Z)-30, 16#

(E)-30, <5A,#

7

25

H

OEt

b

(Z)-31, 0

(E)-31, 32

8

26

Cl

OEt

b

(Z)-32, 5

(E)-32, 41

A

Compound could not be isolated in pure form
Esters 3, 21, 25-26 were synthesised by refluxing the phenylacetic acids in the requisite alcohol (as
solvent) with catalytic H2SO4.
C
Amides 22-24 were synthesised by coupling 2-nitrophenylacetic acid to the requisite amines using
standard amide coupling conditions (HBTU/DIPEA, CH2Cl2).
B

2.7 Anti-Angiogenic Properties of Alkene Products
When designing codrug 1, it was reasoned that the presence of the attached cytotoxin
should render the pro-angiogenesis inhibitor moiety (based on SU5416 2) inactive due
to the added steric bulk. Lack of the oxindole portion of SU5416 was also expected to
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ablate angiogenesis inhibition as all published SAR studies with SU5416, sunitinib and
related analogues retained this key moiety.134 These hypotheses were examined by
testing the antiangiogenic activity of the model cis and trans derivatives of 10, 13 and
27-32 obtained from the Knoevenagel condensations. The Et and Me esters (Z)-10 and
(Z)-27 had been shown to be angiogenesis inhibitors in preliminary experiments at the
start of my PhD studies but none of the other derivatives had been tested.
Compounds were examined using a rat aortic ring angiogenesis assay in the lab of Prof.
Chris Parish at the John Curtin School of Medicine (ANU) by a research assistant Anna
Bezos.192 In this model, 1 mm sections from female rat aortas are suspended in a fibrin
gel matrix and exposed to growth media. The aortic sections form new blood vessel
sprouts over 5 days, which are scored manually as the % field of view (F.O.V.)
occupied under a light microscope. Inhibitors of angiogenesis produce a quantifiable
reduction in the F.O.V. occupied by the sprouting blood vessels. Figure 2.9 provides a
summary of this assay.
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Figure 2.9. Summary of rat aortic ring angiogenesis inhibition assay performed by
Anna Bezos at the John Curtin School of Medicine (ANU).
Two positive controls PI-88 and SU5416 were included in the assays. PI-88 is a highly
sulfated oligosaccharide-based angiogenesis inhibitor that underwent Phase III clinical
trials as a treatment following cancer resection in patients with hepatitis virus-related
hepatocellular carcinoma.193 At 100 µg/mL, PI-88 reduced F.O.V. occupancy to 39.2%.
SU5416 (synthesised by me using the literature method)184 produced significantly
higher inhibition of angiogenesis at 10 µg/mL (F.O.V. occupancy 9.7%) than at 100
µg/mL (F.O.V. occupancy 30.6%), while 61.4% F.O.V. occupancy was observed at 1
µg/mL. Small crystals observed in wells containing 100 µg/mL SU5416 2 suggested
that the poor dose dependency may have been due to low solubility of the compound in
the assay medium.
Et and Me esters (Z)-10, (E)-10, (Z)-27, and (E)-27 were found to completely inhibit
angiogenesis at 100 µg/mL. At 10 µg/mL, (E)-10 continued to show complete
inhibition, whereas the other three esters all showed significantly diminished effects at
this concentration. At 1 µg/mL the four esters showed either minimal effects (< 20%
difference relative to negative control) or no activity. Surprisingly, the cis-allyl ester
(Z)-13 showed the same level of inhibition at both 100 and 10 µg/mL (F.O.V.
occupancy 28.3 and 29.3%, respectively) but no activity at 1 µg/mL. For the trans-allyl
ester (E)-13, strong activity was observed at 100 µg/mL (F.O.V. occupancy 8.3 %), but
this activity was completely ablated at 10 µg/mL. It was concluded that (E)-10 was the
most active angiogenesis inhibitor of the 2-nitrophenylacetic ester series.
The cis-ethylamide (Z)-28 showed reduced effects (F.O.V. occupancy 51.7% at 100
µg/mL, inactive at 10 µg/mL) relative to (Z)-10, confirming that directly substituting the
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ester group for an amide is detrimental to activity. Observing that phenyl and benzyl
amides (Z)-29 and (Z)-30 were inactive at 100 µg/mL supported this conclusion. These
results also implied that 1 should be a poor angiogenesis inhibitor because it also
incorporated an amide linkage.
Removal of the NO2 group from the phenyl ring was found to completely abolish
activity (i.e. (E)-31 v. (E)-10). Interestingly, replacing the NO2 group with Cl had no
effect on activity at 100 µg/mL, with both (E)-32 and (E)-32 completely inhibiting
angiogenesis. At 10 µg/mL, however, (E)-32 showed no activity. Results are
summarised in Figure 2.10.

Figure 2.10. Rat aortic ring angiogenesis inhibition assay. Inhibition of angiogenesis by
compounds 10, 13 and 27-32 relative to negative control (no compound) and positive
controls PI-88 (100 µg/mL) and SU5416 2. Negative control (no compound) showed
85.7% F.O.V. occupancy. Data represent the mean F.O.V. occupancy (%) generated
from at least six replicate cultures of each test compound at each concentration.

2.8 Optimisation of Knoevenagel Condensations with Aryl Amides
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The Knoevenagel condensation conditions used in the preparation of esters 10, 13 and
27 employed 1.0 mol eq. of 2-nitrophenylacetate ester, 1.5 mol eq. of K2CO3, 0.5 mol
eq. of 18-crown-6 and 1.0 mol eq. of pyrrole aldehyde 9. These reactions were typically
stirred for 12-16 hours at 65-75 oC in dry THF. Initial attempts using these conditions to
synthesise amides 29 and 30 revealed the need for scrupulously anhydrous conditions
and the importance of reaction times. Knoevenagel condensations to produce esters 10,
13 and 27 could be left heating beyond completion of the reaction and were not affected
by small changes in the reaction protocol. On the other hand, the amides produced
intractable mixtures without freshly prepared, scrupulously dried reactants, reagents and
solvents, and required strict adherence to the protocol with careful monitoring. The
reactions were low yielding and the trans products were generally unable to be isolated
in pure form (by column chromatography). Several coloured side products were also
formed that were not observed in the ester-based reactions, making purification by
column chromatography difficult. A study was undertaken to examine the side products
formed during the Knoevenagel condensation between pyrrole aldehyde 9 and anilide
23 to form (Z)-29. Importantly, this study aimed to identify conditions that could be
transferred to the synthesis of codrug 1 via Route 2 (Figure 2.1).
Parameters varied during the optimisation study included the solvent, base and reaction
times (Table 2.2). All reactions were carried out using 1.5 mol eq. of the indicated ovendried potassium salts (as base), 1.0 mol eq. of 2-(2-nitrophenyl)-N-phenylacetamide 23
and 1.0 mol eq. of 18-crown-6. Reactions were stirred at 65 oC in freshly distilled dry
solvent under a N2 atmosphere. After 1.0 hour, a solution containing 1.0 mol eq. of
aldehyde 9 in the same solvent was added dropwise to the stirred mixture under N2. The
reactions were monitored by TLC (8:2 pet. spirit:acetone) until complete consumption
of aldehyde 9 was observed. Reactions were then quenched by addition of water and the
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solvent removed under reduced pressure. The remaining aqueous mixture was extracted
with 50 mL of Et2O and washed with saturated NaHCO3 solution and brine. The organic
layers were combined and dried over MgSO4 and evaporated to dryness. The crude
residues were purified by column chromatography and the products isolated and
identified (where possible).
When performing column chromatography, a slow gradient from 100% pet. spirit to 8:2
pet. spirit:acetone (without pressure) yielded a fast eluting non-polar product 33.
Compound 33 was a yellow oil that showed m/z 315 by ESI-MS. After 7 h only trace 33
was isolated by column chromatography but its yield increased to 3% after 10 h and
15% after 14 h (Table 2.2, Entries 1-3).
The non-polar compound was characterised and unambiguously identified as the Nphenyl analogue of SU5416 33, apparently formed via intramolecular cyclisation of the
amide nitrogen onto the phenyl ring carbon bearing the nitro group and loss of HNO2
(Figure 2.11). While uncommon, intramolecular cyclisation of amides onto aryl nitro
groups has been reported in the literature.194,195 This was an interesting result as Naryloxindoles are typically made by transition-metal catalysed reactions between aryl
halides and the oxindole NH. While not examined here, exploration of this chemistry
might reveal a general method for preparing N-aryloxindoles. Based on this observation,
a corresponding product was predicted to form (confirmed, see Chapter 3.2.4) during
Knoevenagel condensations between 8 and 9 to produce 7 enroute to 1 via Route 2.

Figure 2.11. Postulated mechanism for the formation of 33 from (Z)-29.
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A second product identified in the reactions was the N-deprotected pyrrole aldehyde 4,
which was isolated in 9% yield after 7 h, 11% after 10 h and 28% after 14 h (Table 2.2,
Entries 1-3). Compound 4 presented problems during purification as it streaked on silica
gel columns and contaminated fractions containing the cis-product (Z)-29. Compound
(Z)-29 was obtained in 28% yield after 7 h and 38% after 10 h (Table 2.2, Entries 1-2).
After 14 h, (Z)-31 was difficult to separate from compound 4, providing only 22% of
pure material (Table 2.2, Entry 3). Remaining starting materials (i.e. pyrrole aldehyde 9
and amide 23) co-eluted from the column. The trans product (E)-29 eluted very slowly
from the column and it was difficult to separate from the streaking amide 23. The best
column chromatography protocol for purification of (Z)-29 and (E)-29 involved use of a
slow gradient from 100% pet.spirit to 8:2 pet. spirit:acetone without application of
pressure and over a period of 5 h.
Conditions for the synthesis of (Z)-29 and (E)-29 that enabled acceptable purification by
column chromatography involved using 1.0 mol eq. of 23 and 9, 1.5 mol eq. of K2CO3
and 1.0 mol eq. of 18-crown-6, with THF as solvent and a reaction time of 10 h at 65 oC
(Table 2.2, Entry 2). Use of K3PO4 and KOtBu as bases (Table 2.2, Entries 9 and 11)
increased the rate of decarbamoylation of 9 to 4 (39% and 48% with K3PO4 and KOtBu,
respectively). Yields of (Z)-29 and (E)-29 were also reduced to 18% and 7%,
respectively, with K3PO4. No yield of (Z)-29 or (E)-29 was obtained with KOtBu.
Yields of N-phenyl SU5416 33 increased from 3% with K2CO3 to 5% with K3PO4 and
31% with KOtBu, suggesting that stronger bases assist its formation.
Alternative solvents were examined. Et2O (Table 2.2, Entry 5) produced similar yields
with 34% of (Z)-29 formed (c.f. 38% in THF) and 29% of (E)-29 (c.f. 26% in THF). A
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20% yield of N-deprotected pyrrole aldehyde 4 was also produced (c.f. 3% in THF).
CH2Cl2 (Table 2.2, Entry 4) resulted in lower yields of the products (18% yield of (Z)29 and 10% of (E)-29) as did iPr2O (25% (Z)-29, 19% (E)-29. Table 2.2, Entry 8).
t

BuOMe produced slightly lower yields compared to THF, (37% and 20% yields of (Z)-

29 and (E)-29, respectively), although the yield of 33 was increased to 40% (Table 2.2,
Entry 7). Surprisingly, use of 1,4-dioxane failed to produce any (Z)-29 or (E)-29 (Table
2.2, Entry 6).

Table 2.2. Optimisation of Knoevenagel condensation to produce (Z)-29, (E)-29 and 33.
Reagents and conditions: a. base, 18-crown-6, solvent, reflux.

Yield %
Entry

Base

Solvent

Time (h)

(Z)-29

(E)-29

4

33

1

K2CO3

THF

7

28

14

9

<1

2

K2CO3

THF

10

38

26

11

3

3

K2CO3

THF

14

22

< 5*

28

15

4

K2CO3

CH2Cl2

10

18

10

32

5

5

K2CO3

Et2O

10

34

29

20

3

6

K2CO3

1,4-Dioxane

10

7

K2CO3

8

K2CO3

9

K3PO4

10

K3PO4

t

BuOMe

10

37

20

2

40

Pr2O

10

25

19

26

10

THF

10

18

7

39

5

BuOMe

10

12

10

20

10

i

t

NO REACTION

57

11

KOtBu

THF

10

0

0

48

31

*Could not be isolated in pure form.
# Reactions were carried out by dissolving 0.2 g of 23 in 10 mL of dry solvent in a three-neck
roundbottom flask along with 1.5 mol eq. of base and 1.0 mol eq. of 18-crown-6. Reactions were stirred
at reflux for 1 h before adding 1.0 mol eq. of 9 in 3 mL of dry solvent dropwise under N 2 and stirring at
reflux.

2.9 Summary and Future Directions
Work in this chapter showed that Route 2 (Figure 2.1) showed promise as a way of
accessing codrug 1 due to the successful Knoevenagel condensation between 2-(2nitrophenyl)acetanilide 23 and pyrrole aldehyde 9. Failure of the key acid intermediate
(Z)-5 to undergo ester and amide couplings ruled out further investigation of Route 1. A
new class of angiogenesis inhibitors was produced using the novel Knoevenagel
chemistry and several highly coloured reaction products were isolated and structurally
characterised. These products had characteristic colours and it was thought that this
feature might facilitate identification of more complicated byproducts produced when
the reaction was attempted during the synthesis of 1 (Figure 2.12).

Figure 2.12. Coloured compounds synthesised in this Chapter.
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Indole-N-oxides 15-18 were deep purple to violet in colour, whereas oxindoles 2 and 33
were yellow solids. Cyclisation to the 3H-pyrrolizin-3-one 14 produced a deep red
crystalline solid, while the target α,β-unsaturated amide (Z)-29 and ester (Z)-10 were
bright orange-red solids. Placing a hydrogen or chloride atom at the ortho position in
place of the NO2 group (i.e. (E)-32 and (Z)-32), led to solids with a pale yellow colour.
These transformations were all accompanied by characteristic shifts in polarity by TLC
analysis and diagnostic changes in 1H and 13C NMR spectra.
The scope and utility of these reactions could be explored in the future. For example, if
successfully translated into a more general scheme, the synthesis of oxindoles such as
33 from 2-nitrophenylacetate derivatives would appear to be a more substituent-neutral
reaction compared to the typical Fischer indole synthesis with late-stage decoration.
This reaction would allow early substitution at the usually unreactive 5- and 6-positions
as well as alkyl or aryl substituents at the nitrogen which would typically require strong
base and unfavourable N-alkylation or transition-metal catalysis.
Exploration of the indole-N-oxide forming reactions (Chapter 2.4) to produce other
intensely coloured products like 15 and 16 could be quite interesting. While 17 proved
to be only a moderate antiplasmodial, the synthetic pathway to this indolone-N-oxide
was novel. A three-step sequence from 2-nitrophenylacetic acid using a Perkin reaction
followed by decarboxylative cyclisation (Chapter 2.4) and hydrolysis of the imine might
provide indolone-N-oxides that are difficult to synthesise by other methods (Figure
2.13).

Figure 2.13. Proposed sequence to indolone-N-oxides from 2-nitrophenylacetic acid.
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The reaction mechanism described in Chapter 2.4.3 presented much novel chemistry,
although the mechanism was not unambiguously confirmed in this Thesis. Further
confirmation of the mechanism could be obtained by trapping the nitrenium ion PPD+
or guanidine 19 with nucleophiles. Trapping of the 2-(2-nitrophenyl)-allene species with
other electrophiles might also be informative. The trans-alkene 18 resulting from
spontaneous decarboxylation of 5 may also provide similar reactivity in the presence of
strong base. The utility of the novel 3H-pyrrolizin-3-one class of compounds,
exemplified here by compound 14, was examined in detail in Chapter 4.
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Chapter 3
Synthesis of Codrug 1
and Proof-of-Concept Reduction
Reactions
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3.1 Strategy (a)
Work in Chapter 2 identified Route 2 as a promising way to access codrug 1 following
confirmation of a successful Knoevenagel reaction between 2-(2-nitrophenyl)acetanilide
23 and N-protected pyrrole aldehyde 9 to produce (Z)-29. Route 2 required preparation
of a suitably O-protected amide intermediate 8, which could undergo the Knoevenagel
reaction with pyrrole aldehyde 9. Two strategies towards 8 were considered (Scheme
3.1). In Strategy (a), the diethanolamine 35 (or its acid salt) could be prepared and then
coupled with 2-nitrophenylacetic acid to give 34. Protection of the alcohols could be
performed before or after amide formation giving 8. Strategy (b) would start by
coupling p-phenylenediamine to 2-nitrophenylacetic acid to give amide 36. Bis-Nalkylation of 36 with a 2-haloethanol would give 34 and after o-protection intermediate
8.

Scheme 3.1. Retrosynthetic analysis for key amide intermediate 8.

Strategy (a) was preferred for several reasons. Firstly, synthesis of intermediate 35 had
been previously described in the literature.196 Secondly, the diethanolamine moiety
could be introduced using reliable nucleophilic aromatic substitution chemistry (i.e.
using 1-fluoro-4-nitrobenzene, thus avoiding the aryl amine bis-alkylation reaction
required in Strategy (b). These reactions are often complicated by inefficient formation
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of mixtures of primary, secondary and tertiary amines as well as quaternary ammonium
salts which are difficult to separate.
In pursuing strategy (a), the first step involved forming the p-nitro-bis-ethanolamine
derivative 37 (Scheme 3.2). 1-Fluoro-4-nitrobenzene was reacted with freshly distilled
diethanolamine in DMSO at reflux, as per Ferlin et al.196 The high aqueous solubility of
the product 37 made isolation from DMSO very difficult. The reaction was
subsequently repeated neat to avoid this complication, which resulted in a 77% yield of
the desired yellow solid after recrystallisation from MeOH/H2O (Lit. 96%).196
According to Ferlin et al., the free base form of N,N-bis-ethanolamino-pphenylenediamine 35 can be isolated in EtOAc after SnCl2.2H2O-mediated NO2
reduction with careful pH control.196 While conversion of 37 to 35 appeared to be
complete (monitored by TLC, 100% EtOAc), only a small amount of 35 was obtained
in the EtOAc extract, even with careful pH monitoring. The small quantity of free base
35 obtained quickly decomposed into a black tar. The same article suggested that the
more stable HCl salt could be obtained by addition of methanolic HCl to the free base,
followed by evaporation. It was found, however, that the acid salt of 35 also degraded
quickly and could not be obtained in useful quantities.
These challenges triggered investigations into an alternative procedure, where the NO2
to NH2 reduction was performed with H2/Pd/C in order to simplify the workup. The
reduction of 37 was carried out in methanol until TLC showed consumption of starting
material. The mixture was then filtered through celite and concentrated in vacuo. The
residue was redissolved in CH2Cl2 and immediately added to a solution of 2nitrophenylacetic acid in CH2Cl2, which had been pre-activated to the HOBt ester with
HBTU and DIPEA. This procedure failed to yield any of the desired amide 34.
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The H2/Pd reduction was repeated in DMF and again went to completion. The mixture
was filtered through celite directly into a pre-activated solution of the 2nitrophenylacetic acid HOBt ester in DMF. This reaction also failed to yield any of the
amide, suggesting that the phenylenediamine derivative was either insufficiently
nucleophilic or was decomposing too rapidly to undergo amide coupling.
In an attempt to increase stability, 37 was bis-O-TBDMS-protected using standard
literature conditions to produce derivative 38 in 72% yield (Lit. 95%).197 The reduction
reactions described above were each repeated with 38 in attempts to synthesise the
TBDMS-protected amide 8 via amine 39. While the reduction reactions with 38
appeared by TLC to produce 39, subsequent coupling reactions using HBTU as the
coupling reagent failed to yield any 8. Additional attempts with 2-nitrophenylacyl
chloride were similarly unsuccessful. At this point Strategy (a) was abandoned.

Scheme 3.2. Unsuccessful synthesis of key amide intermediate 8 using Strategy (a).
Reagents and conditions: a. neat, reflux, 77%;196 b. TBDMSCl, imidazole, CH2Cl2,
72%.197

3.2 Strategy (b)
3.2.1 Formation of amide 36
Difficulties encountered with Strategy (a) shifted the focus towards Strategy (b). The
first step of this approach involved coupling 2-nitrophenylacetic acid to pphenylenediamine. This previously unreported reaction was attempted under standard
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HBTU/DIPEA coupling conditions at room temperature in CH2Cl2. Several gram scale
reactions were completed where the mol eq. of various reactants/reagents were modified
(Table 3.1). The highest yield of 36 (75%) was obtained with 1.0 mol eq. 2nitrophenylacetic

acid,

1.1

mole

eq.

of

freshly

recrystallised

(EtOH)

p-

phenylenediamine, 1.1 mol eq. HBTU and 2.2 mol eq. DIPEA (Table 3.1, Entry 1).
Increased equivalents of p-phenylenediamine reduced the yield of 36.

Table 3.1. Optimisation of 2-nitrophenylacetic acid couplings with PPD to form 36.

PPD

HBTU

DIPEA

g, mol eq.

g, mol eq.

mL, mol eq.

5.07

3.33, 1.1

11.69, 1.1

10.7, 2.2

75

2

5.01

4.07, 1.4

10.60, 1.0

15.1, 3.1

67

3

3.97

5.11, 2.1

8.75, 1.1

9.2, 2.4

43

4

0.90

1.63, 3.0

2.11, 1.1

2.8, 3.2

40

5

0.20

0.48, 4.0

0.46, 1.1

0.5, 2.6

39

Entry

acid, g

1

36, %

3.2.2 Bis-N-alkylation of 36
The next step in Strategy (b) involved formation of the diethanolamine derivative 34,
which required bis-N-alkylation of 36 with 2 eq. of a 2-haloethanol. K2CO3 was used as
the base and 2-bromoethanol as both reagent and solvent. Test reactions were performed
on a 20 mg scale under a variety of conditions (Table 3.2) with the highest yield being
67%. The reaction conditions were then increased to multigram scale where similar
yields were obtained (Table 3.2 Entries 2 and 2a). The reactions generally required 4
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days at 50 oC to consume the starting material. Temperatures above 50 oC resulted in
intractable mixtures. Addition of 2-butanone as a co-solvent reduced the yield to 25%
and resulted in the formation of a black sludge. Switching to 2-chloroethanol and
addition of catalytic NaI (in situ iodination, i.e. Finkelstein reaction) failed to improve
the yield (Table 3.2, Entries 3,4 and 7).

Table 3.2. Optimisation of bis-alkylation reaction conditions to produce 34.

2-haloethanol

34

Entry

36, g

X, mL

Base, g

Additive

Solvent

yield, %

1

0.02

Br, 1.0

-

-

Neat

NR

2

0.02

Br, 1.0

K2CO3, 0.03

-

Neat

67

2a

1.90

Br, 15

K2CO3, 1.75

-

Neat

67

3

0.02

Br, 1.0

K2CO3, 0.03

NaI

Neat

53

4

0.02

Cl, 1.0

K2CO3, 0.03

NaI

Neat

4

5

0.02

Br, 1.0

-

-

2-butanone

NR

6

0.02

Br, 1.0

K2CO3, 0.03

-

2-butanone

25*

7

0.02

Br, 1.0

K2CO3, 0.04

NaI

2-butanone

21*

*Starting material was not completely consumed.

Amide 34 was subjected to the Knoevenagel reaction with aldehyde 9 under the
optimised conditions (Chapter 2.8) but none of the desired alkene product (Z)-7 was
formed. It was observed that 9 underwent substantial N-deprotection to 4 during the
reaction, suggesting that the nucleophilic diethanolamine hydroxyl groups might be
causing problems.
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3.2.3 Bis-silyl protection of 34
Two protecting groups were considered for the hydroxyl groups of 34. Acetyl protection
was investigated first, with bis-acetylation being achieved using acetic anhydride in
pyridine. While the protection reaction was successful (72% yield), the subsequent
Knoevenagel condensation with the bis-acetyl-protected diol was unsuccessful,
producing only intractable mixtures containing many coloured products.
Bis-silylation of 34 with TBDMSCl to form 8 was examined next. Standard conditions
using imidazole as a nucleophilic base/catalyst were explored in both DMF and CH2Cl2.
Faster and more complete reactions were observed in CH2Cl2 (2 h, 86% yield c.f. 6 h,
72% yield in DMF). The reaction was successfully scaled up, with an 85% yield of 8
from 5 g of starting material 34.

Table 3.3. Bis-silyl protection of 34 with TBDMSCl to form 8.

TBDMSCl

Imidazole

8

Entry

34, g

g, mol eq.

g, mol eq.

Solvent

Time, h

yield, %

1

5.00

7.50, 3.6

8.10, 8.6

CH2Cl2

2.0

85

2

1.40

2.05, 3.5

2.34, 8.8

CH2Cl2

2.0

86

3

0.03

0.05, 4.0

0.06, 10.6

DMF

6.0

72
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3.2.4 Knoevenagel Condensations with 8
With the efficient formation of TBDMS-protected amide 8 established on multigram
scale, attention was next turned to the Knoevenagel condensation reaction between 8
and pyrrole aldehyde 9. Solvents, bases, reaction times and techniques that had been
tested previously on the aniline derivative 23 (Chapter 2.8) were used to guide the
choice of conditions to explore. Several different reactions were examined but the
standard conditions that had been previously optimised using K2CO3, 18-crown-6 in
THF at 65 oC, and with the pyrrole aldehyde 9 added last after the reaction had reached
65 oC, were again found to be the best for this Knoevenagel reaction. The highest yields
obtained of (Z)-7 and (E)-7 were 41% and 22%, respectively (Table 3.4, Entry 5).
The condensation reaction had to be carefully monitored as with the aniline amide 23
(See Chapter 2.6). N-aryloxindole 41 was formed as predicted, but stopping the reaction
after 12 h limited its production such that it could only be isolated in trace amounts.

Table 3.4. Optimisation of Knoevenagel reaction to produce (Z)-7 and (E)-7 from 8.

9

K2CO3

18-Crown-6

Time,

(Z)-7, (E)-7

Entry

8, g

g, mol eq.

g, mol eq.

g, mol eq.

h

yield, %

1

1.13

0.35, 1.0

0.40, 1.5

0.53, 1.0

16

20, 10

2

2.00

0.60, 1.0

0.94, 2.0

0.97, 1.1

14

33, 28

3

2.98

1.10, 1.2

1.39, 2.0

1.01, 0.8

14

20, 11

4

1.00

0.36, 1.2

0.46, 2.0

0.35, 0.8

11

20, 17
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5

1.15

0.47, 1.3

0.37, 1.35

0.67, 1.3

12

41, 22

6

1.08

0.57, 1.7

0.88, 3.5

0.64, 1.3

12

16, 15

7

0.77

0.23, 1.0

0.29, 1.6

0.42, 1.2

12

28, 20

8

0.41

0.22, 1.7

0.29, 3.0

0.39, 2.1

12

15, 10

3.2.5 Isomerisation Reactions with (E)-7
A series of isomerisation reactions were investigated with (E)-7 in an attempt to
increase the yield of (Z)-7 but encouraging results were not obtained. The trans-alkene
(E)-7 could be partially isomerised using catalytic H2SO4 in THF, producing a 19%
yield of the desired (Z)-7 with 62% recovery of (E)-7. Base-promoted isomerisation
using TEA or DIPEA was not successful, instead producing the oxindole derivative 41
as the major product.

3.2.6 Desilylation of (Z)-7
The next step in the synthesis of 1 involved deprotection of the two TBS ethers of (Z)-7.
Desilylation reactions are often carried out using TBAF, a fluoride source that is soluble
in organic solvents. Initial attempts using TBAF in THF at room temperature or at 0 oC
were unsuccessful, resulting in mixtures of coloured products and decomposed starting
material. It was suspected that the basicity of the fluoride ions might be causing
problems.
Glacial acetic acid (1:5 v/v) was subsequently added to the TBAF/THF solutions to
buffer the fluoride ion. These conditions resulted in clean conversions at room
temperature to the bis-ethanolamine product (Z)-42 in 85% yield after column
chromatography. The reaction produced consistent results up to 0.5 g scale.
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Scheme 3.3. Desilylation of (Z)-7 afforded (Z)-42 in 85% yield.

3.2.7 Bis-Chlorination of (Z)-42 to Produce Target Codrug (Z)-1
Several alternative groups could be considered for inclusion in the mustard arms of the
codrug (Z)-1. Literature examples include use of chlorides, bromides or mesylates as
leaving groups, or combinations of these. For example, evofosfamide utilises a
bromophosphoramidite mustard,171 busulfan a dimesyl mustard198 and chlorambucil a
dichloro mustard.53
A two-step process involving mesylation followed by halogen displacement was
pursued in the first instance. Mesylation was achieved under standard conditions (MsCl,
TEA in CH2Cl2), affording 86% isolated yield of the dimesyl product (Z)-43 (500 mg
scale). The compound proved to be unstable, however, and underwent polymerisation to
a black tar, even when dried and stored at -20 oC under Ar. In subsequent halogenations
attempts, mesylation reactions were quickly diluted in CH2Cl2 after completion, washed
with saturated NaHCO3 and brine and evaporated to dryness. The crude product was
purified on a short (~7 cm) silica gel column using EtOAc as eluent and the freshly
prepared bis-mesylate was dried under vacuum before being taken up in minimal DMF
and treated with an excess of LiCl or LiBr. The reactions were stirred at 75 oC until the
starting material was consumed (as observed by TLC analysis, 1:1 EtOAc:pet. spirit)
and the product purified by column chromatography.
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When halogenation reactions were performed on (Z)-43 with lithium bromide, the
desired dibrominated product was not detected. Using LiCl in DMF, however, the target
compound (Z)-1 was formed in 92% yield. Gratifyingly, it proved to be an air stable
compound at room temperature. (E)-1 was also isolated from the chlorination reactions,
although it proved to be less stable than (Z)-1. Both (Z)-1 and (E)-1 were able to be
fully characterised. A summary of the halogenation results is shown in Scheme 3.4.

Scheme 3.4. Two-step procedure for the formation of (Z)-1 from (Z)-42 via mesylation
followed by chlorination. Reagents and conditions: a. MsCl, TEA, CH2Cl2, 86%; b.
LiCl (excess), DMF, 75 oC, 92%.

3.3 Proof-of-Concept Reduction Reactions
For the codrug (Z)-1 to provide dual-action tumour killing in vivo it is necessary for the
nitro group to spontaneously cyclise onto the amide carbonyl following bioreduction to
the aniline, releasing SU5416 2 and the phenylenediamine mustard (Figure 1.20). To
probe this process, chemical reductions of the nitro group were investigated under three
different conditions, including: (a) 10.0 mol eq. Fe0 in 2:3:2 glacial acetic
acid:EtOH:water with ultrasonication,199 (b) 3.0 mol eq. FeCl3.6H2O with 10.0 mol eq.
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Zn in 1:1 DMF:water,200 and (c) 2.0 mol eq. NaBH4 with 10% w/w Pd/C in 2:1
MeOH:water.

201

These reactions were chosen for their mild conditions and because

they were tolerant of alkenes, esters and amides.
If the proof-of-concept reductions were successful, nitro reduction to the amine (or
hydroxylamine) would need to occur and be followed by spontaneous cyclisation,
yielding SU5416 2 (or N-hydroxy-SU5416 2-OH), which is also a potent inhibitor of
VEGFR-2.202 The reactions were monitored by TLC analysis and quenched
immediately after the starting material had been consumed by filtering the reactions
through celite. Reactions were conducted on 20 mg scale and the isolated yields of both
2 and 2-OH were determined after purification by column chromatography. Yields of
the phenylenediamine mustard were not obtained due to the compound’s instability.
Ethyl ester (Z)-10 was investigated as a model substrate for the reduction reactions by
Pichit Sudta earlier in the Kelso Lab. 2 was identified as the major product under each
of the three conditions. Fe0 reduction yielded 81% of 2, FeCl3/Zn reduction produced
70% of 2, along with 21% of 2-OH, while NaBH4 / Pd/C produced 72% of 2 and no 2OH (Figure 3.1).
Reductions were also investigated with the anilide derivative (Z)-29, which contained
an aryl amide moiety like (Z)-1 (reactions were performed by me as part of my PhD).
Under the three reduction conditions, (Z)-29 formed the desired cyclised products,
although the ratios of 2 and 2-OH were different to those observed with (Z)-10. Fe0
reduction yielded 32% of 2 and 35% of 2-OH, FeCl3/Zn reduction produced 58% of 2
and 15% of 2-OH, while NaBH4 / Pd/C produced 20% yield of 2 and 56% of 2-OH
(Figure 3.1). Overall, the yield of cyclised products was similar to (Z)-10, but the
proportion of 2-OH formed was generally higher.
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After results with (Z)-29 confirmed that spontaneous cyclisation could occur for aryl
amides, the same reduction reactions were conducted with (Z)-1. Excitingly, all three
reactions produced the desired cyclised SU5416 products, with the Fe0 reaction yielding
51% of 2 and 28% of 2-OH, the FeCl3/Zn reduction 50% of 2 and 24% of 2-OH, with
NaBH4 / Pd/C 59% of 2 was obtained along with 21% of 2-OH (Figure 3.1, (Z)-1).
These successful reductive cyclisations with (Z)-1 provided chemical proof-of-concept
for the potential dual-activity of the compound in vivo, supporting further investigations
of its biological activity as a hypoxia-activated tumour-targeted codrug.
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Figure 3.1. Summary of proof-of-concept chemical reduction reactions carried out with
(Z)-10, (Z)-29 and (Z)-1. Isolated yields of SU5416 cyclised products 2 and 2-OH are
shown. Reduction conditions: a. Fe/CH3COOH (blue), b. Zn/FeCl3 (red), c. PdC/NaBH4 (green).

3.4 Conclusions and Future Directions
Work in this Chapter led to the successful synthesis of a prototype anti-tumour hypoxiaactivated codrug (Z)-1. A summary of the successful synthesis is provided in Scheme
3.5. Overall, the route developed is satisfactory for producing useful quantities of (Z)-1,
where the overall yield of 12% would be expected to give ~3 g of pure (Z)-1 over 7
steps from 10 g of 2-nitrophenylacetic acid.
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While the yields of steps (a) and (b) were moderate (71% and 70%, respectively), they
were consistent on a multigram scale and the reactions were operationally simple.
Recrystallisation from EtOH was successful for both 36 and 34 and no further
purification was required. The aryl amine alkylation (b) was one shortcoming in the
synthesis, taking at least 4 days to complete. Each of the other 6 steps was completed in
less than 15 hours. Alternative reaction conditions, such as use of microwave heating,
use of other sources of ethanolamine such as oxirane203 or ethylene carbonate204 or the
use of a Buchwald-Hartwig aryl cross coupling reaction205 to produce the key aryl
amine moiety from a p-halo derivative of amide (Z)-29 could be explored. TBDMS
protection in Step (c) was a facile reaction, with recrystallisation from pet. spirit
yielding 86% of pure 8 after only 2.0 hours.
The Knoevenagel reaction (d) was the lowest yielding step, producing 41% of (Z)-7
when performed on 0.5 g scale. Unfortunately, isomerisation of pure (E)-7 to (Z)-7 was
not high yielding, although further explorations are certainly recommended. (Z)-7 was
also difficult to purify, requiring careful column chromatography to isolate it from the
many streaking reactants and side products. Forming the alkene earlier in the synthesis
using Route 1 would have been preferred, but problems with the acid (Z)-5 precluded
this. New chemistry, which forms a higher yield of the desired isomer (Z)-7 from 8
would improve the final yield of (Z)-1 significantly.
Steps (e) to (g) all proceeded well, providing 67% yield of pure (Z)-1 over 3 steps from
(Z)-7 with little isomerisation. Gratifyingly, (Z)-1 was an air stable solid at room
temperature. While column chromatography steps were utilised here after each step
simple extractions may be sufficient to advance the material through before a final
chromatography step on (Z)-1.
75

Scheme 3.5. Summary of the successful synthesis of (Z)-1. Reagents and conditions; a.
p-phenylenediamine, HBTU, DIPEA, CH2Cl2, rt, 4 h, 71%; b. 2-bromoethanol, K2CO3,
50 oC, 5 days, 70%; c. TBDMSCl, imidazole, CH2Cl2, rt, 2 h, 86%; d. 9, K2CO3, 18crown-6, THF, 65 oC, 12 h, (Z)-7 41%, [+ (E)-7 22%]; e. 5:1 1.0M TBAF (in
THF):AcOH, 0 oC to rt, 4 h, 85%; f. MsCl, TEA, CH2Cl2, 0 oC to rt, 1 h, 86%; g. LiCl
(excess), DMF, 75 oC, (Z)-1 92%.

(Z)-1 was shown to produce SU5416 2 and N-hydroxy-SU5416 2-OH upon chemical
reduction under standard aryl nitro reduction conditions. This was a key milestone in
developing (Z)-1 as it supports proof-of-concept for the dual-action scaffold. This
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success suggests that (Z)-1 has potential for hypoxia-selective activation in vivo and
these investigations are the logical next step. The development of evofosfamide
provides a blueprint of experiments for further study here.167,171 The first experiments
on (Z)-1 should confirm selective activation in cell culture by hypoxic tumour cells. A
simple protocol would be to perform two cell viability studies with (Z)-1 present, one
under normoxic conditions and another with initial incubation under a low
concentration of O2 to activate the scaffold.171 Hypoxia-selectivity could be further
quantified by performing these studies with increasing O2 gas concentration, which
should lower activation of (Z)-1.167 These experiments would give a hypoxic-cell
selectivity index which could be used to guide further studies on the scaffold.
Other experiments on (Z)-1 would explore its metabolic and plasma stability. These
properties could easily be determined with commercially available human/mouse liver
microsomes (hLM/mLM) and standard plasma stability assays. Metabolites identified
could be used to guide modifications to the structure of (Z)-1 to reduce metabolism.
Extensive SAR obtained during the development of sunitinib would provide guidance
for predicting the effects of modifications to the aryl NO2 portion of (Z)-1.206,207
The compound could also be modified to incorporate alternative alcohol or amine
containing cytotoxins via ester or amide linkages. The Kelso Lab is currently targeting
codrug 45, incorporating the antimetabolite 5-fluorodeoxyuridine (Floxuridine) as a
cytotoxin, linked via a primary alcohol (Figure 3.2).
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Figure 3.2. Structure of codrug 45 currently being pursued in the Kelso Lab.
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Chapter 4
Synthesis and Evaluation of 2-Aryl-3HPyrrolizin-3-ones as Angiogenesis
Inhibitors
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4.1 Introduction
3H-Pyrrolizin-3-one 14 was the major product formed during attempted coupling
reactions between (Z)-5 or (E)-5 and several amines and alcohols (Chapter 2.3).
Couplings with HBTU/HATU and DIPEA, DCC/EDCI with or without DMAP in a
variety of solvents all produced 14 and failed to yield any of the coupled amides/esters.
It was proposed that heightened acidity of the pyrrole N-H, arising from its
intramolecular H-bond to the carbonyl oxygen, was promoting deprotonation in the
presence of DIPEA or carbodiimide coupling reagents and the resulting pyrrolate anion
was cyclising onto the activated acid (Chapter 2.3; Figure 4.1(a)). Electron donation
from the pyrrole nitrogen into the electron withdrawing 2-nitrophenyl and carboxylate
moieties could increase single bond character of the alkenic double bond of (E)-5,
promoting bond rotation and isomerisation from (E)-5 to (Z)-5, thus facilitating its
transformation to 14 under coupling conditions (Chapter 2.4.2; Figure 4.1(b)). Trace
quantities of 14 were usually observed during Knoevenagel condensations of 2nitrophenylacetate allyl ester 12 with pyrrole aldehyde 9 (Chapter 2.2).
(a)

80

(b)

Figure 4.1. (a) Mechanism of formation of 3H-pyrrolizin-3-one 14 from (Z)-5 under
amide/ester coupling conditions. (b) Explanation for facile isomerisation of (E)-5 to (Z)5, which allowed formation of 14 from (E)-5.

Few 3H-pyrrolizin-3-ones have been described in the literature and there is little known
about their chemistry or biological activity. A SciFinder Scholar structure search on the
3H-pyrrolizin-3-one core returned 277 references (11/06/15). Many of these described
tricyclic pyrrolo-indolones, pyrrolo-isoindolones, tetracyclic isoindolo-indolones and
other polycyclic heterocycles, rather than simple 3H-pyrrolizin-3-ones.208,209 Several of
the structures are marine natural products or their derivatives (Figure 4.2).210
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Figure 4.2. 3H-pyrrolizin-3-one-containing structures returned from a SciFinder
Scholar search.

McNab et al reported the synthesis of an acetoxymethyl-3H-pyrrolizin-3-one in 2 steps.
The first involved reacting 3-acetoxymethyl-pyrrole-2-carboxaldehyde 46 with
Meldrum’s acid to form condensation product 47. Flash vacuum pyrolysis (FVP) of 47
at 600 oC then produced the 3H-pyrrolizin-3-one 48 (Scheme 4.1).211–213 FVP requires
specialised glassware, high vacuum and high temperatures to carry out reactions.
Similar syntheses have been developed by McNab to access other 3H-pyrrolizin-3ones.213–216

Scheme 4.1. Synthesis of (3-oxo-3H-pyrrolizin-7-yl)methyl acetate 48.213 Reagents and
conditions: a. Meldrum’s acid, piperidinium acetate, 60%; b. FVP 600 oC, 90%.
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4.2 Development of a Divergent Synthesis of 3H-Pyrrolizin-3-ones
Discovery of the novel class of angiogenesis inhibitors in Chapter 2 demonstrated that
the indolin-2-one ring system of sunitinib and SU5416 was not essential for activity.217
3H-pyrrolizin-3-ones carrying a pendant aryl ring at the 2-position retain many of the
structural features of SU5416 and it was hypothesised that they may also exhibit antiangiogenic properties. This hypothesis led to exploration of the structure activity
relationships of the class as angiogenesis inhibitors.
The synthetic route that had serendipitously led to formation of 3H-pyrrolizin-3-one 14
was a four-step process that involved: (1) esterification of 2-nitrophenylacetic acid 11
with allyl alcohol to form 12, (2) Knoevenagel condensation between 12 and pyrrole
aldehyde 9 to form (Z)-13 (with significant formation of (E)-13), (3) de-allylation of the
cis-product (Z)-13 with Pd(PPh3)4 and (4) ring closing acylation of the pyrrole nitrogen
under amide coupling conditions. Steps 2-4 required column chromatography to isolate
the pure products. This route was considered too long and inefficient for a structureactivity exploration of the anti-angiogenic properties of 2-aryl-3H-pyrrolizin-3-ones. A
shorter, more divergent approach capable of providing rapid access to multiple 2-aryl3H-pyrrolizin-3-one analogues was desired.
It was proposed that divergent access to the scaffold might be achievable through a onepot procedure from pyrrole aldehyde 4 and the many commercially available ringsubstituted phenylacetic acids. It had already been established that the K+ salt of
aldehyde 4, generated using KH, was cleanly acylated with chloroformates (Chapter
2.2). We hypothesised that this salt would also react with phenylacetic acids, which had
been pre-activated with amide coupling reagents. A procedure was conceived wherein a
phenylacetic acid analogue was activated with coupling reagent in one flask and the K+
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salt of 4 generated in a separate flask. Mixing of the two flasks would trigger a cascade
of reactions, starting with pyrrole-N-acylation, to give intermediate 49 (Scheme 4.2).
Abstraction of a benzylic proton under the basic reaction conditions (excess KH) would
then trigger an intramolecular Knoevenagel condensation, leading to formation of 3Hpyrrolizin-3-ones.

Scheme 4.2. Proposed one-step divergent synthesis of 2-aryl-3H-pyrrolizin-3-ones
carrying substituents on the phenyl ring. LG = Leaving Group.

The procedure was initially explored using unsubstituted phenylacetic acid 50, activated
as the acid chloride, HOBt ester or carbodiimide derivative in CH2Cl2. The potassium
salt of 4 was generated using 1.1 mol eq. of KH in THF. Reactions using carbodiimide
coupling reagent DCC with 10% w/w 4-(dimethylamino)pyridine (DMAP) produced
24% of the desired dark red 3H-pyrrolizin-3-one 51. Replacing KH with 1.1 mol eq. of
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KOtBu reduced the yield to 18% (Table 4.1 entries 1 and 2). Use of the carbodiimide
reagent EDCI produced 51 in 17% yield (Table 4.1, Entry 3).
Activation of 50 to the HOBt ester with HBTU/DIPEA showed more promise (37%
yield, Table 4.1, Entry 4) and was explored further. Substitution of HBTU with HATU
reduced the yield to 23%. The HOBt ester was formed using standard amide coupling
conditions, where 2 mol eq. of DIPEA and 1 mol eq. of HBTU were used and stirred at
RT in CH2Cl2. The potassium salt of pyrrole 4 was formed separately using 1.1 mol eq.
of KH at 0 oC in THF. Rapid addition of the HOBt ester solution to the pyrrolate
solution led to formation of the desired product 51. It was noted that slower addition or
reverse addition resulted in slower reactions and lower yields.
Exploration of the number of mol eq. of KH present in the reaction was studied in the
Kelso lab by a German exchange student Claudia Ries in 2012. She identified that 2.0
mol eq produced the highest yield of 51 (48%, Table 4.1, Entry 6). Under these
conditions, 1.0 mol eq. of KH was generating the potassium salt of 4 and the second 1.0
mol eq. was presumably acting to trigger the Knoevenagel condensation after mixing
the two flasks and following pyrrole N-acylation. Changing from 2.0 mol eq. of KH to
2.0 mol eq. of potassium hexamethyldisilazane (KHMDS) or KOtBu under the
conditions identified by Claudia reduced the yield to 38% in both cases (Table 4.1,
Entries 7 and 8). Use of phenylacetyl chloride in place of the activated ester of 50
resulted in a 32% yield of 51. The yield, however, was not reproducible and the
reactions were much less convenient to carry out.
It appeared that the yield was approaching a maximum of only 50%. One reason for this
may have been the presence of the conjugate acid of DIPEA (formed during HOBt ester
formation in Flask 1). It is likely that a significant portion of hydride was being lost as
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H2 gas through deprotonation of DIPEA.H+. This would leave less than 1.0 mol eq. of
hydride available for the intramolecular Knoevenagel reaction, thereby reducing the
yield.
Table 4.1. Reactions and conditions explored for the one-pot synthesis of 3Hpyrrolizin-3-one 51.

Base 1

Base 2

Entry

Coupling Reagent*

(mol. eq)#

(mol. eq)+

Yield 51 (%)

1

DCC

DMAP (0.1)

KH (1.1)

24

t

2

DCC

DMAP (0.1)

KO Bu (1.1)

18

3

EDCI

DMAP (0.1)

KH (1.1)

17

4

HBTU

DIPEA (2.0)

KH (1.1)

37

5

HATU

DIPEA (2.0)

KH (1.1)

23

6

HBTU

DIPEA (2.0)

KH (2.0)

48

7

HBTU

DIPEA (2.0)

KHMDS (2.0)

38

8

HBTU

DIPEA (2.0)

t

KO Bu (2.0)

38

* Reactions were carried out using 1.0 mol eq. of phenylacetic acid 50 with 1.1 mol eq.
of amide coupling reagent at RT and Base 1 and 1.0 mol eq. of pyrrole aldehyde 4 with
Base 2 in THF at 0 oC.
#
relative to 4
+
relative to 4

The highest yield obtained for 51 was 48% using 1.1 mol eq. HBTU and 2.0 mol eq.
DIPEA to activate 1.0 mol eq. phenylacetic acid 50 to the HOBt ester in Flask 1, and
2.0 mol eq. of KH to activate 1.0 mol eq. pyrrole aldehyde 4 to its potassium salt in
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Flask 2, before pouring Flask 1 into Flask 2 in one portion. Yield improvements may be
possible through use of an alternative activation process in Flask 1 that does not
produce DIPEA.H+ (e.g. use of hydride as base), although this was not explored.
Nevertheless, the reaction was suitable for the synthesis of small quantities of pure 2aryl-3H-pyrrolizin-3-ones for the SAR study. Accordingly, analogues carrying
substituents at the phenyl ortho, meta and para positions were pursued using this
chemistry with pyrrole aldehyde 4 and commercially acquired, ring-substituted
phenylacetic acids.

4.3. Synthesis of 2-Aryl-3H-Pyrrolizin-3-one Analogues
Mono-substituted fluorophenyl (52-54), chlorophenyl (55-57), bromophenyl (58-60),
tolyl (61-63), methoxyphenyl (64-66), and nitrophenyl acetic acids (11, 67-68) were
acquired from Sigma Aldrich and submitted to the optimised procedure (Table 4.2). The
reactions and product purification proceeded smoothly in most cases. The reactions
were generally complete in less than 4 hours, after which they were evaporated to
dryness, taken up in Et2O and washed with saturated sodium bicarbonate and brine,
before being dried over anhydrous MgSO4 and concentrated. The crude products were
purified by silica gel column chromatography using mixtures of pet. spirit and acetone
as eluents. Visualisation of the products was possible during column chromatography
due to their deep red or maroon colour, simplifying the procedure.
The reactions were performed on 200-500 mg scale and the yields obtained were
between 4% and 48%. Phenylacetic acids with larger ortho-substituents provided the
lowest yields of 2-aryl-3H-pyrrolizin-3-ones (e.g. o-bromophenyl 75 13%, ochlorophenyl 72 16% and o-tolyl 78 21%; c.f. o-fluorophenyl 69 37%, Table 4.2) This
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may have been due to steric hindrance hampering the Knoevenagel reaction at the
neighbouring benzylic position. Meta-substituted products were obtained in the highest
yields (e.g. m-fluorophenyl 70 37%, m-chlorophenyl 72 35% and m-bromophenyl 76
44%; Table 4.2). Para-substituted products were also produced in reasonable yields
(e.g. p-fluorophenyl 71, p-chlorophenyl 74 and p-bromophenyl 77 were synthesised in
38%, 30% and 34% yields, respectively; Table 4.2).
Electron-withdrawing substituents that increased acidity at the benzyl position resulted
in lower yields (e.g. 28% and 4% yield for o-nitro 14 and p-nitro 85, respectively).
Electron donating substituents appeared to favour the reaction. o-Methoxyphenyl
derivative 81 was the second highest yielding ortho-substituted 3H-pyrrolizin-3-one at
45% (Table 4.2. Entry 14). One possible explanation for these results is that activated
acids with more acidic benzylic protons favoured neutralisation of the potassium
pyrrolate salt over acylation.
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Table 4.2. Synthesis of 2-aryl-3H-pyrrolizin-3-ones.

Entry

Phenylacetic acid

R1

R2

R3

Product

Yield, %

1

50

H

H

H

51

48

2

52

F

H

H

69

37

3

53

H

F

H

70

37

4

54

H

H

F

71

38

5

55

Cl

H

H

72

16

6

56

H

Cl

H

73

35

7

57

H

H

Cl

74

30

8

58

Br

H

H

75

13

9

59

H

Br

H

76

44

10

60

H

H

Br

77

34

11

61

Me

H

H

78

21

12

62

H

Me

H

79

41

13

63

H

H

Me

80

37

14

64

OMe

H

H

81

33

15

65

H

OMe

H

82

45

16

66

H

H

OMe

83

30

17

11

NO2

H

H

14

28

18

67

H

NO2

H

84

15

19

68

H

H

NO2

85

4
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4.4 Biological Assessment of Mono-Substituted 2-Aryl-3H-pyrrolizin-3-ones
4.4.1 HUVEC Tube Formation Assay
Anti-angiogenesis activity of the nineteen 3H-pyrrolizin-3-ones was examined using a
semi-quantitative, cell-based endothelial tube formation assay with human umbilical
vein endothelial cells (HUVECs).218 HUVECs extracted from umbilical veins are
commonly used for models of angiogenesis as they are easy to culture and sensitive to
growth factors, such as EGF and FGF. Matrix-cultured HUVECs differentiate in
response to growth factors, becoming elongated and motile and able to self-organise
into capillary-like structures over a period of 2-12 hours. This process is disrupted by
small molecule RTK inhibitors of angiogenesis, making it a convenient model for
measurements of angiogenesis inhibition.219 Representative time-lapse images showing
various stages of pro-angiogenic tube formation by EA.hy926 cells (HUVEC/A549
hybrid cell line) are shown in Figure 4.3.218
Quantification of angiogenesis and the inhibitory effects of compounds uses the method
reported by Aranda et al.218 An image of the cells is captured and the cells are tallied
and categorised as ellipsoid (i.e. undifferentiated, Figure 4.3. Image 1), sprouting (i.e.
differentiating, Figure 4.3, Image 2) or connected to other cells (Figure 4.3, Images 3
and 4). The total number of closed polyhedra (Figure 4.3, Images 5 and 6) are also
counted, along with ‘complex meshes’, which are polyhedra containing walls more than
2 cells thick (Figure 4.3, Images 7 and 8).
The numerator of an equation is calculated by summing the number of sprouting cells
and the number of connected cells multiplied by a factor of 2 and the number of
polygons multiplied by a factor of 3. The denominator of the equation is the total
number of cells, including undifferentiated cells.218 Finally, a correction factor is added
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to account for ‘complex meshes’, which represent extensive angiogenesis. A score of 0
is added for no complex meshes, 1 for at least one polyhedra with walls of 2-4 cells
thick or 2 for at least one polyhedra with walls of 4+ cells thick.
Assays were conducted with adherent HUVEC cells (C-003-5C, Life Technologies),
cultured according to the manufacturer’s specifications in 75 cm3 flasks and utilised
between passages 2-4. Tube formation was monitored in Geltrex matrix (Life
Technologies) according to manufacturer’s specifications in standard flat-bottomed
plates using a 24 well format. The cells were seeded at 3.5–4.5× 104 cells per Geltrexcoated well and incubated for 2 hours at 37 oC in 5% CO2/air. Compounds were
solubilised in DMSO to form stock solutions at 100 µM. Aliquots were added to each
well to give a final concentration of 10 µM with 1% DMSO. After 8 hours, the media
was removed and replaced with sterile PBS buffer prior to imaging by light microscopy.
Three to six images were taken and scored for each well over two independent assays,
giving a total of 6-10 counts for each compound. 1% DMSO was used as a negative
control (vehicle) and 10 µM sunitinib as a positive control (inhibition). Angiogenesis
was indicated by the angiogenesis score relative to the negative control (vehicle) i.e. a
low angiogenesis score indicates a potent inhibitor of angiogenesis.
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(a)

(b)

Figure 4.3. (a) Representative images of EA.hy926 cells during the angiogenic tube
formation process.218 (b) Equation used to calculate angiogenesis score.218

The assay showed that the original ortho-NO2-substituted analogue 14 was the most
potent angiogenesis inhibitor and that most other substitutions were not well-tolerated.
Compound 14 produced a score that was 29.7% ± 4.1 of the angiogenesis score
observed with vehicle at 10 µM and 74.0% ± 12.6 of the vehicle score at 1 µM. The
next most potent compounds were the unsubstituted phenyl derivative 51 (68.4% ± 6.6
of vehicle) and 2-fluorophenyl 69 (67.2% ± 6.2 of vehicle). The o-methoxyphenyl 81,
o-bromophenyl 75 and o-tolyl 78 analogues produced modest reductions in
angiogenesis. All other derivatives were essentially inactive. The positive control
sunitinib totally arrested angiogenesis at 10 μM under the assay conditions.
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(a)

(b)

Figure 4.4. (a). Inhibition angiogenesis in an endothelial tube formation assay by 2aryl-3H-pyrrolizin-3-one derivatives and controls. Compounds were present at 10 µM.
Data for 14, the most potent compound, is shown in red and is also provided at 1 µM.
(b) Representative images showing degree of angiogenesis evident with the 2fluorophenyl analogue 69 (left) and the more potent inhibitor 14 (right, both compounds
present at 10 µM).
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4.4.2. Rat Aortic Ring Angiogenesis Assay
The two most potent angiogenesis inhibitors 2-(2-nitrophenyl)-3H-pyrrolizin-3-one 14
and 2-phenyl-3H-pyrrolizin-3-one 51 were submitted to the more physiologically
relevant (though more expensive and labour intensive) rat aortic ring angiogenesis assay
to confirm their angiogenesis inhibition activities (see Chapter 2.7 for assay details).
Compound 14 showed a similar inhibitory potency to the SU5416 in the assay,
producing 4% F.O.V. occupancy at 10 µg/mL (c.f. 10% for SU5416 at 10 µg/mL).
Compound 14 also showed a dose-dependent response, producing 1% F.O.V.
occupancy at 100 µg/mL. The unsubstituted phenyl derivative 51 potently inhibited
angiogenesis at 10 µg/mL (12% F.O.V. occupancy) but solubility issues similar to those
of SU5416 2 (see Chapter 2.7) appeared to interfere with its activity at the higher
concentration of 100 µg/mL (21% F.O.V. occupancy). These results corroborated those
observed in the endothelial tube formation assay, confirming that 14 and 51 are new
anti-angiogenic leads.

Figure 4.5. Rat aortic ring angiogenesis inhibition assay.
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4.5 Conclusions and Future Directions
The chemistry and biological activity of the serendipitously discovered 2-aryl-3Hpyrrolizin-3-one 14 and related analogues was investigated in this chapter. The crystal
structure of 14 was determined by X-ray analysis, revealing a preferred orientation
where the carbonyl oxygen makes a favourable interaction with the NO2 nitrogen
(Chapter 2.3). The 2-nitrophenyl-3H-pyrrolizin-3-one 14 was shown to be a potent
inhibitor of angiogenesis in both the endothelial tube formation assay (29.7% of vehicle
angiogenesis at 10 µM) and the rat aortic ring angiogenesis assay (4% F.O.V.
occupancy at 10 µg/mL).
A divergent synthesis of analogues of 14 was developed using commercially available
mono-substituted phenylacetic acids and pyrrole aldehyde 4. While usable quantities of
all analogues were obtained there is much scope for improving the yields. Eighteen
analogues of 14 were synthesised and tested for anti-angiogenic properties in the
endothelial tube formation assay. Compound 14, the ortho-fluoro compound 69 and
unsubstituted phenyl derivative 51 showed the strongest inhibition of angiogenesis,
while the other analogues were essentially inactive. Based on the results from this assay,
compounds 14 and 51 were advanced to the more sophisticated and physiologically
relevant rat aortic ring angiogenesis assay to confirm their anti-angiogenic properties.
Both compounds showed strong inhibitory effects in this assay, confirming that 2-aryl3H-pyrrolizin-3-ones represent a new class of angiogenesis inhibitors.
There are several biochemical pathways that affect angiogenesis. Screening 14 and 51
against a panel of angiogenesis-modulating RTKs would shine light on the specific
target(s) of the compounds. X-ray or docking studies with the compounds with any
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inhibited receptors would be vital for supporting lead optimisation studies. Key
receptors to test against would be the VEGFR and EGFR families of RTKs.
Very little is known about the chemistry of 2-aryl-3H-pyrrolizin-3-ones like 14 and 51.
Derivatisation at the β-alkene position could be interesting for continuing angiogenesis
inhibitor development since modifications at the phenyl ring appeared to be poorly
tolerated. Work from the McNab lab identified reactivity at this position, suggesting it
may be possible to introduce nucleophiles directly onto 14 and 51.215 Introducing a
stereocentre in this manner would generate interesting SAR information.
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Chapter 5
Experimental
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5.1 General
Reagents and solvents were used without further purification unless otherwise stated.
Dichloromethane (CH2Cl2), dimethylformamide (DMF), toluene and diethyl ether
(Et2O) were used directly from a PureSolv Solvent purification system. THF was
purified by drying over KOH before distillation from sodium benzophenone ketyl.
Compounds were weighed using a Sartorius Extend 220g or OHaus Adventurer
balance. Solvents were removed under reduced pressure (in vacuo) at rt - 40 oC using a
Heidolph or Büchi rotary evaporator with Vacuubrand pumps. Solvent residues were
removed in vacuo using a Javac Vector RD-90 double stage high vacuum pump.
Analytical thin layer chromatography (TLC) analysis was performed using Merck 0.2
mm silica gel 60 F254 coated aluminium plates. Compounds were visualised on TLC
plates under UV light (254 nm). Column chromatography was performed on Merck
silica gel 60 (230-400 mesh). Low resolution electrospray (ESI) mass spectra were
obtained using a Shimadzu LCMS-2010EV spectrometer. ESI High Resolution Mass
Spectra (HRMS) were obtained on a Xevo QToF mass spectrometer with
perfluorokerosene as internal standard. Fourier-Transform Infrared (FTIR) spectra were
obtained using a Shimadzu IRAffinity-1 spectrometer with a MIRacle 10 accessory. 1H,
13

C and two-dimensional (2D) NMR experiments were performed using a Varian Inova

500 MHz or Varian Premium Shielded 500 MHz spectrometer at 25 oC. Chemical shifts
are reported as δ (ppm) relative to internal TMS (1H) or solvent (13C) unless stated
otherwise. The abbreviations s = singlet, d = doublet, t = triplet, q = quartet, dd =
doublet of doublets, m = multiplet and br s = broad singlet are used throughout.
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5.2 Compound Characterisation
(E)-2-(3,5-dimethyl-1H-pyrrol-2-yl)-3-((4-(dimethylamino)phenyl)imino)-3H-indole 1oxide 15
To a solution of (E)-5 (201 mg, 0.70 mmol) in CH2Cl2 (10 mL) was added HATU (372
mg, 0.98 mmol). The solution was stirred at room temperature for 5 minutes before
adding N,N-dimethyl-p-phenylenediamine (DMPD, 95.3 mg, 0.70 mmol) in one
portion. The reaction was then stirred at room temperature and monitored by TLC
analysis (3:7 EtOAc:pet. spirit). After 3 h, the mixture was extracted with EtOAc (3 x
25 mL) and the combined organic phase washed with brine (2 x 25 mL), dried over
anhydrous MgSO4 and concentrated. The residue was purified by column
chromatography (100% pet. spirit to 8:2 pet. spirit:EtOAc) to give 15 (100 mg, 40%
yield) as a dark purple solid. Use of the same procedure with (Z)-5 resulted in similar
yields of 15.
M.P. 146-148 oC. 1H NMR (CDCl3, 500 MHz): δ 2.33 (s, 3H,
H1), 2.51 (s, 3H, H2), 3.04 (s, 6H, H5), 5.96 (d, 1H, J = 3.0
Hz, H3), 6.80 (d, 2H, J = 8.5 Hz, H6), 7.05 (d, 2H, J = 9.0 Hz,
H7), 7.08 (t, 1H, J = 7.5, H9), 7.12 (d, 1H, J = 7.5, H8), 7.45 (t,
1H, J = 7.5 Hz, H10), 7.63 (d, 1H, J = 7.5 Hz, H11), 11.86 (s
(br), 1H, H4).

13

C NMR (CDCl3, 126 MHz): δ 13.5 (C1), 16.5 (C2), 40.7 (C5), 112.6

(C6), 112.7 (C15), 112.9 (C11), 113.7 (C3), 117.0 (C18), 119.0 (C13), 121.5 (C7), 123.7
(C8), 128.0 (C9), 128.5 (C19), 131.8 (C10), 132.3 (C20), 139.3 (C17), 147.9 (C12), 149.2
(C16), 154.8 (C14). HRMS-ESI: m/z calcd for C22H23N4O [M+H+] 359.1872; observed
359.1868. FTIR: neat (cm-1) 2920, 2340, 1730, 1595, 1521, 1448, 1350, 1277, 1205,
1185, 1117.
99

(E)-3-((4-aminophenyl)imino)-2-(3,5-dimethyl-1H-pyrrol-2-yl)-3H-indole 1-oxide 16
Use of p-phenylenediamine in place of N,N-dimethyl-pphenylenediamine in the procedure described for producing
15 afforded 16 (56% yield) as a dark amorphous solid. 1H
NMR* (CDCl3, 500 MHz): δ 2.32 (s, 3H, H1), 2.51 (s, 3H,
H2), 3.70 (v. br, 2H, H5), 5.95 (s, 1H, H3), 6.76 (d, 2H, J = 8.5
Hz, H6), 6.90 (d, 2H, J = 8.5 Hz, H7), 6.95 (d, 1H, J = 7.5 Hz, H8), 7.05 (t, 1H, J = 7.5
Hz, H9), 7.43 (t, 1H, J = 7.5 Hz, H10), 7.60 (d, 1H, J = 7.5 Hz, H11), 11.79 (br s, 1H, H4).
13

C NMR (CDCl3, 126 MHz): δ 13.4 (C1), 16.4 (C2), 113.0 (C11), 113.8 (C3), 115.6 (C6),

117.0 (C18), 118.8 (C13), 120.69 (C7), 124.1 (C8), 127.7 (C9), 128.8 (C19), 132.0 (C10),
132.6 (C20), 134.1 (C17), 141.4 (C16), 144.7 (C15), 148.0 (C12), 156.1 (C14). HRMS-ESI:
m/z calcd for C20H19N4O [M+H+] 331.1553; observed 331.1551. * NMR peaks were
taken from an impure sample due to the compound’s instability. Melting point and
coherent FTIR data could not be obtained due to the compound’s instability.

2-(3,5-dimethyl-1H-pyrrol-2-yl)-3-oxo-3H-indole 1-oxide 17
To a solution of 0.05 g 15 or 16 (0.14 mmol or 0.15 mmol, respectively) in THF (2 mL)
was added 2 mL of 1 M HCl. The reaction was stirred at rt and monitored by TLC
analysis (7:3 pet. spirit:EtOAc). After 30 minutes, the mixture was extracted with
EtOAc (2 x 25 mL). The combined organic phase was washed with saturated NaHCO3
(2 x 30 mL) and brine (2 x 30 mL), dried anhydrous MgSO4 and concentrated to give 17
(quantitative) as a deep violet solid.
M.P. 158-160 oC. 1H NMR (CDCl3, 500 MHz): δ 2.32 (s, 3H, H1), 2.50 (s, 3H, H2), 5.97
(s, 1H, H3), 7.36 (t, 1H, J = 7.5 Hz, H6), 7.52 (m, 2H, H5,8), 7.60 (t, 1H, J = 7.5 Hz, H7),
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11.64 (br s, 1H, H4).

13

C NMR (CDCl3, 126 MHz): δ 13.5

(C1), 15.0 (C2), 112.8 (C8), 114.4 (C3), 117.1 (C13), 121.9
(C5), 122.4 (C10), 129.0 (C6), 129.3 (C14), 129.7 (C12), 133.6
(C15), 135.2 (C7), 148.8 (C9), 185.3 (C11). HRMS-ESI: m/z calcd for C14H13N2O2
[M+H+] 241.0972; observed 241.0972. FTIR: neat (cm-1) 3281, 2918, 1727, 1576, 1522,
1461, 1458, 1370, 1329, 1265, 1208, 1117, 1065.

(E)-3,5-dimethyl-2-(2-nitrostyryl)-1H-pyrrole 18
Compound 18 was isolated as a trace product from the reactions used to produce 16 and
by rt storage of (Z)-5 in CDCl3 over 2 weeks.
M.P. and FTIR not recorded due to scarcity and lack of purity
of product. 1H NMR (CDCl3, 500 MHz): δ 2.16 (s, 3H, H1),
2.29 (s, 3H, H2), 5.79 (s, 1H, H3), 6.97 (d, 1H, J = 16.1 Hz,
H5), 7.04 (d, 1H, J = 16.1 Hz, H6), 7.27 (t, 1H, J = 7.5 Hz, H9),
7.53 (t, 1H, J = 7.5 Hz, H8), 7.74 (d, 1H, J = 8.0 Hz, H7), 7.90 (d, 1H, J = 8.0 Hz, H10).
13

C NMR (CDCl3, 126 MHz): δ 11.1 (C1), 13.2 (C2), 110.3 (C3), 113.0 (C6), 122.2 (C5),

123.3 (C13), 123.9 (C15), 125.0 (C10), 125.6 (C14), 126.2 (C9), 126.7 (C7), 131.1 (C12),
132.83 (C8), 133.8 (C11). HRMS-ESI: m/z calcd for C14H15N2O2 [M+H+] 243.1128;
observed 243.1131.

(Z)-

and

(E)-3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(2-nitrophenyl)-N-phenylacrylamide

(Z)-29 and (E)-29
To a dry round-bottom flask under N2 was added 2-(2-nitrophenyl)-N-phenylacetamide
23 (1.104 g, 4.31 mmol), oven-dried anhydrous K2CO3 (0.893 g, 6.46 mmol), 18101

crown-6 (1.139 g, 4.31 mmol) and dry THF (20 mL). After stirring at 70 oC for 1 h a
brown to dark blue solution appeared. 1-methoxycarbonyl-5-dimethyl-1H-pyrrole-2carboxaldehyde 9 (0.820 g, 4.52 mmol. Prepared as per Sudta, et al.)217 dissolved in dry
THF (8 mL) was added dropwise over 15 minutes and the mixture stirred at 70 oC for a
further 10 h. The reaction was quenched with water (30 mL) and evaporated to dryness.
The residues were taken up in EtOAc (50 mL) and washed with saturated NaHCO3 (2 x
50 mL) and brine (2 x 50 mL), dried over anhydrous MgSO4 and concentrated. The
crude product was purified by silica gel column chromatography (100% pet. spirit to 8:2
pet. spirit:acetone) to provide (Z)-29 (0.591 g, 38% yield) as an orange-red solid, (E)-29
(0.405, 26% yield) as a red oil and trace quantities of N-phenyl-SU5416 33 (typically 25% yield).
(Z)-29. Red crystalline solid. M.P. 177-179 oC. 1H NMR
(CDCl3, 500 MHz): δ 2.12 (s, 3H, H1), 2.32 (s, 3H, H2), 5.86
(s, 1H, H3), 6.56 (s, 1H, H5), 6.87 (br s, 1H, H9), 7.12 (t, 1H,
J = 7.5 Hz, H6), 7.32 (t, 2H, J = 7.5 Hz, H7), 7.37 (t, 2H, J =
7.5 Hz, H8), 7.56 (t, 1H, J = 8.0 Hz, H12), 7.60 (d, 1H, J =
8.0 Hz, H10), 7.71 (t, 1H, J = 8.0 Hz, H11), 8.03 (d, 1H, J = 8.0 Hz, H13), 12.00 (br s,
1H, H4). 13C NMR (CDCl3, 126 MHz): δ 11.4 (C1), 13.6 (C2), 111.1 (C3), 115.6 (C16),
121.4 (C8), 124.1 (C18), 124.9 (C6, C13), 129.0 (C7), 129.1 (C12), 130.1 (C19), 133.48
(C11), 133.52 (C10), 133.8 (C20), 135.8 (C15), 137.4 (C21), 149.7 (C14), 166.2 (C17).
HRMS-ESI: m/z calcd for C21H20N3O3 [M+H+] 362.1499; observed 362.1501. FTIR:
neat (cm-1) 3400, 1650, 1595, 1592, 1518, 1498, 1436, 1362, 1352, 1318, 1229, 1188,
1151, 1004.
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(E)-29. Red oil. 1H NMR* (CDCl3, 500 MHz): δ 1.92 (s, 3H,
H1), 2.13 (s, 3H, H2), 5.70 (s, 1H, H3), 6.47 (br s, 1H, H9),
7.04 (t, 1H, J = 7.0 Hz, H6), 7.14 (br s, 1H, H4), 7.24 (t, 2H,
J = 7.5 Hz, H7), 7.43 (d, 2H, J = 8.0 Hz, H8), 7.57 (d, 1H, J
= 7.5 Hz, H10), 7.68 (s, 1H, H5), 7.75 (t, 1H, J = 7.5 Hz,
H11), 7.66 (m, 1H, H12), 8.13 (d, 1H, J = 8.0 Hz, H13).

13

C

NMR (CDCl3, 126 MHz): δ 11.2 (C1), 13.1 (C2), 110.6 (C3), 118.9 (C16), 120.4 (C8),
123.3 (C19), 124.1 (C6), 125.1 (C5), 125.4 (C13), 128.7 (C7), 129.6 (C20), 130.3 (C12),
131.5 (C15), 133.5 (C21), 133.8 (C10), 134.3 (C11), 138.0 (C18), 149.4 (C14), 165.0 (C17).
HRMS-ESI: m/z calcd for C21H20N3O3 [M+H+] 362.1499; observed 362.1503. *Peaks
obtained from impure sample.
33. Yellow oil. 1H NMR (CDCl3, 500 MHz): δ 2.33 (s, 3H,
H2), 2.36 (s, 3H, H1), 5.98 (s, 1H, H3), 6.83 (m, 1H , H12),
7.11 (m, 2H, H10/H11), 7.43 (t, 1H, J = 7.5 Hz, H6), 7.45 (d,
2H, J = 7.0 Hz, H8), 7.50 (s, 1H, H5), 7.57 (m, 3H, H7/H9),
13.06 (br s, 1H, H4).

13

C NMR (CDCl3, 126 MHz): δ 11.7

(C1), 13.9 (C2), 109.0 (C12), 111.2 (C15), 112.8 (C3), 117.1
(C9), 122.0 (C10), 123.7 (C5), 125.4 (C11), 125.6 (C14), 127.1 (C8), 127.1 (C18), 127.9
(C6), 129.6 (C7), 132.8 (C19), 135.1 (C17), 137.2 (C20), 139.7 (C13), 168.0 (C16). HRMSESI: m/z calcd for C21H19N2O [M+H+] 315.1492; observed 315.1497.
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(Z)- and (E)-N-benzyl-3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(2-nitrophenyl)acrylamide (Z)30 and (E)-30.
Protocol as per 29, using 2-(2-nitrophenyl)-N-benzylacetamide 24 in place of 23.
(Z)-30. 16% yield, red crystalline solid. M.P. 140-142 oC.
1

H NMR (CDCl3, 500 MHz): δ 2.09 (s, 3H, H1), 2.31 (s,

3H, H2), 4.50 (d, 2H, J = 6.0 Hz, H9), 5.50 (br s, 1H, H10),
5.83 (s, 1H, H3), 6.48 (s, 1H, H5), 7.20 (d, 2H, J = 8.0 Hz,
H8), 7.22 (m, 1H, J = 7.0 Hz, H6), 7.28 (t, 2H, J = 7.5 Hz,
H7), 7.47 (m, 1H, J = 8.0 Hz. H13), 7.49 (m, 1H, J = 6.5 Hz, H11), 7.61 (t, 1H, J = 7.5
Hz, H12), 7.94 (d, 1H, J = 8.5 Hz, H14), 12.21 (br s, 1H, H4).

13

C NMR (CDCl3, 126

MHz): δ 11.3 (C1), 13.6 (C2), 43.9 (C9), 110.7 (C3), 115.8 (C17), 124.0 (C20), 124.7
(C14), 127.33 (C8), 127.34 (C6), 128.3 (C5), 128.6 (C7), 128.9 (C13), 129.2 (C21), 133.1
(C22), 133.3 (C12), 133.4 (C11), 136.0 (C16), 138.0 (C19), 149.5 (C15), 167.6 (C18).
HRMS-ESI: m/z calcd for C22H22N3O3 [M+H+] 376.1656; observed 376.1667. FTIR:
neat (cm-1) 3435, 1643, 1570, 1543, 1507, 1453, 1362, 1341, 1316, 1237, 1217, 1150.

(E)-30. < 5%, red amorphous solid (impure). 1H NMR
(CDCl3, 500 MHz): δ 1.92 (s, 3H, H1), 2.15 (s, 3H, H2),
4.46 (d, 2H, J = 6.0 Hz, H9), 5.50 (br s, 1H, H10), 5.69 (s,
1H, H3), 6.36 (br s, 1H, H4), 7.20-7.33 (m, 5H, H8-10),
7.54 (d, 1H, J = 7.0 Hz, H11), 7.67 (m, 2H, H5,13), 7.74 (t,
1H, J = 7.5 Hz, H12), 8.14 (d, 1H, J = 8.5 Hz, H14). Note: owing to impurities, the
chemical shift of the pyrrolic N-H signal could not be assigned unambiguously.

13

C

NMR (CDCl3, 126 MHz): δ 11.3 (C2), 13.1 (C1), 43.9 (C9), 110.4 (C3), 118.6 (C17),
123.3 (C20), 124.9 (C5), 125.4 (C14), 127-129 (C6-8), 129.2 (C21), 130.1 (C13), 132.0
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(C16), 132.9 (C22), 133.4 (C12), 133.8 (C11), 138.0 (C19), 149.7 (C15), 166.7 (C18).
Melting point and coherent FTIR not obtained due to impurity. HRMS-ESI: m/z calcd
for C22H22N3O3 [M+H+] 376.1656; observed 376.1677.

N,N-bis(2-hydroxyethyl)-4-nitroaniline 37
p-Fluoronitrobenzene (1.250 g, 8.86 mmol) and freshly
distilled diethanolamine (0.767 g, 7.30 mmol) were added
to a roundbottom flask under N2. The reaction was stirred at
100 oC for 12 h, until consumption of starting material was observed by TLC analysis
(EtOAc). The crude reaction mixture was diluted in EtOAc (50 mL) and washed with
saturated NaHCO3 (3 x 50 mL) and brine (3 x 50 mL). The organic layer was
concentrated in vacuo and then recrystallised from MeOH/water to give 37 (1.27 g, 77%
yield) as a yellow crystalline solid. Spectroscopic data for 37 were in accordance with
the literature.220

N,N-bis(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-nitroaniline 38
TBDMSCl (80.0 mg, 0.53 mmol) and imidazole (78.4 mg, 1.15 mmol) were added to a
roundbottom flask and stirred for 5 min in CH2Cl2 (5 mL). To the stirring solution was
then added a solution containing N,N-bis(2-hydroxyethyl)-4-nitroaniline 37 (50.0 mg,
0.22 mmol)

CH2Cl2 (5 mL) over 5 minutes. The reaction was stirred for 20 h,

monitored by TLC analysis (EtOAc). The reaction was diluted with CH 2Cl2 (20 mL)
and cooled to -18 oC for 1 h. The precipitate was filtered off and the filtrated collected
and added to a separating funnel. The organic phase was washed with saturated
NaHCO3 (5 x 25 mL) and brine (3 x 25 mL). The organic phase was then concentrated
105

and the residue purified by silica gel column
chromatography (1:1 EtOAc:pet. spirit) to give 38 (72.8
mg, 72% yield) as a dark yellow crystalline product.
Spectroscopic data were in accordance with the
literature.197

N-(4-aminophenyl)-2-(2-nitrophenyl)acetamide 36
2-nitrophenylacetic acid (5.065 g, 28.0 mmol), p-phenylenediamine (3.333 g, 30.8
mmol) and HBTU (11.694 g, 30.8 mmol) were stirred in a roundbottom flask with
CH2Cl2 (50 mL) under N2 at 0o C. DIPEA (10.7 mL, 61.4 mmol) was then added
dropwise over 5 minutes to the stirring solution and the reaction allowed to warm to rt
and stirred for 4 h with monitoring by TLC (EtOAc). The reaction was diluted with
CH2Cl2 (100 mL), added to a separating funnel and extracted with 1 M hydrochloric
acid (3 x 50 mL). The combined aqueous acidic phase was washed with CH2Cl2 (3 x 50
mL), removing a white precipitate. The combined acidic aqueous phase was neutralised
using 1 M sodium hydroxide resulting in an off-white precipitate. The solid was filtered,
washed with cold water and dried in vacuo afford 36 (5.70 g, 75% yield) as an off-white
solid. Product purity could be increased by recrystallisation from hot EtOH. While
compound 36 is commercially available (e.g. Aurora Building Blocks), no
characterisation data have been reported in the literature.
M.P. 174-176 oC. 1H NMR (d6-DMSO, 500 MHz): δ 4.03
(s, 2H, H5), 4.82 (s, 2H, H1), 6.48 (d, 2H, J = 9.0 Hz, H2),
7.16 (d, 2H, J = 9.0 Hz, H3), 7.53 (m, 2H, H6,8), 7.68 (t,
1H, J = 7.5 Hz, H7), 8.01 (d, 1H, J = 8.0 Hz, H9), 8.75 (s,
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1H, H4).

13

C NMR (d6-DMSO, 126 MHz): δ 40.7 (C5), 113.8 (C2), 120.9 (C3), 124.5

(C9), 128.2 (C8,13), 130.9 (C11), 133.4 (C6), 133.5 (C7), 144.8 (C14), 149.2 (C10), 166.4
(C12). HRMS-ESI: m/z calcd for C14H14N3O3 [M+H+] 272.1031; observed 272.1035.
FTIR: neat (cm-1) 3344, 1684, 1517, 1424, 1410, 1357, 1307, 1275, 1237, 1175.

N-(4-(bis(2-hydroxyethyl)amino)phenyl)-2-(2-nitrophenyl)acetamide 34
N-(4-aminophenyl)-2-(2-nitrophenyl)acetamide 36 (1.902 g, 7.01 mmol) was added to a
roundbottom flask along with anhydrous K2CO3 (1.750 g, 12.7 mmol) under N2. 2bromoethanol (15 mL) was added and the reaction mixture stirred at 50 oC for 5 days, or
until complete consumption of starting material was observed by TLC analysis
(EtOAc). The reaction mixture was concentrated and the residue taken up in EtOAc (50
mL). The organic phase was washed with brine (3 x 50 mL), dried over anhydrous
MgSO4 and evaporated to dryness. The crude residue was recrystallised from hot EtOH
to afford 34 (1.69 g, 67% yield) as a pale yellow solid.
M.P. 134-136

o

C.

1

H NMR (d6-DMSO, 500

MHz): δ 3.35 (t, 4H, J = 6.5 Hz, H3), 3.50 (q, 4H,
J = 6.5 Hz, H2), 4.04 (s, 2H, H7), 4.69 (t, 2H, J =
5.5 Hz, H1), 6.60 (d, 2H, J = 9.0 Hz, H4), 7.29 (d,
2H, J = 9.0 Hz, H5), 7.53 (m, 2H, H8,9), 7.68 (t, 1H, J = 7.5 Hz, H10), 8.02 (d, 1H, J =
8.0 Hz, H11), 9.82 (s, 1H, H6). 13C NMR (d6-DMSO, 126 MHz): δ 40.0 (C7), 53.7 (C3),
58.5 (C2), 111.6 (C4), 121.2 (C5), 124.8 (C11), 128.1 (C15), 128.5 (C10), 131.2 (C13),
133.7 (C8), 133.8 (C9), 144.7 (C16), 149.5 (C12), 166.8 (C14). HRMS-ESI: m/z calcd for
C18H22N3O5 [M+H+] 360.1554; observed 360.1559. FTIR: neat (cm-1) 3276, 1653,
1559, 1539, 1517, 1507, 1340, 1261, 1180, 1074, 1049.
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N-(4-(bis(2-((tert-butyldimethylsilyl)oxy)ethyl)amino)phenyl)-2-(2nitrophenyl)acetamide 8
To to a roundbottom flask was added N-(4-(bis(2-hydroxyethyl)amino)phenyl)-2-(2nitrophenyl)acetamide 34 (1.400 g, 3.90 mmol), TBDMSCl (2.046 g, 13.6 mmol) and
imidazole (2.3369 g, 34.3 mmol), along with CH2Cl2 (30 mL). The reaction was stirred
at rt for 2 h or until complete consumption of starting material was observed by TLC
analysis (7:3 pet. spirit:EtOAc). The reaction was diluted with CH2Cl2 (50 mL) and
cooled to -18 oC for 2 h. The precipitated solids were removed by gravity filtration and
the filtrate added to a separating funnel. The organic phase was washed with saturated
NaHCO3 (5 x 50 mL) and brine (2 x 50 mL), dried over anhydrous MgSO4 and
concentrated. The crude residue was recrystallised from pet. spirit (-18 oC, overnight) to
afford 8 (1.96 g, 86% yield) as orange crystals.
M.P. 118-119 oC. 1H NMR (CDCl3 500
MHz): δ 0.02 (s, 12H, H2), 0.88 (s, 18H,
H1), 3.46 (t, 4H, J = 6.5 Hz, H4), 3.71 (t,
4H, J = 6.5 Hz, H3), 3.96 (s, 2H, H8),
6.60 (d, 2H, J = 9.0 Hz, H5), 7.27 (d, 2H,
J = 9.0 Hz, H6), 7.45 (t, 1H, J = 7.5 Hz, H11), 7.56 (br s, 1H, H7), 7.57 (d, 1H, J = 7.5
Hz, H9), 7.61 (t, 1H, J = 7.5 Hz, H10), 8.04 (d, 1H, J = 8.0 Hz, H12). 13C NMR (CDCl3,
126 MHz): -5.4 (C2), 18.2 (C18), 25.9 (C1), 41.6 (C8), 53.7 (C4), 60.3 (C3), 111.6 (C5),
122.1 (C6), 125.1 (C12), 126.5 (C16), 128.4 (C11), 130.4 (C14), 133.4 (C9), 133.6 (C10),
145.3 (C17), 148.9 (C13), 166.7 (C15). HRMS-ESI: m/z calcd for C30H50N3O5Si2 [M+H+]
588.3284; observed 588.3289. FTIR: neat (cm-1) 2950, 1682, 1653, 1528, 1517, 1343,
1254, 1238, 1194, 1131, 1100, 1071, 929, 899, 836, 812.
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(Z)-

and

(E)-N-(4-(bis(2-((tert-butyldimethylsilyl)oxy)ethyl)amino)phenyl)-3-(3,5-

dimethyl-1H-pyrrol-2-yl)-2-(2-nitrophenyl)acrylamide (Z)-7 and (E)-7
N-(4-(bis(2-((tert-butyldimethylsilyl)oxy)ethyl)amino)phenyl)-2-(2nitrophenyl)acetamide 8 (1.150 g, 1.96 mmol), oven-dried anhydrous K2CO3 (0.366 g,
2.65 mmol) and 18-crown-6 (0.6657 g, 2.52 mmol) were added to a three-necked
roundbottom flask and dissolved in 15 mL of THF under N2. The reaction was stirred at
65 oC for 1 h giving a brown to light blue coloured solution. 1-methoxycarbonyl-5dimethyl-1H-pyrrole-2-carboxaldehyde 9 (0.4650 g, 2.57 mmol) in dry THF (10 mL)
was then added dropwise over 15 minutes to the stirring solution. The reaction was
heated at 65 oC for a further 12 h. After quenching with water, the reaction was
extracted with EtOAc (2 x 50 mL) and the combined organic phase washed with
saturated NaHCO3 (2 x 50 mL) and brine (2 x 50 mL), dried over anhydrous MgSO4
and concentrated. The crude residue was purified by silica gel column chromatography
(100% pet. spirit to 8:2 pet. spirit:EtOAc) affording (Z)-7 (0.56 g, 41% yield) as a red
amorphous solid and (E)-7 (0.30 g, 22% yield) as a red oil, along with trace amounts of
the N-arylindolin-2-one 41.
(Z)-7. M.P. 174-176 oC. 1H NMR (CDCl3, 500
MHz): δ 0.03 (s, 12H, H5), 0.88 (s, 18H, H4),
2.10 (s, 3H, H2), 2.28 (s, 3H, H1), 3.46 (t, 4H, J
= 6.5 Hz, H7), 3.71 (t, 4H, J = 6.5 Hz, H6), 5.82
(s, 1H, H3), 6.51 (s, 1H, H12), 6.61 (d, 2H, J =
9.0 Hz, H8), 6.66 (s, 1H, H10), 7.13 (d, 2H, J =
9.0 Hz, H9), 7.55 (t, 1H, J = 8.0 Hz, H15), 7.59
(d, 1H, J = 7.5 Hz, H13), 7.68 (t, 1H, J = 8.0 Hz, H14), 8.01 (d, 1H, J = 8.0 Hz, H16),
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12.08 (br s, 1H, H11).

13

C NMR (CDCl3, 126 MHz): δ -5.4 (C5), 11.4 (C2), 13.6 (C1),

18.3 (C23), 25.9 (C4), 53.7 (C7), 60.2 (C6), 110.8 (C3), 111.6 (C8), 116.2 (C19), 124.2
(C24, C9), 124.8 (C16), 125.7 (C21), 128.6 (C12), 128.9 (C15), 129.4 (C25), 133.4 (C26),
133.4 (C14), 133.5 (C13), 136.2 (C18), 145.9 (C22), 149.6 (C17), 166.3 (C20). HRMS-ESI:
m/z calcd for C37H57N4O5Si2 [M+H+] 693.3862; observed 693.3861. FTIR: neat (cm-1)
3313, 2928, 1654, 1612, 1595, 1514, 1379, 1360, 1322, 1289, 1250, 1095, 1054, 833,
810.

(E)-7. Red oil. 1H NMR (CDCl3, 500 MHz):
δ -0.02 (s, 12H, H5), 0.85 (s, 18H, H4), 2.22
(s, 3H, H2), 2.26 (s, 3H, H1), 3.41 (t, 4H, J =
6.4 Hz, H7), 3.67 (t, 4H, J = 6.4 Hz, H6), 3.90
(br s, 1H, H10), 5.79 (s, 1H, H3), 6.53 (d, 2H,
J = 9.0 Hz, H8), 7.23 (d, 2H, J = 9.0 Hz, H9),
7.34 (t, 1H, J = 8.0 Hz, H15), 7.43 (d, 1H, J =
7.0 Hz, H13), 7.49 (t, 1H, J = 7.0 Hz, H14), 7.95 (d, 1H, J = 8.0 Hz, H16), 8.03 (br s, 1H,
H11). 13C NMR (CDCl3, 126 MHz): δ -5.5 (C5), 12.9 (C1,2), 18.1 (C23), 25.8 (C4), 53.6
(C7), 60.2 (C6), 111.5 (C8), 111.9 (C3), 122.0 (C9,12), 124.8 (C16), 126.7 (C19), 126.8
(C21), 128.1 (C15), 128.6 (C25), 130.5 (C26), 131.3 (C24), 133.3 (C13,14), 138.8 (C18),
145.0 (C22), 148.8 (C17), 167.0 (C20). HRMS-ESI: m/z calcd for C37H57N4O5Si2 [M+H+]
693.3862; observed 693.3860.
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(Z)-1-(4-(bis(2-((tert-butyldimethylsilyl)oxy)ethyl)amino)phenyl)-3-((3,5-dimethyl-1Hpyrrol-2-yl)methylene)indolin-2-one 41.
1

H NMR (CDCl3, 500 MHz): δ 0.07 (s, 12H, H5), 0.91

(s, 18H, H4), 2.31 (s, 3H, H1), 2.34 (s, 12H, H2), 3.56
(t, 4H, J = 6.5 Hz, H7), 3.80 (t, 4H, J = 6.5 Hz, H6),
5.96 (s, 1H, H3), 6.77 (d, 1H, J = 7.0 Hz, H15), 6.81 (d,
2H, J = 9.0 Hz, H8), 7.08 (m, 2H, H13,H14), 7.24 (d,
2H, J = 9.0 Hz, H9), 7.45 (s, 1H, H11), 7.54 (d, 1H, J =
7.0 Hz, H12), 13.21 (br s, 1H, H10). 13C NMR (CDCl3,
126 MHz): δ -5.3 (C5), 11.6 (C2), 13.9 (C1), 18.3 (C22), 25.9 (C4), 53.6 (C7), 60.3 (C6),
109.1 (C15), 111.7 (C18), 112.0 (C8), 112.5 (C3), 117.0 (C12), 121.7 (C13), 122.8 (C20),
123.3 (C11), 125.4 (C14), 125.5 (C17), 127.1 (C24), 128.0 (C9), 132.2 (C23), 136.7 (C25),
140.7 (C16), 147.7 (C21), 168.5 (C19). HRMS-ESI: m/z calcd for C37H56N3O3Si2 [M+H+]
646.3855; observed 646.3860. FTIR: neat (cm-1) 2928, 1666, 1610, 1596, 1564, 1518,
1462, 1371, 1360, 1316, 1278, 1239, 1180, 1150, 1095, 995, 967, 911, 833, 810.

(Z)-N-(4-(bis(2-hydroxyethyl)amino)phenyl)-3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(2nitrophenyl)acrylamide (Z)-42
To a solution of (Z)-7 (0.500 g, 0.721 mmol) in THF (5 mL) at 0 oC was added 5:1 1 M
TBAF (in THF):glacial acetic acid (3 mL) dropwise over 1 minute. The reaction was
stirred at 0 oC for 4 h or until complete consumption of starting material was observed
by TLC analysis (1:1 pet. spirit:EtOAc). The reaction was quenched with saturated
NaHCO3 (10 mL) and extracted with EtOAc (2 x 40 mL) and the combined organic
phase washed with saturated NaHCO3 (2 x 50 mL) and brine (2 x 50 mL), dried over
anhydrous MgSO4 and concentrated. The crude residue was purified by silica gel
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column chromatography (EtOAc) to afford (Z)-42 (0.28 g, 85%) as a red crystalline
solid.
M.P. 102-104 oC. 1H NMR (CDCl3, 500 MHz): δ
2.10 (s, 3H, H2), 2.26 (s, 3H, H1), 3.50 (t, 4H, J =
6.0 Hz, H5), 3.78 (t, 4H, J = 6.0 Hz, H4), 5.82 (s,
1H, H3), 6.54 (s, 1H, H10), 6.61 (d, 2H, J = 8.5 Hz,
H6), 6.74 (s, 1H, H8), 7.12 (d, 2H, J = 8.5 Hz, H7),
7.53 (t, 1H, J = 8.0 Hz, H13), 7.58 (d, 1H, J = 7.5
Hz, H11), 7.68 (t, 1H, J = 7.5 Hz, H12), 8.00 (d, 1H, J = 8.5, H14). 13C NMR (CDCl3, 126
MHz): δ 11.4 (C2), 13.6 (C1), 55.2 (C5), 60.5 (C4), 110.9 (C3), 112.8 (C6), 116.0 (C17),
124.1 (C21), 124.2 (C7), 124.9 (C14), 126.6 (C19), 128.8 (C10), 129.0 (C13), 129.6 (C22),
133.4 (C23), 133.5 (C11/12), 136.1 (C16), 145.8 (C20), 149.4 (C15), 166.5 (C18). HRMSESI: m/z calcd for C25H29N4O5 [M+H+] 465.2132; observed 465.2138. FTIR: neat (cm1

) 3274, 2868, 1641, 1513, 1341, 1321, 1262, 1235, 1202, 1179, 1151, 1041, 1001.

(Z)-((4-(3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(2nitrophenyl)acrylamido)phenyl)azanediyl) bis(ethane-2,1-diyl) dimethanesulfonate (Z)43 and (Z)- and (E)-N-(4-(bis(2-chloroethyl)amino)phenyl)-3-(3,5-dimethyl-1H-pyrrol2-yl)-2-(2-nitrophenyl)acrylamide (Z)-1 and (E)-1
Diol (Z)-42 (0.350 g, 0.75 mmol) was stirred in CH2Cl2 (10 mL) at 0 oC under N2 and
triethylamine (0.30 mL, 2.15 mmol) was added, followed by mesyl chloride (0.15 mL,
1.94 mmol). The reaction was stirred at 0 oC for 1 h or until complete consumption of
starting material by TLC analysis (EtOAc). The reaction was diluted with CH2Cl2 (40
mL) and the combined mixture was added to a separating funnel. The organic phase was
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washed with saturated NaHCO3 (2 x 50 mL) and brine (2 x 50 mL), dried over
anhydrous MgSO4 and concentrated. The crude residue was purified by column
chromatography (EtOAc) to afford (Z)-43 (0.40 g, 86% yield) as an unstable red oil.
(Z)-43. 1H NMR (CDCl3, 500 MHz): δ 2.10 (s,
3H, H2), 2.22 (s, 3H, H1), 2.94 (s, 6H, H4),
3.70 (br s, 4H, H6), 4.30 (br s, 4H, H5), 5.83 (s,
1H, H3), 6.56 (s, 1H, H11), 6.68 (d, 2H, J = 8.5
Hz, H7), 6.67 (br s, 1H, J = 4.0 Hz, H9), 7.21
(d, 2H, J = 8.0 Hz, H8), 7.55 (t, 1H, J = 7.0 Hz,
H14), 7.59 (d, 1H, J = 7.0 Hz, H12), 7.70 (t, 1H,
J = 7.0 Hz, H13), 8.01 (d, 1H, J = 7.0 Hz, H15), 12.01 (br s, 1H, H10). 13C NMR (CDCl3,
126 MHz): δ 11.2 (C2), 13.4 (C1), 37.1 (C4), 50.8 (C6), 66.6 (C5), 110.8 (C3), 112.9 (C7),
116.1 (C18), 123.9 (C22), 124.0 (C8), 124.8 (C15), 128.0 (C20), 128.7 (C11), 129.0 (C14),
129.5 (C23), 133.2 (C24), 133.4 (C12), 133.6 (C13), 135.7 (C17), 143.7 (C21), 149.1 (C16),
166.2 (C19). HRMS-ESI: m/z calcd for C27H33N4O9S2 [M+H+] 621.1683; observed
621.1689.

Dimesylate (Z)-43 was immediately taken into DMF (8 mL) and excess lithium chloride
(~0.2 g) added. The solution was stirred at 75 oC for 45 minutes until complete
consumption of starting material by TLC analysis (1:1 pet. spirit:EtOAc). The reaction
was concentrated and taken up in EtOAc (50 mL), washed with water (3 x 50 mL),
dried over anhydrous MgSO4 and concentrated. The crude residue was purified by silica
gel column chromatography (100% pet. spirit to 8:2 pet. spirit:EtOAc) to afford (Z)-1
(0.30 g, 92% yield) as an orange crystalline product. Trace amounts of (E)-1 (0.01 g,
3% yield) was also obtained from the reaction.
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(Z)-1. M.P. 180 oC (dec.). 1H NMR (CDCl3, 500
MHz): δ 2.11 (s, 3H, H2), 2.28 (s, 3H, H1), 3.60 (t,
4H, J = 7.0 Hz, H5), 3.70 (t, 4H, J = 7.0 Hz, H4),
5.83 (s, 1H, H3), 6.55 (s, 1H, H10), 6.64 (d, 2H, J =
9.0 Hz, H6), 6.69 (br s, 1H, H8), 7.21 (d, 2H, J = 8.5
Hz, H7), 7.56 (t, 1H, J = 8.0 Hz, H13), 7.60 (d, 1H, J
= 7.5 Hz, H11), 7.70 (t, 1H, J = 7.5 Hz, H12), 8.02 (d, 1H, J = 8.0 Hz, H14), 12.03 (br s,
1H, H9).

13

C NMR (CDCl3, 126 MHz): δ 11.4 (C2), 13.6 (C1), 40.4 (C5), 53.6 (C4),

110.9 (C3), 112.4 (C6), 115.8 (C17), 124.1 (C21), 124.5 (C7), 124.9 (C14), 127.6 (C19),
129.0 (C10, C13), 129.8 (C22), 133.5 (C11, C12), 133.6 (C23), 136.1 (C16), 143.8 (C20),
149.5 (C15), 166.8 (C18). HRMS-ESI: m/z calcd for C25H27(35Cl)2N4O3 [M+H+]
501.1455; observed 501.1455. FTIR: neat (cm-1) 3402, 2921, 2852, 1647, 1521, 1513,
1460, 1353, 1322, 1235, 1178, 1150, 747.

(E)-1. M.P. 70-72 oC. 1H NMR (CDCl3, 500
MHz): δ 1.93 (s, 3H, H1), 2.16 (s, 3H, H2), 3.58 (t,
4H, J = 7.0 Hz, H4), 3.67 (t, 4H, J = 7.0 Hz, H5),
5.71 (s, 1H, H3), 6.43 (br s, 1H H9), 6.60 (d, 2H, J
= 8.0 Hz, H6), 6.91 (s, 1H, H8), 7.30 (d, 2H, J =
8.0 Hz, H7), 7.59 (d, 1H, J = 7.5 Hz, H11), 7.67 (s,
1H, H10), 7.70 (t, 1H, J = 7.5 Hz, H13), 7.78 (t, 1H, J = 8.0 Hz, H12), 8.16 (d, 1H, J = 8.0
Hz, H14).
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C NMR (CDCl3, 126 MHz): δ 11.3 (C2), 13.1 (C1), 40.5 (C4), 53.6 (C5),

110.5 (C3), 112.5 (C6), 119.0 (C17), 122.7 (C7), 123.4 (C22), 124.9 (C10), 125.4 (C14),
128.9 (C21), 129.3 (C19), 130.2 (C13), 131.8 (C16), 133.2 (C23), 133.9 (C11), 134.2 (C12),
143.1 (C20), 149.6 (C15), 164.8 (C18). HRMS-ESI: m/z calcd for C25H27(35Cl)2N4O3
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[M+H+] 501.1455; observed 501.1453. FTIR: neat (cm-1) 3309, 2912, 1653, 1525, 1517,
1346, 1249, 1216, 807, 636.

5.2.1 2-Aryl-3H-pyrrolizin-3-ones
5.2.1.1 General Procedure
An oven-dried 50 mL round-bottom flask containing a magnetic stirrer bar was sealed
with a septum, charged with Ar and tared. KH (~0.5 g, 30% mineral oil dispersion) was
then added to the flask and mineral oil was removed by washing with pet. spirit (2 x 30
mL) using a syringe under N2 flow. The flask containing dry KH was charged with Ar
and weighed to obtain an accurate mass of KH. Dry THF (10 mL) was added to the
flask containing KH (0.15 g, 3.7 mmoles, under Ar) and the mixture cooled to 0 oC. 3,5dimethyl-1H-pyrrole-2-carbaldehyde 4 (0.23 g, 1.9 mmoles) was dissolved in dry THF
(5 mL) under Ar and slowly cannulated into the stirring KH solution (caution: flask
requires outlet needle to release evolving H2 gas). The mixture was left to stir for 5
minutes at 0 oC. Phenylacetic acid derivative (1.9 mmoles) was added to a separate 50
mL round-bottom flask under Ar along with HBTU (0.71 g, 1.9 mmoles) and dry
CH2Cl2 (10 mL) under Ar. DIPEA (0.65 mL, 3.7 mmoles) was added dropwise to the
solution and stirred for 5 minutes until the HBTU completely dissolved. The HBTU
solution was cooled to 0 oC before addition in a single portion to the pyrrole
carboxaldehyde solution at 0 oC. The reaction was allowed to warm slowly to room
temperature. A dark red colour was observed in each reaction indicating formation of
the desired product. The reaction was quenched with ice-cold water after 2 h and
extracted with Et2O (2 x 50 mL). The combined organic phase was washed with
saturated NaHCO3 solution (2 x 50 mL) and brine (2 x 50 mL), dried over anhydrous
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MgSO4 and concentrated. The crude residue was purified by silica gel column
chromatography using a gradient from 100% pet. spirit to 1:9 acetone:pet. spirit) to
afford the 2-aryl-3H-pyrrolizin-3-one product as a dark red solid.

5.2.1.2 Compound Chatacterisation
5,7-dimethyl-2-(2-nitrophenyl)-3H-pyrrolizin-3-one 14
27% yield. M.P. 122-124 oC. 1H NMR (CDCl3, 500 MHz): δ
2.03 (s, 3H, H2), 2.29 (s, 3H, H1), 5.57 (s, 1H, H3), 7.14 (s, 1H,
H4), 7.45 (t, 1H, J = 8.5 Hz, H7), 7.47 (d, 1H, J = 8.5 Hz, H5),
7.59 (t, 1H, J = 8.5 Hz, H6), 7.95 (d, 1H, J = 8.5 Hz, H8). 13C
NMR (CDCl3, 126 MHz): δ 11.4 (C2), 12.4 (C1), 116.2 (C3),
124.6 (C8), 126.3 (C10), 126.6 (C11, C14), 128.8 (C6), 130.7 (C4), 130.8 (C5), 132.1 (C13),
132.8 (C7), 135.8 (C15), 148.6 (C9), 163.7 (C12). ESI-HRMS: m/z calculated for
C17H16N2O4 [M + H]+ 269.0926; observed 269.0898. FTIR: neat (cm-1) 2921, 2360,
1727, 1603, 1560, 1523, 1395, 1354, 1288, 1248, 1209, 1128.

5,7-dimethyl-2-phenyl-3H-pyrrolizin-3-one 51
48% yield. M.P. 46-48 oC. 1H NMR (CDCl3, 500 MHz): δ 2.01
(s, 3H, H2), 2.33 (s, 3H, H1), 5.55 (s, 1H, H3), 7.22 (s, 1H, H4),
7.27 (t, 1H, J = 7.5 Hz, H7), 7.36 (t, 2H, J = 8.0 Hz, H6), 7.77
(d, 2H, J = 8.0 Hz, H5).
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C NMR (CDCl3, 126 MHz): δ 11.4

(C2), 12.4 (C1), 115.9 (C3), 124.6 (C11), 126.0 (C6), 127.6 (C7), 128.2 (C4), 128.5 (C5),
130.0 (C8), 130.0/132.1 (C9, C12), 134.7 (C13), 165.6 (C10). ESI-HRMS: m/z calculated
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for C15H14NO [M + H]+ 224.1068; observed 224.1075. FTIR: neat (cm-1) 2919, 1719,
1700, 1598, 1527, 1445, 1360, 1293, 1269, 1207, 1131.

2-(2-fluorophenyl)-5,7-dimethyl-3H-pyrrolizin-3-one 69
37% yield. M.P. 37-38 oC. 1H NMR (CDCl3, 500 MHz): δ 1.99
(s, 3H, H2), 2.31 (s, 3H, H1), 5.53 (s, 1H, H3), 7.06 (dd, 1H, J =
12.0, 8.0 Hz, H8), 7.14 (m, 1H, H6), 7.19 (m, 1H, H7), 7.43 (d,
1H, J = 2.5 Hz, H4), 8.15 (m, 1H, H5). 13C NMR (CDCl3, 126
MHz): δ 11.3 (C2), 12.3 (C1), 115.5 (C8, 2JC-F = 22.6 Hz), 116.1
(C3), 120.1 (C10, 2JC-F = 11.6 Hz), 123.1 (C11, 3JC-F = 2.5 Hz), 124.03 (C6, 4JC-F = 3.4
Hz), 125.6 (C13), 128.4 (C7, 3JC-F = 8.7 Hz), 129.0 (C5, 3JC-F = 2.9 Hz), 132.29 (C14),
132.6 (C4), 135.0 (C15), 160.4 (C9, 1JC-F = 249.9 Hz), 165.4 (C12). ESI-HRMS: m/z
calculated for C15H13FNO [M + H]+ 242.0981; observed 242.0981. FTIR: neat (cm-1)
2922, 1734, 1716, 1530, 1486, 1397, 1368, 1302, 1260.54, 1211, 1136, 770.

2-(3-fluorophenyl)-5,7-dimethyl-3H-pyrrolizin-3-one 70
37% yield. M.P. 55-57 oC. 1H NMR (CDCl3, 500 MHz): δ 2.01
(s, 3H, H2), 2.32 (s, 3H, H1), 5.56 (s, 1H, H3), 6.95 (m, 1H, H7),
7.23 (s, 1H, H4), 7.30 (dd, 1H, J = 14.0 Hz, 7.5 Hz, H6), 7.53
(d, 1H, J = 11.0 Hz, H8) , 7.54 (d, 1H, 6.5 Hz, H5). 13C NMR
(CDCl3, 126 MHz): δ11.4 (C2), 12.4 (C1), 112.8 (C8, 2JC-F =
23.0 Hz), 114.3 (C7, 2JC-F = 21.6 Hz), 116.1 (C3), 121.49 (C5, 4JC-F = 2,9 Hz), 125.7
(C14), 128.5 (C11, 4JC-F = 2.8 Hz), 129.0 (C4), 129.9 (C6, 3JC-F = 8.7 Hz), 131.7 (C14),
134.1 (C10, 3JC-F = 8.7 Hz), 135.2 (C15), 161.9 (C9, 1JC-F = 245 Hz), 165.2 (C12). ESI117

HRMS: m/z calculated for C15H13FNO [M + H]+ 242.0981; observed 242.0979. FTIR:
neat (cm-1) 2916, 1707, 1601, 1582, 1530, 1437, 1397, 1366, 1298, 1265, 1215, 1138,
1134, 910, 874, 809, 782.

2-(4-fluorophenyl)-5,7-dimethyl-3H-pyrrolizin-3-one 71
38% yield. M.P. 56-58 oC. 1H NMR (CDCl3, 500 MHz): δ
2.00 (s, 3H, H2), 2.31 (s, 3H, H1), 5.54 (s, 1H, H3), 7.04 (t,
2H, J = 8.5 Hz, H6), 7.15 (s, 1H, H4), 7.75 (dd, 2H, J = 8.5,
5.5 Hz, H5).
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C NMR (CDCl3, 126 MHz): δ11.4 (C2), 12.4

(C1), 115.5 (C6, 2JC-F = 21.5 Hz), 115.9 (C3), 124.8 (C11), 127.7 (C4), 127.8 (C5), 128.2
(C9), 129.0 (C8), 131.9 (C12), 134.7 (C13), 161.3/163.2 (C7, 1JC-F = 247.8 Hz), 165.5
(C10). ESI-HRMS: m/z calculated for C15H13NOF [M + H]+ 242.0981; observed
242.0981. FTIR: neat (cm-1) 2917, 1711, 1608, 1557, 1531, 1499, 1450, 1394, 1364,
1299, 1267, 1225, 1158, 1139, 1133, 1095, 828.

2-(2-chlorophenyl)-5,7-dimethyl-3H-pyrrolizin-3-one 72
16% yield. M.P. 84-86 oC. 1H NMR (CDCl3, 500 MHz): δ 2.03
(s, 3H, H2), 2.33 (s, 3H, H1), 5.57 (s, 1H, H3), 7.21 (m, 1H, H6),
7.28 (m, 1H, H7), 7.42 (dd, 1H, J = 7.5, 1.0 Hz, H5), 7.43 (s,
1H, H4), 7.62 (dd, 1H, J = 8.0, 1.5 Hz, H8). 13C NMR (CDCl3,
126 MHz): δ 11.4 (C2), 12.3 (C1), 116.0 (C3), 125.6 (C13), 126.6 (C7), 127.5 (C14), 128.6
(C6), 130.2 (C5), 130.2 (C9), 131.0 (C8), 131.9 (C10), 132.8 (C11), 133.6 (C4), 135.1
(C15), 165.3 (C12). ESI-HRMS: m/z calculated for C15H13(35Cl)NO [M + H]+ 258.0686;
observed 258.0681. FTIR: neat (cm-1) 2924, 2357, 1719, 1612, 1533, 1295, 768, 734.
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2-(3-chlorophenyl)-5,7-dimethyl-3H-pyrrolizin-3-one 73
35% yield. M.P. 84-86 oC. 1H NMR (CDCl3, 500 MHz): δ 2.01
(s, 3H, H2), 2.32 (s, 3H, H1), 5.56 (s, 1H, H3), 7.23 (t, 1H, J =
8.5 Hz, H7), 7.23 (s, 1H, H4), 7.27 (t, 1H, J = 8.0 Hz, H6), 7.66
(d, 1H, J = 8.0 Hz, H5), 7.78 (t, 1H, J = 1.5 Hz, H8). 13C NMR
(CDCl3, 126 MHz): δ 11.4 (C2), 12.4 (C1), 116.1 (C3), 123.96 (C5), 123.97 (C11), 125.7
(C13), 125.9 (C8), 127.4 (C7), 128.3 (C14), 129.0 (C4), 129.7 (C6), 133.7 (C10), 134.5
(C9), 135.2 (C15), 156.1 (C12). ESI-HRMS: m/z calculated for C15H13NO(35Cl) [M + H]+
258.0680; observed 258.0695. FTIR: neat (cm-1) 2913, 1716, 1589, 1530, 1477, 1379,
1364, 1137, 1093, 782, 722, 683.

2-(4-chlorophenyl)-5,7-dimethyl-3H-pyrrolizin-3-one 74
30% yield. M.P. 87-89 oC. 1H NMR (CDCl3, 500 MHz): δ
2.01 (s, 3H, H2), 2.32 (s, 3H, H1), 5.55 (s, 1H, H3), 7.20 (s,
1H, H4), 7.32 (d, 1H, J = 7.5 Hz, H6), 7.72 (d, 1H, J = 7.5 Hz,
H5).

13

C NMR (CDCl3, 126 MHz): δ11.4 (C2), 12.4 (C1),

116.1 (C3), 125.3 (C11), 127.2 (C5), 128.3 (C4), 128.7 (C6), 128.7 (C9), 130.5 (C8), 131.9
(C12), 133.3 (C7), 135.0 (C13), 165.4 (C10). ESI-HRMS: m/z calculated for
C15H13(35Cl)NO [M + H]+ 258.0680; observed 258.0681. FTIR: neat (cm-1) 2932, 1721,
1604, 1525, 1262, 875, 796.

119

2-(2-bromophenyl)-5,7-dimethyl-3H-pyrrolizin-3-one 75
13% yield. M.P. 114-116 oC. 1H NMR (CDCl3, 500 MHz): δ
2.02 (s, 3H, H2), 2.32 (s, 3H, H1), 5.57 (s, 1H, H3), 7.14 (m, 1H,
H7), 7.32 (m, 1H, H6), 7.50 (dd, 1H, J = 8.0, 1.5 Hz, H5), 7.62
(dd, 1H, J = 8.0, 1.0 Hz, H8). 13C NMR (CDCl3, 126 MHz): δ
11.4 (C2), 12.3 (C1), 115.9 (C3), 122.8 (C9), 125.6 (C14), 127.1 (C6), 128.9 (C7), 129.5
(C11), 131.2 (C5), 131.7 (C15), 132.2 (C10), 133.4 (C8), 133.5 (C4), 135.1 (C13), 165.0
(C12). ESI-HRMS: m/z calculated for C15H13(79Br)NO [M + H]+ 302.0175; observed
302.0177. FTIR: neat (cm-1) 3100, 2917, 1720, 1610, 1556, 1533, 1467, 1426, 1365,
1252, 1132, 768, 733, 629.

2-(3-bromophenyl)-5,7-dimethyl-3H-pyrrolizin-3-one 76
44% yield. M.P. 103-105 oC. 1H NMR (CDCl3, 500 MHz): δ
2.01 (s, 3H, H2), 2.32 (s, 3H, H1), 5.56 (s, 1H, H3), 7.21 (t, 1H,
J = 8.0 Hz, H6), 7.24 (s, 1H, H4), 7.37 (d, 1H, J = 8.0 Hz, H7),
7.72 (d, 1H, J = 8.0 Hz, H5), 7.93 (s, 1H, H8).
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C NMR

(CDCl3, 126 MHz): δ 11.4 (C2), 12.4 (C1), 116.2 (C3), 122.7 (C10), 124.4 (C7), 125.8
(C15), 128.2 (C11), 128.8 (C8), 129.1 (C4), 130.0 (C6), 130.3 (C5), 131.8 (C13), 134.0
(C9), 135.2 (C14), 165.1 (C12). ESI-HRMS: m/z calculated for C15H13(79Br)NO [M + H]+
302.0175; observed 302.0172. FTIR: neat (cm-1) 2932, 2367, 1712, 1663, 1587, 1530,
1475, 1364, 1297, 1256, 1136, 863, 782, 682.
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2-(4-bromophenyl)-5,7-dimethyl-3H-pyrrolizin-3-one 77
34% yield. M.P. 93-95 oC. 1H NMR (CDCl3, 500 MHz): δ
2.00 (s, 3H, H2), 2.31 (s, 3H, H1), 5.55 (s, 1H, H3), 7.22 (s,
1H, H4), 7.47 (d, 2H, J = 8.5 Hz, H6), 7.65 (d, 2H, J = 8.5
Hz, H5).

13

C NMR (CDCl3, 126 MHz): δ 11.4 (C2), 12.4

(C1), 116.1 (C3), 121.5 (C9), 125.4 (C11), 127.5 (C5), 128.4 (C4), 128.7 (C7), 130.9 (C8),
131.6 (C6), 131.7 (C13), 135.1 (C12), 165.3 (C10). ESI-HRMS: m/z calculated for
C15H13(79Br)NO [M + H]+ 302.0175; observed 302.0176. FTIR: neat (cm-1) 2923, 2363,
1719, 1608, 1527, 1457, 1362, 1262, 1207, 1130, 1028, 881, 817, 803, 788.

5,7-dimethyl-2-o-tolyl-3H-pyrrolizin-3-one 78
21% yield. M.P. 48-50 oC. 1H NMR (CDCl3, 500 MHz): δ 2.00
(s, 3H, H2), 2.31 (s, 3H, H1), 2.38 (s, 3H, H5), 5.54 (s, 1H, H3),
6.97 (s, 1H, H4), 7.21 (m, 3H, H7,8,9), 7.35 (d, 1H, H6).

13

C

NMR (CDCl3, 126 MHz): δ 11.3 (C2), 12.3 (C1), 20.9 (C5),
115.6 (C3), 124.2 (C14), 125.6 (C7/8/9), 127.9 (C7/8/9), 129.7 (C6), 130.5 (C7/8/9), 131.3,
131.7, 131.8 (C4), 132.2, 134.7, 136.4, 165.5 (C13). ESI-HRMS: m/z calculated for
C16H16NO [M + H]+ 238.1232; observed 238.1220. FTIR: neat (cm-1) 3308, 2925, 1707,
1375, 1231, 1138, 1081, 1033, 968, 923, 790.

5,7-dimethyl-2-m-tolyl-3H-pyrrolizin-3-one 79
41% yield. M.P. 70-71 oC. 1H NMR (CDCl3, 500 MHz): δ 2.00
(s, 3H, H2), 2.32 (s, 3H, H1), 2.36 (s, 3H, H5), 5.54 (s, 1H, H3),
7.09 (d, 1H, J = 7.5 Hz, H8), 7.20 (s, 1H, H4), 7.25 (t, 1H, J =
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7.5 Hz, H7), 7.56 (d, 1H, J = 8.0 Hz, H6), 7.60 (s, 1H, H9).

13

C NMR (CDCl3, 126

MHz): δ 11.4 (C2), 12.4 (C1), 21.5 (C5), 115.8 (C3), 123.1 (C6), 124.4 (C14), 126.7 (C9),
128.1 (C4), 128.39/128.41 (C7, C8), 130.1 (C12), 131.9 (C11), 132.0 (C15), 134.6 (C16),
138.0 (C10), 165.7 (C13). ESI-HRMS: m/z calculated for C16H16NO [M + H]+ 238.1232;
observed 238.1225. FTIR: neat (cm-1) 2915, 1707, 1600, 1533, 1442, 1368, 1276, 1172,
1091, 918, 862, 783, 776, 690.

5,7-dimethyl-2-p-tolyl-3H-pyrrolizin-3-one 80
37% yield. M.P. 67-69 oC. 1H NMR (CDCl3, 500 MHz): δ
1.98 (s, 3H, H2), 2.30 (s, 3H, H1), 2.34 (s, 3H, H5), 5.51 (s,
1H, H3), 7.13 (s, 1H, H4), 7.16 (d, 2H, J = 8.0 Hz, H7), 7.66
(d, 2H, J = 8.0 Hz, H6).

13

C NMR (CDCl3, 126 MHz): δ

11.3 (C2), 12.3 (C1), 21.2 (C5), 115.7 (C3), 124.1 (C12), 125.9 (C6), 127.2 (C4), 129.1
(C7), 129.2 (C9), 130.0 (C10), 132.1 (C13), 134.4 (C14), 137.4 (C8), 165.7 (C11). ESIHRMS: m/z calculated for C16H16NO [M + H]+ 238.1232; observed 238.1229. FTIR:
neat (cm-1) 2915, 1723, 1711, 1615, 1531, 1451, 1365, 1297, 1266, 1135, 966, 811.

2-(2-methoxyphenyl)-5,7-dimethyl-3H-pyrrolizin-3-one 81
33% yield. M.P. 96-98 oC. 1H NMR (CDCl3, 500 MHz): δ 2.01
(s, 3H, H2), 2.31 (s, 3H, H1), 3.89 (s, 3H, H5), 5.53 (s, 1H, H3),
6.99 (t, 1H, J = 7.5 Hz, H7), 6.92 (d, 1H, J = 8.5 Hz, H9), 7.23
(m, 1H, H8), 7.55 (s, 1H, H4), 8.05 (dd, 1H, J = 7.5, 1.0 Hz, H6).
13

C NMR (CDCl3, 126 MHz): δ 11.3 (C2), 12.3 (C1), 55.4 (C5), 110.7 (C9), 115.8 (C3),

120.6 (C7), 120.9 (C11), 124.1 (C15), 125.7 (C12), 128.2 (C8), 129.3 (C6), 132.2 (C4),
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132.6 (C14), 134.4 (C16), 157.4 (C10), 166.3 (C13). ESI-HRMS: m/z calculated for
C16H16NO2 [M + H]+ 254.1181; observed 254.1169. FTIR: neat (cm-1) 2919, 2363,
1712, 1605, 1529, 1492, 1433, 1369, 1287, 1246, 1184, 1121, 1061, 1022.

2-(3-methoxyphenyl)-5,7-dimethyl-3H-pyrrolizin-3-one 82
45% yield. M.P. 62-64 oC. 1H NMR (CDCl3, 500 MHz): δ 2.01
(s, 3H, H2), 2.32 (s, 3H, H1), 3.83 (s, 3H, H5), 5.54 (s, 1H, H3),
6.82 (dd, 1H, J = 8.0 / 2.5 Hz, H8), 7.21 (s, 1H, H4), 7.26 (t, 1H,
J = 8.0 Hz, H7), 7.33 (d, 1H, J = 8.0 Hz, H6), 7.40 (s, 1H, H9).
13

C NMR (CDCl3, 126 MHz): δ 11.4 (C2), 12.4 (C1), 55.2 (C5),

111.1 (C9), 113.7 (C8), 115.9 (C3), 118.4 (C6), 124.8 (C14), 128.4 (C4), 129.4 (C7), 129.7
(C12), 131.9 (C15), 133.3 (C16), 134.8 (C11), 159.7 (C10), 165.6 (C13). ESI-HRMS: m/z
calculated for C16H16NO2 [M + H]+ 254.1181; observed 254.1181. FTIR: neat (cm-1)
2936, 1712, 1597, 1579, 1531, 1484, 1429, 1396, 1365, 1295, 1278, 1261, 1171, 1037.

2-(4-methoxyphenyl)-5,7-dimethyl-3H-pyrrolizin-3-one 83
33% yield. M.P. 57-59 oC. 1H NMR (CDCl3, 500 MHz): δ
1.98 (s, 3H, H2), 2.30 (s, 3H, H1), 3.82 (s, 3H, H5), 5.51 (s,
1H, H3), 6.89 (d, 2H, J = 9.0, H7), 7.07, (s, 1H, H4), 7.72
(d, 2H, J = 9.0, H7). 13C NMR (CDCl3, 126 MHz): δ 22.3
(C2), 12.3 (C1), 55.2 (C5), 113.9 (C7), 115.7 (C3), 123.7 (C12), 124.8 (C9), 126.1 (C4),
127.3 (C6), 129.8 (C10), 132.2 (C13), 134.2 (C14), 159.2 (C8), 165.9 (C11). ESI-HRMS:
m/z calculated for C16H16NO2 [M + H]+ 254.1181; observed 254.1190. FTIR: neat (cm1

) 2919, 1713, 1614, 1534, 1436, 1376, 1364, 1291, 1255, 1235, 1182, 1138, 1028.
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5,7-dimethyl-2-(3-nitrophenyl)-3H-pyrrolizin-3-one 84
15% yield. M.P. 177-179 oC. 1H NMR (CDCl3, 500 MHz): δ
2.05 (s, 3H, H2), 2.34 (s, 3H, H1), 5.60 (s, 1H, H3), 7.39 (s, 1H,
H4), 7.52 (t, 1H, J = 8.0 Hz, H6), 8.09 (dd, 1H, J = 7.5, 1.5 Hz,
H7), 8.17 (d, 1H, J = 7.5 Hz, H5), 8.60 (t, 1H, J = 1.5 Hz, H8).
13

C NMR (CDCl3, 126 MHz): δ 11.5 (C2), 12.4 (C1), 116.5 (C3),

120.5 (C8), 121.8 (C7), 127.07/127.09 (C11, C14), 129.4 (C6), 130.2 (C4), 131.5 (C5),
131.6 (C15), 133.6 (C10), 135.9 (C13), 148.5 (C9), 164.8 (C12). ESI-HRMS: m/z
calculated for C17H16N2O4 [M + H]+ 269.0926; observed 269.0932. FTIR: neat (cm-1)
2920, 1712, 1598, 1516, 1397, 1347, 1295, 1258, 1212, 1140, 1137, 1100.

5,7-dimethyl-2-(4-nitrophenyl)-3H-pyrrolizin-3-one 85
4% yield. M.P. 178-181 oC. 1H NMR (CDCl3, 500 MHz): δ
2.06 (s, 3H, H2), 2.35 (s, 3H, H1), 5.62 (s, 1H, H3), 7.43 (s,
1H, H4), 7.96 (d, 2H, J = 8.5 Hz, H5), 8.21 (d, 2H, J = 8.5
Hz, H6).

13

C NMR (CDCl3, 126 MHz): δ 11.6 (C2), 12.5

(C1), 116.8 (C3), 123.9 (C6), 126.0 (C5), 126.9 (C9), 128.0 (C11), 131.3 (C4), 131.8 (C12),
136.4 (C13), 138.4 (C8), 146.3 (C7), 164.7 (C10). ESI-HRMS: m/z calculated for
C17H16N2O4 [M + H]+ 269.0926; observed 269.0931. FTIR: neat (cm-1) 3160, 2920,
2369, 1723, 1586, 1522, 1505, 1397, 1335, 1316, 1270, 1210, 1142, 1106.
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5.3 Proof of Concept Chemical Reduction Reactions
Reduction with Fe(0) in CH3COOH
Compound (Z)-1 (17.5 mg, 0.035 mmol) was dissolved in a
mixture of 1:1:1 glacial acetic acid:EtOH:water (3 mL).
Reduced iron powder (23.1 mg, 0.41 mmol) was added and the
reaction subjected to ultrasonic irradiation for 1 h at 30 C or
until complete consumption of starting material by TLC
analysis (7:3 pet. spirit:acetone). The reaction mixture was
filtered through a celite plug and washed with EtOH (10 mL).
The filtrate was concentrated and taken into Et2O (25 mL). The
organic layer was washed with saturated NaHCO3 (20 mL) and brine (20 mL), dried
over anhydrous MgSO4 and concentrated. The crude residue was purified by silica gel
column chromatography (100% pet. spirit to 85:15 pet. spirit:acetone) to afford SU5416
2 (4.2 mg, 50% yield) as a yellow solid and 2-OH (2.5 mg, 28%) as a dark orange solid.
A similar procedure using (Z)-10 (50.8 mg, 0.161 mmol) also afforded SU5416 2 (30.9
mg, 81.4%).

Reduction with FeCl3.6H2O/Zn (dust)
A mixture of ferric chloride hexahydrate (60.2 mg, 0.22 mmol), zinc dust (53.1 mg,
0.81 mmol) and (Z)-1 (18.0 mg, 0.036 mmol) was stirred at room temperature in 1:1
DMF:water (2 mL). After 3 h or complete consumption of starting material by TLC
analysis (7:3 pet. spirit:acetone), the reaction mixture was diluted with Et2O (30 mL)
and filtered through celite. The filtrate was added to a separating funnel and washed
with brine (2 x 20 mL), dried over anhydrous MgSO4 and concentrated. The crude
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residues were purified by silica gel column chromatography (100% pet. spirit to 85:15
pet. spirit:acetone) to afford SU5416 2 (4.3 mg, 50%) as a yellow solid, along with 2OH (2.2 mg, 24%) as a dark orange solid. A similar procedure using (Z)-10 (53.3 mg,
0.169 mmol) also afforded SU5416 2 (26.5 mg, 70%) and 2-OH (8.6 mg, 20%).

Reduction with NaBH4/Pd-C
To a stirred suspension of (Z)-1 (16.8 mg, 0.034 mmol) and Pd-C (10 mg) in 2:1
MeOH:H2O (2.5 mL), NaBH4 (13.1 mg, 0.35 mmol) was added. The reaction mixture
was stirred at rt for 30 mins before the catalyst was removed through a celite plug. The
plug was washed with MeOH and the filtrates concentrated. The crude product was
taken into Et2O (25 mL), washed with brine (2 x 25 mL), dried over anhydrous MgSO4
and concentrated. The crude residue was purified by column chromatography using a
gradient from 100% pet. spirit to 85:15 pet. spirit:acetone to give SU5416 2 (4.7 mg,
58%) as a yellow solid along with 2-OH (1.8 mg, 21%) as a dark orange solid. A similar
procedure using (Z)-10 (52 mg, 0.17 mmol) afforded 2 (27 mg, 72%).

5.4 Rat Aortic Ring Angiogenesis Assay
Compounds were tested for angiogenesis inhibition by Anna Bezos in Professor Chris
Parish’s lab at the John Curtin School of Medical Research (ANU). Experiments were
carried out in 48-well culture plates using the previously reported assay conditions with
some modifications.192 Briefly, thoracic aortas from female Fischer 344 rats were
excised and the 2.5 cm long vessels placed in Hank’s buffered salt solution (HBSS)
media containing 2.5 µg/mL amphotericin B and cross-sectioned at 1 mm intervals. In
the angiogenesis assay, 15 mL of bovine thrombin (50 NIH unit/mL in 0.15M NaCl)
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was added to each well, followed by 0.5 mL per well of 3 mg/mL bovine fibrinogen in
Medium 199. The thrombin and fibrinogen were mixed rapidly and one aortic section
was quickly placed in the centre of the well before clot formation. Fibrin gel formation
usually occurred within 0.5 min, leaving the vessel fragment suspended in the gel.
On gel formation, 0.5 mL of Medium 199 supplemented with 20% foetal calf serum
(FCS), 0.1% 6-aminohexanoic acid, L-glutamine, and antibiotics (gentamicin sulfate
and amphotericin B) and test compound were added to each well. Six replicate cultures
were examined for each concentration of compound. Vessels were cultured at 37 oC in
5% CO2 in a humidified environment for 7 days, with the medium being changed on
Day 4. On Day 5, the percentage of the field of view occupied by vessel outgrowths
(F.O.V. occupancy %) was used as a quantitative measure of angiogenesis (inhibition)
relative to control (no compound added).

5.5 HUVEC Tube Formation Assay
The endothelial tube formation assay was performed in accordance with the vendor’s
recommendations.219 Briefly, adherent human umbilical vein endothelial cells (C-0035C, Life Technologies) were seeded at 2.5 x 103 cells/cm2 in standard T75 flasks and
incubated at 37 ºC and 5% CO2 in a humidified cell culture incubator with Medium 200
supplemented with low serum growth supplement (LSGS, Life Technologies). Media
was refreshed every 36 hours and cultures were passaged at 80% confluency (5-6 days).
HUVECs were used for assays between passages 2-4.
Geltrex was thawed overnight at 4 oC and 50-100 µL was added to coat the base of 24well culture plates and the plates incubated at 37 oC for 1 hour to set the gel. Cells were
seeded at 4 x 103 cells/200 µL in LSGS-supplemented Medium 200 and incubated for 2
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hours at 37 oC to allow adherence. Compounds were added to give a final concentration
of 10 uM in LSGS-supplemented Medium 200 containing 1% DMSO. Cells were
incubated at 37 oC for a further 5 hours before the media was carefully aspirated and
replaced with PBS for visualisation by optical microscopy.
A series of 3-5 images of each well were taken using a microscope camera at 20x
magnification and used for the analysis. Experiments were performed twice with
individual cultures of HUVECs, giving 6-10 images for each compound. Angiogenesis
analysis was performed according to Aranda et al.218 Briefly, total cell count, sprouting
(i.e. differentiating, elongated) cells, connected cells, enclosed polygons and complex
polygons (those with 2-3 cells thick edges and those with 4+) were counted and each
image was scored according to the following equation:

Where 0 is no complex polygons, 1 is at least one polygon with walls 2-3 cells thick and
2 is at least one polygon with walls 4+ cells thick. 1% DMSO in LSGS-supplemented
Medium 200 was used as a positive control (vehicle) and 10 µM sunitinib malate was
used as a negative control. Experiments containing test compounds were scored as a
percentage of vehicle.
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6.1 Appendix 1
6.1.1 Crystallographic data
(a) Compound (Z)-5.
C15H14N2O4, Mr = 286.29, T = 150 K; monoclinic, space group P21/n, Z = 4; a =
13.8996 (1) Å, b = 7.3274 (1) Å, c = 14.6266 (1) Å; β = 113.1054 (9)°; V = 1370.19 (2)
Å3; Dx = 1.388 g.cm-3; 20464 reflections measured (θ = 4-72°) merged to 2692 unique
data; R = 0.033 (for 2610 data with I > 2ơ(I)), Rw = 0.089 (all data); S = 1.01.
(b) Compound 14.
C15H12N2O3, Mr = 268.27, T = 150 K; triclinic, space group P1, Z = 2; a = 7.9103 (7) Å,
b = 8.2020 (4) Å, c = 10.8545 (9) Å; α = 79.807 (6)°; β = 69.688 (8)°; γ = 87.445 (6)°;
V = 649.92 (9) Å3; Dx = 1.371 g.cm-3; 9934 reflections measured (θ = 4-72°) merged to
2534 unique data; R = 0.059 (for 2263 data with I > 2ơ(I)), Rw = 0.178 (all data); S =
1.01.
(c) Compound (Z)-13.
C18H18N2O4, Mr = 326.35, T = 200 K; monoclinic, space group P21/c, Z = 4; a =
12.5669 (4) Å, b = 7.9086 (3) Å, c = 17.6200 (4) Å; β = 103.730 (2)°; V = 1701.15 (6)
Å3; Dx = 1.274 g.cm-3; 32664 reflections measured (2θ = 5-55°) merged to 3903 unique
data; R = 0.053 (for 2656 data with I > 2ơ(I)), Rw = 0.147 (all data); S = 0.95.
(d) Compound (E)-13.
C18H18N2O4, Mr = 326.35, T = 298(2) K; triclinic, space group P-1, Z = 2; a = 8.4326
(4) Å, b = 10.2147 (4) Å , c = 11.0598 (6) Å; α = 72.485 (3)°, β = 76.605 (2)°, γ =
71.312 (3)°; V = 850.89 (7) Å3; Dx = 1.274 g.cm-3; 7615 reflections measured (2θ = 454.2°) merged to 3674 unique data R = 0.064 (for 2849 data with I > 2ơ(I)), Rw = 0.187
(all data); S = 0.99.
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(e) Compound 15.
C22H22N4O, Mr = 358.44, T = 150 K; monoclinic, space group P21/n, Z = 4; a = 10.7644
(2) Å, b = 7.0938 (2) Å, c = 23.6831 (4) Å; β = 101.3654 (19)°; V = 1772.99 (7) Å3; Dx
= 1.343 g.cm-3; 8260 reflections measured (θ = 5-72°) merged to 3501 unique data; R =
0.036 (for 3202 data with I > 2ơ(I)), Rw = 0.097 (all data); S = 0.99.
(f) Compound 17.
C14H12N2O2, Mr = 240.26, T = 150 K; orthorhombic, space group Pca21, Z = 8; a =
26.7517 (16) Å, b = 5.4982 (5) Å, c = 15.7489 (16) Å; V = 2316.4 (3) Å3; Dx = 1.378
g.cm-3; 8621 reflections measured (θ = 3-69°) merged to 2285 unique data; R = 0.080
(for 1797 data with I > 2ơ(I)), Rw = 0.183 (all data); S = 1.04.

6.1.2 Crystal Structure Determination
Images of (Z)-13 and (E)-13 were measured on Nonius Kappa CCD diffractometers
(Mo Kα radiation, graphite monochromator, λ 0.71073Å) and data were extracted using
the DENZO package.221 Images of (Z)-5, 14, 15 and 17 were measured on Agilent
SuperNova diffractometers (Cu Kα radiation, graphite or mirror monochromators, λ
1.54180 Å) and data were extracted using the CrysAlis PRO package.222
For (Z)-13, (Z)-5, 14, 15 and 17 structure solution was by direct methods (SIR92)223 and
the structure was refined using the CRYSTALS program package.224 For (E)-13,
structure solution was by direct methods (SIR97)225 and the structure was refined using
the SHELXL-97 program package.226 Atomic coordinates, bond lengths and angles, and
displacement parameters of (Z)-13 and (E)-13 have been deposited at the Cambridge
Crystallographic Data Centre (CCDC accession numbers 905343 and 905344
respectively).
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6.2 Appendix 2
(a)

(b)

Appendix 2. NMR spectra of compound 15. (a) 1H NMR spectrum of 15; (b) 13C NMR
spectrum of 15. Assignments were derived from 2D NMR experiments, including
gCOSY, NOESY, gHSQC and gHMBC.
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